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Background: Patients diagnosed with rifampicin resistant (RR) tuberculosis (TB) in South 
Africa frequently fail to link to appropriate drug resistant (DR) TB treatment. The aim of this 
study was to explore barriers and enablers to expedited linkage to treatment following RR-TB 
diagnosis in the Western Cape Province, within the context of ongoing decentralisation of DR-
TB services and the scale-up of Xpert MTB/RIF diagnostics. 
 
Methods: An embedded case study approach, using qualitative research methods, was 
employed to explore barriers and enablers to expedited treatment linkage following RR-TB 
diagnosis. The case of investigation in this study was ‘treatment linkage following RR-TB 
diagnosis in the Western Cape Province during the ongoing decentralisation of DR-TB services 
and scale-up of Xpert diagnostics’. DR-TB is used in this study as an encompassing term to 
refer to RR, multidrug resistant and extensively drug resistant TB. The embedded units of 
analysis in this study were patients’ linkage outputs, defined as: (1) expedited treatment 
initiation, (2) delayed treatment initiation and (3) non-initiation of treatment following 
sputum collection on which RR-TB was diagnosed. Seventeen patient, 8 family member, 49 
healthcare worker and 4 key informant open-ended, in-depth interviews were conducted and 
59 patient folders were reviewed. Additionally, an extensive literature review was conducted. 
The tools used for data collection in this study were developed from the literature review and 
Coker et al.’s (201) conceptual framework for evaluation of a communicable disease 
intervention. A framework approach using Coker et al.’s conceptual framework was applied 
for analysis. 
 
Results: This study identified multiple factors that enabled and constrained expedited 
treatment linkage following RR-TB diagnosis. Enabling factors included: 1) the availability of 
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clinic level DR-TB counsellors and tracers; 2) living in walking distance of decentralised 
services and 3) having a strong social support network. Constraining factors included: 1) low 
usage of Xpert diagnostics, 2) delays in acting on results and missed (or unseen) results, 3) 
rotation of nurses or the lack of dedicated TB nurses in clinics, 4) limited clinic-level 
administrative support, 5) information systems challenges and 6) waiting lists for beds and 
limited access to transport services in rural areas.  
In linking to treatment, patients commonly face challenges due to competing 
subsistence needs and household or employment responsibilities. Additionally, substance 
addiction, having a history of treatment interruption, hopelessness regarding treatment, as 
well as not having a stable place to stay or social support may increase patients’ risks of 
linkage failure.  
 
Conclusion: Within the Western Cape Province there is significant opportunity to improve 
linkage to treatment through strengthening the health systems mechanisms to link patients 
to treatment following RR-TB diagnosis. Expanding access to psychosocial services (substance 
abuse rehabilitation and psychosocial evaluations) following RR-TB diagnosis may assist in 
linking high risk patients to treatment. Additionally, the provision of food support (in addition 
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Tuberculosis (TB): Tuberculosis or TB is an infectious illness that is spread through air-
borne bacteria in the respiratory fluids of people with active TB.  
 
Drug susceptible TB (DS-TB): Drug susceptible TB or DS-TB is regular TB that is not 
resistant to any of the main medicines used to treat TB. DS-TB is treated with a combination 
of medicines - comprising of rifampicin, isoniazid, ethambutol and pyrazinamide - that are 
taken daily for a period of 6 months.  
 
Drug resistant TB (DR-TB): For the purposes of this study, drug resistant TB or DR-TB 
is used as an encompassing term to talk about all types of drug resistance, including 
rifampicin-mono resistant TB, multi-drug resistant TB and extensively-drug resistant TB. 
 
Rifampicin resistant TB (RR-TB): For this study rifampicin resistant TB or RR-TB is 
used to indicate that a patient has been diagnosed with rifampicin resistant TB and should be 
started on a standard MDR-TB regimen while awaiting the results of further resistance testing. 
Further resistance testing should be performed on patients diagnosed with RR-TB to 
determine whether the patient has rifampicin-mono resistant TB, MDR-TB or XDR-TB. 
 
Rifampicin-mono resistant TB: Patients that are resistant to rifampicin, while 
remaining susceptible to isoniazid, are categorised as rifampicin-mono resistant. While these 
patients are not categorised as multi-drug resistant, they should be treated with standard 
MDR-TB treatment regimens, in combination with isoniazid. 
 
Multi-drug resistant TB (MDR-TB): Patients that are resistant to both rifampicin and 
isoniazid are categorised as multi-drug resistant. These patients should be treated with 
standard MDR-TB regimens. Depending on the time of a patient’s culture conversion, this 
regimen should be taken for 18 months to 2 years. 
 
Extensively-drug resistant TB (XDR-TB): Patients that are resistant to rifampicin 
and isoniazid, plus at least one fluoroquinole (moxifloxacin, levofloxacin, ofloxacin) and one 
injectable (kanamycin, amikacin, capreomycin) are categorised as extensively-drug resistant. 
Patients with XDR-TB should be treated with South Africa’s standard XDR-TB regimens or, 
preferably, with individualised regimens that reflect patients’ drug susceptibility profiles. 
 
Linkage to treatment/ Treatment linkage: Linkage to treatment and treatment 
linkage are used interchangeably throughout the dissertation. Linkage to treatment is defined 
as the initiation of an appropriate DR-TB regimen (according to available resistance results) 
following diagnosis of RR-TB. Patients are defined as ‘linked to treatment’ if they initiated 
drug resistant TB treatment for the episode of DR-TB under investigation, regardless of 




Non-initiators: Patients that did not initiate DR-TB treatment within six months of sputum 
collection on which RR-TB was diagnosed are defined as ‘non-initiators’. In academic 
literature, these patients are also defined as initial defaulters. 
 
Expedited initiators: Patients that initiated treatment within one month of the date that 
sputum collection, on which RR-TB was diagnosed, are defined as ‘expedited initiators’. 
 
Delayed initiators: Patients that initiated treatment more than one month and less than 
six month of the date of sputum collected, on which RR-TB  was diagnosed, are defined as 
‘delayed initiators’. 
 
Lost to follow-up/ Loss to follow-up: Patients that are defined as ‘lost to follow-up’ 
are patients that cannot be traced by the health system if ‘loss to follow-up’ occurs. Loss to 
follow-up may occur due to health system and patient factors, and the interactions between 
these factors. This may occur when inadequate information is collected from patients in order 
to locate and communicate with them further. Loss to follow-up may also occur when health 
facilities’ procedures and systems for tracing patients are inadequate. 
 
Diagnostic delay: Diagnostic delays are defined as delays between the collection of 
sputum and the processing of results. 
 
Action delay: Action delays are defined as delays between processing diagnostic results 
and recalling patients. 
 
Missed results: Missed results are defined as results that were never seen by HCWs at 
diagnosing and/or referral facilities. 
 
Centralised treatment initiation: In this study, centralised treatment is defined as 
hospital-level treatment initiation. 
 
Decentralised treatment initiation: In this study, decentralised treatment is 
defined as clinic-level treatment initiation. 
 
Coker et al. domains: In their conceptual framework for comparative analysis of 
communicable disease interventions, Cocker et al. define key domains for consideration, 
which include: 1) context, 2) epidemiological problem, 3) intervention, 4) output and 5) 
outcome. 
 
Context: A key domain of Coker et al.’s framework, context “denotes the political, 
legislative, social, economic and technical environments within which communicable 
disease control programmes sit” (Coker et al., 2010, p. i23). Context encompasses the local, 
regional and international environments in which the programme is operating, which may 




Epidemiological problem:  A key domain of Coker et al.’s framework, epidemiological 
problem “refers to infection levels and various diseases characteristics” (Coker et al. 2010, p. 
i23) that the health programme seeks to respond to. For this study, the epidemiological 
problem refers to large burden of DR-TB, coupled with high rates of HIV co-infection. The 
epidemiological problem also encompasses the low rate of treatment linkage, which drives 
onward transmission of DR-TB. 
 
Intervention: A key domain of Coker et al.’s framework, intervention refers to “the 
intervention intended to serve public health” which are generally “recommended through 
clinical and policy guidelines and are evidence-based, thus lending themselves to scrutiny 
against gold standards” (p. i23). The interventions of focus in this study are the Xpert rollout 
and the decentralisation of DR-TB services. 
 
Mechanisms: A key domain of Coker et al.’s framework, mechanisms refer to the 
“mechanism(s) by which interventions are delivered”, as such it encompasses the 
“mechanisms within a programme, required to function effectively” (Coker et al., 2010, p. 
i23). Coker et al. link mechanisms to the health system functions - representing the functions 
of the health system necessary to implement the intervention. 
 
Output: A key domain of Coker et al.’s framework, output refers to “public health concepts 
that can be measured or determined and include equity, acceptability, efficiency and 
effectiveness of the control programmes as a result of interventions” (p. i23). This study will 
use outputs of treatment linkage (expedited, delayed and non-initiation of treatment) as 
selection criteria for patients. 
 
Outcome: A key domain of Coker et al.’s framework, outcome refers to the impact of the 
intervention and health programme on the epidemiological problem, “such as reduced 
incidence of disease or decreased mortality” (p. i23). 
 
Patient: In this study, Coker et al.’s framework has been amended to include ‘patient’ as an 
additional key domain. This study has drawn from Shippee et al.’s (2012) model of patient 
complexity to define the patient domain. In this study, the patient domain encompasses 
factors arising from patients’ workloads and capacity as defined by Shippee et al. 
 
Patient workloads: Adopting Shippee et al.’s definition, patient workloads 
“encompasses all the demands in patients’ lives, including everyday responsibilities alongside 
the demands of patient-hood… includ[ing] job, family, travel/transportation, childcare, 
scheduling and attending clinical appointments” (p. 1042). 
 
Patient capacity: Adopting Shippee et al.’s definition, patient capacity “denotes the 
resources and limitations affecting patients’ ability or readiness to do [patient-related] work, 
such as mental/physical functioning, unpleasant symptoms… pain, stress, or fatigue… 
Capacity also encompasses socioeconomic and psychological resources, literacy, language, 




Dimensions of access: In their conceptual framework for measuring access, McIntyre et 
al. (2009) define 3 dimensions of access: availability, affordability and acceptability. 
 
Availability: Adopting McIntyre et al.’s (2009) definition, “availability is concerned with 
whether the appropriate health care providers or services are supplied in [the right manner] 
to meet the prevailing needs of the population” (p. 184) 
 
Affordability: Adopting McIntyre et al.’s (2009) definition, “affordability is concerned with 
the ‘degree of fit’ between the full costs to the individual of using the service and the 
individual’s ability to pay” (p. 186) 
 
Acceptability: Adopting McIntyre et el.’s (2009) definition, “acceptability is concerned 













CCW: Community care workers 
HCW: Healthcare worker 
DS-TB: Drug susceptible TB 
DR-TB: Drug resistant TB 
EDR: National electronic DR-TB registry 
KI: Key informant 
MDR-TB: Multidrug resistant TB 
RR-TB: Rifampicin resistant TB 
NDoH: National Department of Health 
NHLS: National Health Laboratory Services 
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Over the past decade, South Africa has witnessed an increasing burden of drug resistant (DR) 
tuberculosis (TB). Between 2004 and 2012, the number of laboratory diagnosed cases of 
multidrug-resistant (MDR) TB rose from 3,219 to 14,161. During this time, the number of 
extensively drug-resistant (XDR) TB cases rose from 85 to 1,545 (Ndjeka, 2013).  
South Africa’s efforts to curb DR-TB have historically been plagued by poor case 
detection and long delays to diagnosis and treatment initiation (Streicher et al., 2012). 
Seeking to improve case detection and linkage to treatment, the National Department of 
Health (NDoH) embarked on a national rollout of the Xpert MTB/RIF diagnostic tools during 
2011. Since March 2011, the NDoH has placed 284 testing machines in sites around the 
country and performed more than 2 million tests (NHLS, 2013, p. 3). 
However, as DR-TB case detection has improved, treatment rates have failed to keep 
pace - leading to a widening treatment gap. According to NDoH estimates, less than half of 
patients diagnosed with MDR-TB initiated treatment during 2012 in the Western Cape and 
nationally (Ndjeka, 2013).  
The study will use a qualitative, embedded case study approach to explore barriers 
and enablers to expedited treatment linkage following diagnosis of rifampicin resistant TB 
(RR-TB). RR-TB is a good marker of multi drug resistance as around 90% of patients that are 
resistant to rifampicin are also resistant to isoniazid and are therefore categorised as MDR. 
(Coovadia et al., 2013; Dlamini-Mvelase et al., 2014).  The case in this study is ‘linkage to 
treatment following RR-TB diagnosis in the Western Cape during the Xpert rollout and 
ongoing decentralisation of DR-TB services.’ The embedded units of analysis are patients’ 
treatment linkage outputs, defined as: expedited initiation of treatment, delayed initiation of 
5 
 
treatment and non-initiation of treatment following sputum collection on which RR-TB was 
diagnosed.  
Thirty six RR-TB patients diagnosed between January and March 2013 in the Western 
Cape will be purposively sampled as data sources for the embedded units. Although, 
additional patients may be sampled to achieve data saturation. Patients that initiated 
treatment within one month of sputum collection on which RR-TB was diagnosed will be 
categorised as expedited initiators. Patients that initiated treatment more than one month 
and less than six months after sputum collection on which RR-TB was diagnosed will be 
categorised as delayed initiators. Finally, patients that did not start treatment within 6 
months of sputum collection on which RR-TB was diagnosed will be categorised as non-
initiators. 
Each sample patient’s journey will be investigated through a combination of patient 
record review and multiple perspective interviews. Multiple perspective interviews will be 
conducted with patients, their family members and healthcare workers. Additional key 
informants may also be identified and interviewed during the research period.  A framework 
approach, using Coker et al.’s (2010) conceptual framework for evaluation of communicable 
disease interventions in the health system, will be applied to analyse data.  
Purpose of the study 
The aim of this study is to investigate why patients diagnosed with DR-TB in the Western Cape 
frequently fail to link to timely treatment. Seeking to understand this phenomenon, the study 
will explore barriers and enablers to expedited treatment linkage following RR-TB diagnosis 
in the Western Cape. The study will explore how health system, contextual and patient 
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factors, and the interactions between these factors, contribute to: 1) expedited initiation of 
treatment, 2) delayed initiation of treatment and 3) non-initiation of treatment. 
Background 
Xpert rollout 
Historically, South Africa’s efforts to curb and treat DR-TB have been hampered by poor case 
detection (MSF, 2011), as well as delayed diagnosis and initiation onto treatment (NDoH, 
2011b). Recent studies in KwaZulu-Natal revealed delays ranging between 72 and 93 days 
between the collection of sputum and initiation of MDR-TB treatment  (Loveday et al., 2013; 
Narasimooloo & Ross, 2012).  Troublingly, two studies in South Africa found that over a third 
of MDR-TB patients died prior to receiving their test results  (Gandhi et al., 2010; Heller et al., 
2010). 
During 2011, the NDoH embarked on a national rollout of Xpert MTB/RIF diagnostic 
tools in an effort to improve DR-TB case detection and reduce diagnostic turn-around times 
(NDoH, 2011a). The Xpert MTB/RIF is an automated diagnostic tool that achieves more 
sensitive and accurate diagnosis of TB than traditional smear microscopy, particularly 
amongst patients co-infected with HIV (Menzies et al., 2012). The Xpert is also able to detect 
rifampicin resistance in less than two hours (Menzies et al., 2012), allowing for early 
treatment initiation. Patients that are resistant to both rifampicin and isoniazid are 
categorised as multidrug resistant (MDR-TB). Patients that are resistant to rifampicin, 
isoniazid, any fluoroquinolone and at least one injectable second-line TB drug are categorised 
as extensively drug resistant (XDR-TB) (WHO, 2008).  
Following the Xpert rollout, a large increase in the number of patients diagnosed with 
MDR-TB (Ndjeka, 2013)  and a reduction in diagnostic turn-around time has been observed  
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(Claassens et al., 2013; Naidoo et al., 2013; Niekerk et al., 2013). According to NDoH figures, 
a 48% increase in the number of laboratory confirmed MDR-TB cases was observed between 
2010 and 2012. However, during the same period, the percentage of laboratory diagnosed 
MDR-TB patients that are reported to have not started treatment increased from 28% to 54% 
(Ndjeka, 2013).  
While these figures may be subject to some error due to problems with the NDoH 
monitoring and evaluation systems (Rose et al., 2013), they highlight a widening gap between 
the number of patients diagnosed with DR-TB versus those initiated onto treatment. The 
health system’s failure to link DR-TB patients to timely treatment is not only harmful to the 
health of patients, but also to the wider community, as delayed treatment significantly 
contributes to a patients’ risks of onward transmission of DR-TB (Cox et al., 2010; Ebonwu et 
al., 2013). 
 
2011 Decentralisation guidelines 
The 2011 national Xpert rollout was not introduced within a static DR-TB programme or 
health system. Rather, the rollout was coupled with the adoption  of national guidelines for 
the decentralisation of MDR-TB treatment (NDoH, 2011b).  The 2011 MDR-TB 
decentralisation guidelines recommend that sputum smear-negative MDR-TB patients and 
patients that refuse hospitalisation are initiated onto out-patient treatment - recognising that 
traditional, centralised hospital sites are  increasingly unable to accommodate the rising 
number of patients with MDR-TB (NDoH, 2011b).To date, there have been few evaluations of 
the extent to which the decentralisation guidelines have been successfully implemented 
across the country. However, a recent article described implementation of MDR-TB treatment 
decentralisation across provinces as ‘patchy’ (Besada, 2013). 
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Western Cape context 
Incidence of drug susceptible TB in the Western Cape falls amongst the highest in the world 
(Western Cape Goverment, 2012). The province also faces a high burden of DR-TB. Between 
2004 and 2012, 22% of the laboratory confirmed MDR-TB cases detected in South Africa were 
in the Western Cape (Ndjeka, 2013) - although this is likely due in part to better detection 
rates than other provinces in the country.  
Importantly, within high burden communities, direct transmission, rather than 
acquired resistance, is becoming the main driver of new DR-TB infections in the Western Cape 
(Cox et al., 2010). Onward transmission of DR-TB is exacerbated by a combination of poor 
case detection and late diagnosis and initiation onto treatment (Cox et al., 2010). 
Previous research in Khayelitsha, Western Cape has shown that reduced times to 
treatment can be achieved through decentralising care (MSF, 2011). In line with this evidence, 
the Western Cape Department of Health has begun to decentralise DR-TB care in the province 
- although access to decentralised, clinic-level care remains varied across the Western Cape’s 
six districts. Around 80% of patients initiated onto MDR-TB treatment in the urban City of 
Cape Town during 2013 were initiated at clinics, whereas less than half of patients initiated 





Patients commonly face barriers and delays prior to diagnosis  and initiating treatment 
(Jacobson et al., 2013; Naidoo et al., 2013). Previous studies have demonstrated that linkage 
barriers may occur at many stages along the pathway to care for DR-TB patients. 
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A 2013 Gauteng cohort study demonstrated that patients’ location of diagnosis impacts on 
linkage to treatment. Patients referred to treatment from clinics were eight times more likely 
to initiate treatment than patients referred from hospitals. The authors speculated that this 
may be due to better systems at a clinic level for following up with newly diagnosed patients 
(Ebonwu et al., 2013). 
The initiation of DR-TB treatment at centralised versus decentralised sites further 
impacts on linkage to treatment. During 2011, Médecins Sans Frontières reported that the 
decentralisation of MDR-TB care in Khayelitsha improved rates of treatment initiation and 
reduced time to treatment (MSF, 2011). Similarly, a comparative study in KwaZulu-Natal 
demonstrated shorter times to treatment amongst patients initiated onto treatment at 
decentralised sites versus patients that initiated treatment at the centralised hospital 
(Loveday et al., 2012).  
Shortages of beds at centralised sites commonly contribute to linkage delays. 
According to the NDoH, “waiting lists for patients [who] need to be admitted to centralised 
units are long, delaying the initiation of treatment in some provinces for three or four months. 
In addition, several patients die before starting treatment” (NDoH, 2011b, p. 5). Similarly, 
Jacobson et al. (2013) found that poor clinical infrastructure and a shortage of beds contribute 
to treatment delays at Brewelskloof Hospital in the Western Cape. 
However, while available evidence demonstrates that decentralisation improves 
linkage to treatment, many areas face challenges in implementing decentralised care. 
Challenges within Western Cape’s rural districts include patients’ preferences for in-patient 
treatment given difficulties in accessing decentralised sites daily and perceptions of better 
support at hospitals (Theron, 2013).  
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Surprisingly, given evidence that decentralisation improves linkage, a recent KwaZulu-Natal 
study did not identify an association between time to treatment and the distance that 
patients travel between diagnosing and treatment initiating facilities (Smith et al., 2013) - 
although this may be due to inadequate decentralisation to date. Further research is needed 
to investigate how costs of, and access to, transport impacts on linkage to treatment. 
Shortages of healthcare workers may further encumber linkage to treatment. To 
address this, the NDoH has identified the need for nurse initiated and managed MDR-TB care 
(NDoH, 2011b),  although this has not been implemented to date. Amongst healthcare 
workers providing MDR-TB care, inadequate training and confusion regarding DR-TB 
diagnostic and treatment algorithms further exacerbate treatment delays (Bamford & 
Taljaard, 2010; Farley et al., 2012). 
Along with health facility factors, multiple overlapping patient factors influence 
linkage to treatment. A recent qualitative study in Cape Town found that patients may miss 
appointments due to family, financial and employment responsibilities (Niekerk et al., 2013). 
Similarly, according to the NDoH, patient’s household responsibilities may contribute to 
treatment delays amongst patients referred to centralised services (NDoH, 2011b). For 
patients that take care of young children in single headed households, initiating in-patient 
treatment may not be feasible. Importantly, a study in the KwaZulu-Natal found that 70% of 
MDR-TB patients’ households were headed by females (Marra, 2009). 
A recent cohort study of MDR-TB patients in Gauteng found that patients that were 
previously treated for TB or co-infected with HIV face significantly higher risks of linkage 
failure. The study also found that patients’ places of residency significantly influence their 
risks of linkage failure. Reasons for non-initiation onto treatment identified in the study 
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included: death (31.2%), loss to follow up (19.8%), refusal (2.6%), or not being traceable 
(46.4%) (Ebonwu et al., 2013). 
Finally, a systematic review of studies examining diagnostic and treatment delays 
amongst patients with drug susceptible TB found that poor perceptions of public sector care, 
substance abuse, education, stigma, beliefs and migrancy influence linkage to treatment. 
Similar factors have been identified as contributing to MDR-TB treatment default in South 




Given the complex nature of health systems, the Alliance for Health Policy and System 
Research and the World Health Organization recommend the use of a conceptual framework 
when undertaking health systems research (Gilson, 2012). The use of a conceptual framework 
can be employed to navigate and identify the ‘complex casual pathways’ that influence the 
outcome of an intervention. The framework can be used to generate hypotheses, organise 
data and generate explanations for the phenomenon of investigation  (Gilson, 2012).  
This study will draw on a conceptual framework developed by Coker et al. (2010) in 
order to allow for comparative analyses of the health systems’ effectiveness in implementing 
interventions to combat communicable diseases. Coker et al. employed the framework in 
undertaking a cross-country analysis of integration of HIV and TB programmes. The 
framework has since been adapted to undertake a country analysis of HIV and TB integration 
in South Africa ( Loveday & Zweigenthal, 2011).  
Coker et al.’s framework allows for investigation into a complex array of overlapping 
factors that influence a patient’s journey through the health system and whether or not the 
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patient is linked to the appropriate treatment. The five critical domains for analysis identified 
within the framework include: context, epidemiological problem, intervention, mechanisms 
(for implementation of the intervention), output and outcome. For the purposes of this study, 
the framework has been amended to investigate critical factors that may impede or facilitate 
DR-TB patients’ pathways to treatment. 
 
Table 1. Amended Coker et al. (2010) framework 
 
Domain Health system and patient related factors 
Context Urban versus rural location 
Economic and socio-demographic context 
Community knowledge, attitudes and beliefs 
Patient’s household and employment responsibilities 
Leadership – national, provincial, district, facility 
Location and provincial support 
Staff motivation and attitudes 
Epidemiological problem Incidence of MDR and XDR-TB 
MDR and DR-TB related morbidity and mortality 
Intervention National Xpert rollout – access to Xpert testing tools 
Decentralisation of MDR-TB sites and treatment – access to 
decentralised versus centralised treatment 
Rapid initiation of rifampicin resistant patients onto 
treatment 
Mechanisms Diagnostic tools 
Medicines 
Information systems 





Output Accessibility of care 
Quality and acceptability of care 
Outcome Expedited initiation of treatment 
Delayed initiation of treatment 






It is anticipated that numerous, overlapping health system factors contributing to linkage 
barriers will be identified in this study – as seen in previous linkage literature. However, with 
the recent adoption of decentralisation guidelines in South Africa, it is hypothesised that: 1) 
level of decentralisation, 2) location of care, 3) availability of transport, and 4) living in an 




The study will use a qualitative, embedded case study approach in order to explore how 
health system, contextual and patients factors, and the interactions between these factors, 
impact on linkage to treatment. The case in this study is ‘linkage to treatment following RR-
TB diagnosis in the Western Cape during the Xpert rollout and decentralisation of DR-TB 
services’. Embedded units of analysis are patients linkage to treatment outputs, defined as: 
expedited treatment initiation, delayed treatment initiation and non-initiation of treatment. 
Thirty six patients will be purposively sampled to explore as data sources for the embedded 
units. Additional patients in each embedded unit may be sampled to achieve data saturation.  
Each purposively sampled patient’s journey will be mapped out through reviewing 
their medical records and conducting multiple perspective interviews with the patient, a 
family member of the patient and a healthcare worker that provided care to the patient 
between RR-TB diagnosis and treatment initiation. Interviews with additional key informants 
may also be conducted in order to achieve data saturation. Comparative analysis of 
embedded units will be performed in order to draw out explanations regarding why many RR-
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TB patients fail to initiate treatment or experience delays in linking to treatment following 
diagnosis. 
 
Characteristics of the study population 
Patient selection criteria 
Thirty six patients will be purposively sampled whose experiences following diagnosis will be 
examined in-depth. Sample patients will be selected from a larger cohort of patients 
identified in the national ‘Linkage to care for drug resistant TB following Xpert 
implementation in South Africa’ study (hereafter referred to as ‘the National Linkage Study’). 
The cohort from the National Linkage Study includes all of the patients that were 
diagnosed with RR-TB in the Western Cape between January and March 2013. As part of the 
National Linkage Study, each of these patients will be defined as expedited initiators, delayed 
initiators or non-initiators. The 36 sample patients selected for this study will include, 12 
‘expedited initiators’, 12 ‘delayed initiators’ and 12 ‘non-initiators’.  
It is anticipated that some patients in the National Linkage Study cohort may have 
subsequently died. Patients that have died will not be excluded from being sampled, as their 
journeys may provide important insight regarding the barriers that patients face in linking to 
treatment. In the event that sample patients have subsequently died, their journeys will be 
investigated using record review and interviews with family members and healthcare 
workers.  
Amongst expedited and delayed initiators, it is also anticipated that some of these 
patients will have defaulted from treatment, given the high rates of DR-TB treatment default 
in the country (Holtz et al., 2006). Both treatment defaulters and patients retained in care will 
be eligible to be sampled. However, for sample patients that are retained in care, effort will 
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be made to select patients that are retained in care within one of the study districts and 
facilities to allow for in-person interviews. This will be done through reviewing their recent 
NHLS records to determine where their most recent tests were performed. This data is 
available for the National Linkage Study cohort. 
A similar proportion of male and female patients will be selected in order to explore 
how gender impacts on linkage to treatment. Within each gender group, effort will also be 
made to select patients with a wide age range - representative of the age range seen in the 
National Linkage Study cohort - in order to explore how age influences linkage to treatment. 
Patients under 18 will be excluded given the complexity involved in securing their informed 
consent to participate in the study. 
 
District and facility selection criteria 
 
Figure 1: Western Cape districts 
 
With the decentralisation of DR-TB treatment to a primary care level, districts play an 
increasingly important role in linking patients to treatment (NDoH, 2011b). Sample patients 
for this study will be selected from 3 districts – the Cape Town metro, the Cape Winelands 
and the West Coast. Each of these districts has been selected as a ‘study district’ due to 
characteristics of interest.  
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  The Cape Town metro has been selected as the only urban district within the Western 
Cape (Western Cape Goverment, 2012b). The district has spearheaded decentralised DR-TB 
care in the province, initiating approximately 80% of MDR-TB patients onto treatment at a 
primary level during 2013 (Caldwell, 2013). 
The Cape Winelands district has been selected as a rural district with low rates of 
decentralised care. Similarly to the  Eden and Central Karoo districts, only around 5% of MDR-
TB patients diagnosed in Cape Winelands East initiated treatment at a primary care level 
during  2013 (Theron, 2013). Finally, the West Coast district has been selected given its 
relative success in implementing decentralised care in comparison to the other rural districts 
in the province. Within the West Coast district, approximately 40 – 50% of MDR patients are 
initiated onto treatment at a primary level (Theron, 2013). 
 
Table 2: Sampling strategy by district and treatment linkage outputs 
 Cape Town metro Cape Winelands West Coast Total 
Expedited 
initiators 
4 4 4 12 
Delayed initiators 4 4 4 12 
Non-initiators 
 
4 4 4 12 
Total 12 12 12 36 
 
Finally, patients may be sampled due to convenience. In other words, a few sample patients 
may be chosen from a single facility in order to avoid the need to visit a different facility for 
each sample patient and to ensure that the study is feasible within available time and 
resources. Sample patients will be selected from a maximum of seven facilities within each 
district. 
These seven ‘study facilities’ per district may be primary level clinics, community health 
centres or hospitals. These facilities should include the facilities where sample patients were 
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diagnosed, as well as the facilities where patients were initiated onto treatment (when 
relevant). Additional selection criteria may be clarified once the data from the National 
Linkage Cohort is reviewed. Additional selection criteria to be reviewed include: 
- Initiation of treatment at a clinic versus a hospital 
- Distance between the diagnosing and treatment initiating site. 
Inclusion criteria 
- Part of the National Linkage Study cohort 
- Diagnosed and/or initiated onto treatment in the Cape Town metro, Cape Winelands 
or West Coast district 
- Diagnosed and/or initiated onto treatment within one of five facilities per district 
- Male or female 
- Over 18 years old 
Exclusion criteria 
- Under 18 years old 
 
Research procedures and data collection methods 
Patient record review 
Following the identification of sample patients in each district, the facilities that diagnosed 
each sample patient and/or initiated treatment (if relevant) will be visited in order to review 
each patient’s medical records. It is anticipated that reviewing the records of sample patients 
will provide important insight regarding why patients did or did not initiate treatment and/or 
experience a delay in initiating treatment following diagnosis.  
A recent study in KwaZulu-Natal demonstrated the richness of data that may be 
extracted from the medical records of patients with DR-TB.  Loveday et al. (2013) identified 
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numerous barriers that patients face in accessing DR-TB treatment through reviewing clinical 
notes in medical records – including descriptions of missed appointments due to lack of 
transport, health facility strikes and medicine stock-outs. A limitation of this method is that 
the availability of clinical notes in medical records will likely be inconsistent. In reviewing 1549 
patient records in KwaZulu-Natal, Loveday et al. found that clinical notes were missing from 
approximately 15% of records. 
 
Multiple perspective interviews 
Data on sample patients’ journeys following RR-TB diagnosis will also be collected through 
undertaking open-ended interviews with patients, their family members and healthcare 
workers. This approach, known as multiple perspective interviews, involves the triangulation 
of data from multiple sources regarding one patient’s journey. The use of multiple perspective 
interviews allows for a deeper exploration of the factors that influence linkage to treatment 
than individual perspective interviews (Kendall et al., 2009).  
Multiple perspective interviews are recommended in researching childhood illnesses 
and palliative care (Kendall et al., 2009). In the case of DR-TB, multiple perspective interviews 
are particularly valuable for exploring patients’ journeys following diagnosis, as some sample 
patients may have died, or may no longer be traceable.  
For sample patients that can be traced, interviews will be requested with the patient 
and a family member (or alternate carer) nominated by the patient. Interviews will also be 
requested with the healthcare worker (or healthcare workers) responsible for the patient’s 
care. 
For sample patients that have died or cannot be traced, interviews will be requested 
with the healthcare worker (or healthcare workers) responsible for the patient’s care.  An 
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interview will also be requested with the patient’s emergency contact and/or an alternate 
family member nominated by the emergency contact. This method of enquiry is similar to 
conducting ‘verbal autopsies’, which are recommended by the World Health Organization 
when investigating the cause of death in patients where mortality records are unavailable 
(WHO, 2012). However, in this study the tactic will investigate patients’ experiences leading 
up to death, rather than cause of death.   
Finally, patients and family members that consent to be interviewed will be given the 
opportunity to be interviewed together or separately. Sakellariou et al.(2013) and Kendall et 
al. (2009) recommend that patients and their family members decide whether or not to be 
interviewed together, and highlight that joint interviews can provide richer data than 
individual interviews, as participants may build on each other’s explanations to provide a 
more detailed narrative. Similarly, in the case that more than one healthcare worker provided 
care to a sample patient in the diagnosing or treatment initiating facility, then the healthcare 
workers will be given the opportunity to be interviewed jointly or individually. 
 
Key informant interviews 
Within each district, additional interviews may be conducted with key informants that are 
able to provide additional insight regarding the factors that impede or enable linkage to 
treatment in each district. A flexible approach will be used to identify and recruit key 
informants during the research process, with the aim of achieving data saturation. Key 
informants may include district heads of DR-TB services or alternate individuals responsible 





The date, time and location of interviews will be arranged over the phone (see recruitment 
procedures below). For the most part all of the interviews will be conducted with two 
interviewers present – the principle researcher, as well as an Afrikaans and Xhosa speaking 
interviewer. Each interview will be conducted in the interviewee’s language of preference.  
Semi-structured, open-ended interview guides will be used to guide the interviews. 
Open-ended questions will be used to draw out interviewees perceptions regarding why 
sample patients did or did not initiate treatment and/or experience a delay. However, as the 
study is exploratory, the interviewers will not be limited to questions in the guides. The 
interviewers will be trained to ask probing questions to gain more detail regarding 
interviewees’ responses and to ask reflexive questions in response to new issues that emerge. 
All of the interviews will last approximately 30 minutes and will be recorded and 
transcribed. Field notes will also be recorded after each interview in order to recall 
observations made during the interviews. 
 
Recruitment, enrolment and data collection strategy 
A phased, multi-step approach will be used in order to identify and recruit healthcare workers, 
patients and their family members to the study.  While the multi-step approach adds 
complexity to the study design it has been selected in order to minimise harm to sample 
patients and their families. 
 
Step 1: Visit diagnosing and treatment initiating facilities to review patient records 
Following the identification of sample patients from the National Linkage Study cohort, the 
facilities that diagnosed and initiated treatment (when relevant) for each sample patient will 
be visited. The sequencing of facility visits will be arranged for convenience. 
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Upon visiting the diagnosing and treatment initiating facilities, each sample patient’s records 
will be reviewed. Clinical notes relevant to why the patient did or did not initiate treatment 
and/or experience a delay will be extracted by manually copying the clinical notes into the 
data extraction form. Extracted clinical notes will be stored under a unique patient identifier 
code. 
 
Step 2: Identify healthcare workers responsible for sample patients’ care and request 
interviews 
 
During initial facility visits, the primary healthcare worker (doctor or nurse) responsible for 
providing care to the sample patient will be identified through reviewing the patient’s records 
and discussing the patient case with the TB-room/unit manager.  
- In the event that the patient never initiated treatment, then the healthcare worker 
identified as responsible for the patient’s care at the diagnosing facility will be 
requested to consent to be interviewed. (1 interview to be conducted) 
- In the event that the patient was diagnosed and initiated treatment at the same 
facility, an interview will be requested with the healthcare workers identified as 
responsible for the patient’s care. (1 interview to be conducted) 
- In the event that the patient was diagnosed in one facility and initiated treatment in 
another, then an interview will be requested with the healthcare workers identified 
as responsible for the patient’s care at both the diagnosing and treatment initiating 
facilities. (2 interviews to be conducted). 
While the study researchers will seek to identify and interview the primary doctor or nurse 
responsible for the patient’s care at each facility, additional interviews may be conducted if it 
becomes apparent that additional healthcare workers are able to provide further insight 
regarding the sample patient (I.e. assistant nurses, counsellors, community health workers). 
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Additional interviews may be conducted to achieve ‘data saturation’, which is a central goal 
of qualitative research. Data saturation is concerned with collecting adequate data in order 
to generate theory that is balanced and without gaps regarding the phenomenon of 
investigation (Given & Saumure, 2008). 
 
Step 3: Categorising sample patients for follow up 
After reviewing data from the National Linkage Study cohort data, reviewing patients’ records 
and conducting interviews with healthcare workers, sample patients will be categorised as: 
- ‘Known to be alive’ 
-  ‘Known to be dead’ 
- ‘Circumstances unknown’ 
Patients that are known to be alive will be further defined as ‘Retained in care’, ‘Defaulted 
care‘, or ‘Never initiated care’. 
 
Step 4: Locating potential participants and requesting their consent to be contacted and 
participation in the study 
 
The approach to requesting consent from sample patients – or their emergency contacts in 
the event that sample patients have died or cannot be traced – will be guided by the category 
in which each patient falls. 
Locating patients that are ‘known to be alive’ and ’retained in care’ and requesting their 
consent to be contacted 
 
Given the study selection criteria, patients retained in care should be receiving treatment 
from one of the seven ‘study facilities’ per district. Under these circumstances, the doctor or 
nurse currently overseeing the patient’s care will be identified at the facility and asked to 
request consent from the patient to be contacted by study researchers. 
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If sample patients are currently receiving treatment at a facility outside of the ‘study facilities’, 
the doctor or nurse that initiated the patient onto treatment will be asked to contact the 
patient via telephone to request their consent to be contacted via by the study researchers. 
The feasibility of conducting in-person interviews with these patients will be judged on a case 
by case basis, taking into account the location of where they are currently receiving 
treatment.  
Locating patient that are ‘known to be alive’, yet not retained in care and requesting their 
consent to be contacted 
 
Healthcare workers will also be asked to attempt to contact patients that are defined as 
‘known to be alive’, yet never initiated or defaulted treatment, as well as patients defined as 
‘circumstances unknown’. The healthcare worker responsible for the patient’s care at the 
diagnosing facility will be asked to contact the sample patient to request their consent to be 
contacted by study researchers. 
In the event that a patient cannot be located, then the healthcare workers will be 
asked to contact the sample patient’s emergency contact to request updated contact 
information for the patient. If the emergency contact is able to provide updated contact 
information, then a second attempt should be made to contact patients to request their 
consent to be contacted by study researchers.  
If the emergency contact is unable to provide updated information for the patient, 
then the healthcare worker should request consent from the emergency contact to be 
contacted by study researchers. 
Contacting patients that provide consent to be contacted and identifying relevant family 
members 
 
Patients that provide consent to be contacted by the study researchers will be contacted via 
telephone. Effort will be made to contact patients in their first language, as identified by the 
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health facility. Upon contacting patients, a standard script will be used by study researchers 
to request their participation in the study.  
Patients that agree to participate in the study will be asked to nominate a family 
member (or alternate carer) whose participation in the study may be requested. Patients that 
nominate a family member will be asked to contact the nominated family member to discuss 
their participation in the study. A follow up call will be arranged to clarify whether the family 
members is willing to participate in the study and to obtain his/her contact details. 
Locating family members of patients that cannot be traced or have died 
In the event that a patient cannot be traced or has died, then the responsible healthcare 
worker at the diagnosing facility will be asked to contact the patient’s emergency contact to 
request their consent to be contacted by study researchers. 
Emergency contacts that provide consent to be contacted will be contacted via 
telephone by the study researchers. A standard script will be used to explain the purpose of 
the study and effort will be made to contact emergency contacts in their first language. The 
emergency contact will be asked to consent to be interviewed or to nominate another family 
member that may be contacted to participate in the study.  
In the case that patients have died or cannot be traced, the emergency contact or 
nominated family member may choose to be interviewed on his/her own or together with 
another family member that is able to provide additional insight.  
 
Data safety and monitoring 
A study database will be developed and housed by the University of Cape Town’s Department 
of Medical Microbiology. Data for this study will be catalogued as a sub-study housed within 
the secure database developed for the national ‘Linkage to care for drug resistant TB following 
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Xpert implementation in South Africa’ study. The National Linkage Study has hired a data 
manager in order to oversee issues of data security. The database will be securely password 
protected and only authorised staff members will have access to it. 
Audio recordings and transcriptions of interviews will be stored in the study database. 
Interview recordings will be uploaded to the study database as soon as possible after the 
interview and deleted from the audio recording device. In the case that access to the study 
data is requested by researchers outside of the study, access to audio recordings will not be 
granted. Access to interview transcripts may be granted to other researchers solely for 
research purposes. All names and other identifiable information will be extracted from the 
transcripts, which will be stored under unique identifier codes. 
The database will also store data collected from medical records. This data will be 
extracted manually from medical records into data extraction forms. Each form will be given 
a unique identifier code and no names or other identifiable information will be extracted from 
records or recorded on the data extraction forms. Data collected using extraction forms will 
be uploaded to the study database as soon as possible following facility visits and the forms 
will be destroyed. 
 
Data analysis 
The transcripts of open-ended interviews and clinical notes extracted from records will be 
coded and categorised using NVivo software. Initially, deductive coding will be done, using 
pre-defined codes and categories drawn out of the themes identified in the conceptual 
framework. New codes and categories will be created for new themes that emerge from the 
data and fall outside of pre-existing themes in the conceptual framework. Below is a visual 
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depiction of how data will be summarised following interviews in order to facilitate individual 
analysis. 
 Record review 
at diagnosing 
site 
Record review at 
treatment 
initiating site 











Expedited initiators: Patients 1 – 12 
 
Patient 1 × √ √ × √ √ 
Details Records could 
not be located 
Records reviewed Patient 
interviewed 
Family member 






Patient 2 … … … … … … 
Patient 3 … … … … … … 
 
Delayed initiators: Patients 13 – 24 
 
Patient 13 √ √ √ √ √ × 
Details Records 
reviewed 















Patient 14 … … … … … … 
Patient 15 … … … … … … 
 
Non-initiators: Patients 25 - 36 
 
Patient 25 √ Not relevant × √ √ Not relevant 
Details Records 
reviewed 






Patient  26 … … … … … … 
Total       
 
Initially, data collected for each sample patient will be analysed in order to develop narrative 
descriptions of each patient’s journeys and to identify why individual patients did or did not 
initiate treatment and/or experience delays. It is anticipated that both agreements and 
contradictions will emerge from the multiple perspective interviews. However the aim of this 
study is not to rank the ‘accuracy’ or ‘importance’ of narratives from different sources. Rather 
it seeks to develop a fuller picture of each patient’s experience, as well as illuminate where 
contradictions and agreements exist.  
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After the data for each sample patient is analysed individually, comparative analysis of 
embedded units will be performed in order to draw out explanations and develop theories 
regarding the main factors that influence linkage to treatment. Sample patients will be 
grouped and compared across embedded units (i.e. expedited initiators, delayed initiators 
and non-initiators). Below is a visual summary of how data will be summarised for 
comparative analysis across embedded units. 










Validity and reliability 
In seeking to establish validity in qualitative research, it is necessary to establish the trust-
worthiness of the data analysis process and the findings drawn from this process. This is 
necessary to prevent any subjective biases of the researcher from entering the study’s 
conclusions, as well as to ensure that any causal conclusions drawn from the data are based 
on logical and replicable processes.  
Expedited initiators - 12 patients 
- X patient record reviews (at diagnosing and 
treatment initiating facilities) 
- X healthcare worker interviews   
(at diagnosing and treatment initiating facilities) 
- X patient interviews 




Delayed initiators – 12 patients 
 
- X patient record reviews (at diagnosing and 
treatment initiating facilities) 
- X healthcare worker interviews (at diagnosing 
and treatment initiating facilities) 
- X patient interviews 
- X family member interviews 
 
Non-initiators – 12 patients 
 
- X patient record reviews (at diagnosing facility) 
- X healthcare worker interviews 
(at diagnosing facility) 
- X patient interviews 






Gilson (2012) and Yin (2014) recommend a number of strategies in order to establish validity 
when undertaking qualitative research, including using an established framework or theory 
to guide the data analysis process. In this study, analysis of the study data will be guided by 
the Coker et al.’s (2010) framework for investigation of health systems interventions for 
communicable diseases. Along with the use of theory, triangulation of data, peer review and 
field notes will be used during data analysis in order to strengthen the validity of the study’s 
findings. 
Triangulation of data involves using more than one source of data in order to increase 
the trustworthiness of the study’s findings. Data collected from patient records and multiple 
perspective interviews will be triangulated in order to develop explanations regarding why 
linkage delays did or did not occur for individual patients. However, for the purposes of this 
study, data triangulation will not be used to establish the accuracy of interview narratives. 
Rather triangulation will be used to identify where concordance and contradictions emerge 
in order to strengthen the study’s findings or identify alternate explanations. 
Peer review of the data analysis methods, as well as conclusions drawn from the data 
will be used to further protect against bias. Peer researchers involved in collaborating 
quantitative and qualitative studies (see Collaboration) will be requested to review the 
study’s data and provide input into conclusions drawn out of the data. Review of the study’s 
findings will also be undertaken by my dissertation supervisors. 
Finally, field notes will be drafted after each interview to record observations made 
during the interview process. Field notes are a useful tool for recalling and making sense of 
data during the later stage of data analysis. Furthermore, drafting of field notes during the 




Along with validity, establishing reliability is a concern that must be addressed in conducting 
qualitative research. Yin (2014) explains that reliability in qualitative research is concerned 
with the internal reliability of the study’s findings and whether the findings would be 
reproduced if the study was repeated. As recommended by Yin and Gilson (2012), an audit 
trail will be developed and stored in order to strengthen the reliability of the study’s results 
through allowing the study design, data, methods and conclusions to be audited if requested. 
A study database will be developed and housed within UCT’s Department of Medical 
Microbiology. All the data extracted from patient records and interview transcripts will be 
stored in the database.  
 
Limitations 
A limitation of this study is that a number of patients may have died, may not be traced or 
may no longer be located within a study district. For most of these patients, it will not be 
possible to conduct a patient interview. Another limitation of this study is that clinical notes 
in patient records will not be consistent (Loveday et al., 2013). An additional limitation of the 
study is that recall bias may be present in some of the interview narratives. Some recall bias 
is anticipated given that the sample patients were diagnosed in early 2013.  
Finally, for the purposes of this study, interviewers speaking English, Afrikaans and 
Xhosa will be hired. Patients and family members that do not speak one of these three 
languages will not be interviewed. However, given that these are the main languages spoken 
within the province, it is anticipated that few (if any) potential participants will not speak one 




Description of risks and benefits/ Reimbursement for participation 
Risks and benefits to participants 
 
The main benefit to individual participants will be the receipt of a R100 Shoprite voucher and 
refreshments during the interview. Additionally, participants that travelled away from home 
to participate in the study will be reimbursed for their transport costs up to R50. 
Patients that have defaulted from DR-TB treatment or never initiated treatment will 
be encouraged to return to care through a brief treatment literacy session that will conducted 
by the interviewer after the interview. All participants will also be provided with a simple 
treatment literacy booklet explaining the importance of adhering to and completing DR-TB 
treatment in order to protect one’s own health and prevent onward transmission.  
The study will seek to prevent any personal, social or professional repercussions by 
ensuring that the identities of all participants remain confidential through removing their 
names and any other identifiable information from study reports and papers.  The names of 
primary clinics will also be removed to ensure that participants, and particularly healthcare 
workers, may not be identified through study reports and papers. 
Another potential risk to healthcare workers and the surrounding community is that 
the visits to facilities by study researchers may disrupt normal service functioning. The study 
will seek to minimise any disruption through communicating with facilities prior to visits in 
order to identify the most convenient and least disruptive times to conduct visits.  
A further risk to participants is that their participation may evoke emotional anxiety 
or grief, as participating in the interview may raise difficult and painful memories.  Careful 
efforts will be taken to minimise and properly address this risk, particularly when carrying out 
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interviews with family members or carers of patients that have died. This study will draw from 
the ethical standards recommended when conducting verbal autopsies with family members 
of patients that have died. 
A key ethical consideration in conducting verbal autopsies is the training of the interviewers 
that are present during the interview. It is recommended that interviewers receive 
counselling training prior to undertaking interviews (Chandramohan et al., 2005).This is both 
to avoid causing distress, as well as to appropriately respond to distress that arises. The 
interviewers that conduct interviews for this study will undertake a short course in counselling 
prior to conducting the interviews. Furthermore all participants will be provided with a 
counselling card listing toll-free numbers that provide counselling and support, including: 
The National AIDS Helpline (also provides TB assistance)   0800 012 322 
The Depression and Mental Health Helpline    0800 567 567 
The Social Grants Helpline      0800601011 
The National HIV & TB Health Care Workers Hotline   0800 212 506 
Lifeline          0861 322 322 
 
Risks and benefits to interviewers 
 
Another ethical consideration of this study is the risk to interviewers of contracting DR-TB 
during the interview process. Effort will be taken to minimise this risk by ensuring that 
infection control procedures are in place during interviews with DR-TB patients. Whenever 
possible, interviews will be conducted outside. According to the WHO, the risk of contracting 
tuberculosis when outdoors is very low (WHO, 2012). In the event that interviews with 
patients cannot be conducted outside, the interviewers will wear N95 respirators during 
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interviews. Patients and their family members will also be given the option to wear N95 
respirators during interviews. 
 
Informed consent process 
Consent will be obtained through a multi-stage process. Prior to contacting patients or their 
emergency contacts to request their participation in the study, consent must be obtained 
from the patient or emergency contact to be contacted by study researchers. Healthcare 
workers responsible for sample patients’ care will be asked to contact sample patients and/or 
their emergency contacts to request their consent to be contacted by study researchers. 
Patients and emergency contacts that provide consent to be contacted by study researchers 
will be asked to assist in identifying family members or alternate carers that may also be 
contacted to request their participation in the study.  
Upon meeting potential participants to conduct in-person interviews, written consent 
must be obtained. Prior to requesting written consent, interviewers will read through the 
consent forms in potential participants’ language of preference. The informed consent forms 
explain the purpose of the study, the rights of potential participants to decline participation 
at any point during interviews and the rights of participants to decline to respond to any 
specific questions. The informed consent forms will be available in English, Afrikaans and 
Xhosa. Potential participants must demonstrate their understanding of the informed consent 
form by responding to a number of questions at the end of the consent forms prior to 
providing consent. 
 
Privacy and confidentiality 
A key ethical consideration of this study is to ensure the confidentiality of all of the study 
participants, and particularly of sample patients. Given that sample patients will be selected 
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from the National Linkage Study cohort, it will be necessary to use named data in order to 
locate patient records, and to contact patients or their emergency contacts to request their 
consent to be contacted by study researchers. Once patient records and interviewees have 
been located, all names and other identifiable information will be removed from the data that 
is collected, stored and published by the study in order to ensure the confidentiality of sample 
patients and interviewees. 
Each sample patient will be assigned a unique identifier code under which their 
medical record data and interview data will be stored. All interviewees will be given 
pseudonyms to ensure that their identities remain confidentially. Finally, no names of primary 
clinics will be included in the final study report or any published data to further protect the 
confidentiality of sample patients and interviewees. 
Another important ethical consideration when conducting multi-perspective 
interviews is ensuring that there is no cross-disclosure of what one participant has said to 
another participant during the interview process. In other words, healthcare workers must be 
assured that the information that they provided regarding a patient’s journey will not be 
disclosed to the patient or family member and vice versa. Kendall et al. (2009) highlight that 
when conducting multiple perspective interviews, study participants may be curious as to 
what other participants have said and may question this. The interviewers will be trained not 
to disclose what has been said in other interviews and will sign a confidentiality agreement to 
this regard. 
 
Dissemination of study results 
The results of this research will be useful to the Department of Health, as well as advocacy 
groups and funders that are concerned with improving linkage to DR-TB treatment and 
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thereby reducing mortality and onward transmission. The results of this study will be 
summarised and circulated to all relevant stakeholders in a succinct policy paper. Additionally, 
the study report will be submitted to journals for publication. 
Collaboration 
This study will be undertaken as a sub-study to the national ‘Linkage to care for drug resistant 
TB following Xpert implementation in South Africa’ study (the National Linkage Study).  The 
National Linkage Study is run by the University of Cape Town’s Department of Medical 
Microbiology and funded by the Bill and Melinda Gates Foundation.  The primary aims of the 
National Linkage Study are to assess delays in initiating second-line treatment for patients 
with a rifampicin resistant Xpert result in South Africa, and to determine the critical points 
along this pathway at which delays occur. The principle investigators for the National Linkage 
Study are Prof Mark Nicol, University of Cape Town, Microbiology and NHLS and Prof Wendy 
Stevens, University of Witwatersrand, Microbiology and NHLS.  
The National Linkage Study has received ethical approval from UCT’s Human Research 
Ethics Committee (REF NO: 540/2013; REF NO: 241/2014). 
Timeline  
 April May June  
July 
Aug Sep Oct Nov 
Obtain ethical approval from UCT         
Review data from National 
Linkage Cohort and identify 
sample patients and facilities 
        
Request approval and access to 
study facilities from WC 
Provincial DoH and the City of 
Cape Town 
        
Initial facility visits to review 
patient records, interview 
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healthcare workers and request 
assistance from healthcare 
workers in obtaining consent 
from patients and family 
members to be contacted 
Contact patients and family 
members that consent to be 
contacted to request their 
participation in the study and 
arrange interviews 
        
Interview patients and family 
members 
        
Conduct analysis         
Draft study report         
 
Interview schedule 







3 4 5 6 7 8 
Initial visit to Cape Town metro facilities that diagnosed and/or initiated care 
for 12 sample patients in the district. 12 sample patients will be selected from 
a maximum of 5 facilities within the Cape Town metro. 
 
During initial visits, each sample patient’s records will be reviewed and 
interviews will be conducted with the healthcare worker(s) identified as 
responsible for their care.  After the interviews, HCWs will be asked to contacts 
patients (or their emergency contacts if patients cannot be reached) to request 
their consent to be contacted by study researchers. 
 
  
9 10 11 12 13 14 15 
Initial visits to Cape Town 
metro facilities continued… 
Initial visits to the West Coast facilities that diagnosed and/or initiated 
treatment for 12 sample patients in the district. 12 sample patients will be 
selected from a maximum of five facilities. 
 
The same activities will be carried out during initial visits as described for the 
Cape Town Metro District. 
16 17 18 19 20 21 22 
Initial visits to West Coast facilities continued…   
23 24 25 26 27 28 29 
Initial visits to the Cape Winelands facilities that diagnosed and/or initiated treatment for 12 sample patients 
in the district. 12 sample patients will be selected from a maximum of five facilities. 
 
The same activities will be carried out during initial visits as described for the Cape Town Metro District. 
July 30 1 2 3 4 5 6 
Continued…  Contact sample patients and emergency 
contacts that consent to be contacted. Ask 
them to nominate an additional family 
member that may be interviewed. Arrange 
date and time for interviews. 
  
7 8 9 10 11 12 13 






14 15 16 17 18 19 20 




21 22 23 24 25 26 27 
Continued…   
28 29 30 31 1 2 3 
Aug Conduct interviews with sample patients and family members in the West Coast district. 
 
4 5 6 7 8 9 10 
Continued…      
11 12 13 14 15 16 17 
Conduct interviews with sample patients and family members in the Cape Winelands district 
 
18 19 20 21 22 23 24 
Continued…      
25 26 27 28 29 30 31 
       
 
Expenses 
The main study expenses include the cost of travel to sites, hiring Xhosa and Afrikaans 
speaking interviewers and translation and transcription of interview transcripts. These 
expenses are budgeted for under the Bill and Melinda Gates Foundation grant provided to 
UCT’s Department of Medical Microbiology for the National Linkage Study underway (see 
collaboration) (HREC/NO: 540/2013; 241/2014).  The study’s principle researcher will receive 
support from a Wits Health Economics and Epidemiology Research Office (HE2RO) bursary, 
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Part 1: Introduction 
1.1. Objectives of the study  
 
The aim of this study is to investigate why patients diagnosed with drug resistant (DR) 
tuberculosis (TB) in the Western Cape frequently fail to link to timely treatment following 
diagnosis. Seeking to understand this phenomenon, the study will endeavour to understand 
what factors enabled or constrained linkage to treatment following diagnosis of rifampicin 
resistant (RR) TB between January and March 2013 – considering how the rollout of Xpert 
MTB/RIF (Xpert) diagnostic tools and ongoing decentralisation of DR-TB services, which were 
underway during this time, impacted on treatment linkage. DR-TB is used in this study as an 
encompassing term to refer to RR, multidrug resistant (MDR) and extensively drug resistant 
(XDR) TB. 
In seeking to understand why patients do - or do not - experience treatment linkage 
delays and failure following RR-TB diagnosis, this study will seek to identify factors that led 
to: 1) expedited treatment initiation, 2) delayed treatment initiation or 3) non-initiation of 
treatment amongst sample patients following sputum collection on which RR-TB was 
diagnosed.  
I will apply Coker et al.’s (2010) conceptual framework as a lens to explore contextual 
factors, health system mechanisms and patient factors that enabled or constrained linkage to 
treatment following RR-TB diagnosis between January and March 2013. For intervention 





1) Linkage to treatment is defined as the initiation of an appropriate DR-TB regimen 
(according to available resistance results) following the detection of RR-TB.   
2) Expedited treatment initiation is defined as the initiation of DR-TB treatment within 
one month of sputum collection, on which RR-TB was diagnosed.  
3) Delayed treatment initiation is defined as the initiation of DR-TB treatment more than 
one month and less than six months after sputum collection, on which RR-TB was 
diagnosed.  
4) Non-initiation is defined as non-initiation of DR-TB treatment within six months of 
sputum collection, on which RR-TB was diagnosed. 
1.2. Objectives of the literature review 
 
Part 1 of the literature review outlines the research question and literature search strategy. 
Part 2 of the literature review justifies the study purpose by providing an overview of the 
most up-to date evidence regarding DR-TB treatment linkage in South Africa and the Western 
Cape Province. Part 3 of the literature review provides a description of Coker et al.’s (2010) 
conceptual framework, which was selected as an analytic guide for this study. Part 3 also 
provides an overview of other conceptual frameworks considered for this study and a 
justification for why the Coker et al. framework was selected.  
Part 4 of the literature review discusses two national health systems interventions 
underway to improve treatment linkage within South Africa, the evidence for these 
interventions and their effects on linkage so far. The two interventions of focus are 1) the 
rollout of Xpert diagnostics, coupled with updated DR-TB diagnostic and treatment guidelines, 




review provides an overview of available academic evidence regarding barriers and enablers 
to treatment linkage following DR-TB diagnosis. 
1.3. Literature search strategy 
 
Reference material for this literature review was primarily sourced from peer reviewed 
journals. In order to identify relevant literature, combinations of words and Boolean phrases 
were tested on PubMed and Google Scholar. Articles from all countries, published after 2000 
and available in English were eligible for inclusion. Multiple searches were done between 
February 2014 and February 2015. Examples of the Boolean phrases tested are listed below. 
PubMed searches for these phrases yielded 12,039 results. 
Table 1. Examples of search phrases used 
 
        “Linkage” and “tuberculosis”     
“Linkage” and “drug resistant tuberculosis” or “DR-TB” or “MDR-TB”   
“Linkage barriers” and “TB” or “DR-TB” or “MDR-TB”   
“Time to diagnosis” and “TB” or “DR-TB” or “MDR-TB”   
“Time to treatment” and “TB” or “DR-TB” or “MDR-TB”      
“Diagnostic and treatment delays” and “TB” or “DR-TB” or “MDR-TB”   
“Rapid diagnosis” or “rapid treatment” and “TB” or “DR-TB” or “MDR-TB”   
“Xpert” and “DR-TB” and “South Africa”     
“Decentralisation” and “DR-TB” and “South Africa”  
 
Potentially relevant articles for inclusion were initially selected through reviewing article titles 
and, when available, abstracts. Articles that appeared relevant were downloaded through 
open access agreements or UCT’s online journal database, following which the abstract and 
results of each article were read in order to assess each article’s relevance for full review. 
Articles were considered relevant if they were 1) central to the disease focus of the paper, 2) 
considered Xpert diagnosis or decentralisation of DR-TB services, or 3) provided data on 
linkage barriers or enablers. Eighty nine articles were selected for full review and drawn from 




While evidence from all countries was eligible for inclusion, evidence from South Africa is 
featured more strongly in this literature review. This was in part due to the dearth of literature 
from other high burden DR-TB countries, in comparison to the large body of literature on DR-
TB in South Africa. Further, evidence from South Africa was prioritised over evidence from 
other countries when it provided more contextually relevant insight.  
Literature published in the past 5 years (since 2010) was prioritised over older articles. 
During the past 5 years there have been large programmatic shifts in South Africa’s efforts to 
treat and combat DR-TB (the rollout of Xpert diagnostics and decentralisation of services) and 
globally a massive increase in diagnosed RR-TB cases, coupled with a growing DR-TB 
treatment gap in a number of high burden countries including South Africa, has been 
documented (WHO, 2014, p. 141). 
This literature review also draws strongly from government policy documents and grey 
literature (i.e. government presentations and reports). Given the recent escalation in the gap 
between the number of patients diagnosed with RR-TB and those initiated onto treatment, 
relevant academic literature is sometimes unavailable and government sources provide the 
most up-to date data on DR-TB treatment linkage in South Africa.  
While limited academic literature on the scale of DR-TB linkage challenges in South Africa 
is currently available, there are a number studies underway seeking to describe and measure 
these challenges, including the national ‘Linkage to care for drug resistant TB following Xpert 
implementation in South Africa’ study that is being conducted by the University of Cape 





Part 2. The challenge of TB and DR-TB in South Africa 
2.1. Overview of TB and DR-TB in South Africa  
 
Tuberculosis (TB) is the leading cause of natural death within South Africa. In 2011, TB 
accounted for 10.7% of deaths in the country (STATSSA, 2014, p. 35). According to the World 
Health Organisation (WHO), when adjusted for population size, South Africa has both the 
highest estimated incidence and prevalence of TB globally (WHO, 2014, p. 141). 
The rise of the TB epidemic in South Africa has been closely related to the HIV epidemic 
in the country. People living with HIV are more at risk of developing active TB illness than HIV-
negative people, even when stable on antiretroviral therapy (Gupta et al., 2012, p. 6). Over 
the past two decades, HIV prevalence has increased to 12.2% in the general population (HSRC, 
2014, p. 35). During 2013, 62% of TB patients that knew their HIV status in South Africa were 
co-infected with HIV (WHO, 2014, p. 13). According to the WHO, South Africa has the highest 
number of HIV positive incident TB cases globally (WHO, 2014, p. 13). 
A major challenge to South Africa’s TB response is the growing epidemic of drug resistant 
TB. South Africa had the second largest number of diagnosed MDR-TB cases globally during 
2013, falling only behind India (WHO, 2014, p. 65). The WHO estimates that 1.8% of new TB 
cases, and 6.7% of retreated TB cases were drug resistant in 2013 (WHO, 2014, p. 141). During 
2012, the NHLS reported 14,161 laboratory confirmed MDR-TB and 1,545 XDR-TB cases, up 
from 7,386 and 741 respectively in 2010 (WHO & NDoH, 2014, p. 2). The WHO recently 
reported that the number of patients diagnosed with RR and/or MDR-TB rose to 26,023 




The large increase in diagnosed drug resistant TB cases witnessed in South Africa in recent 
years is due to a combination of an increasing incidence of DR-TB, as well as improved case 
detection and diagnosis (WHO, 2014, p. 141).  While the figures reported by the NHLS and 
WHO are likely subject to some error due to challenges with duplicate specimens and 
reporting (Dickson-Hall & Nicol, 2014, p. 1), what is clear is that South Africa has experienced 
a dramatic growth in diagnosed DR-TB cases in recent years.  
This study will consider factors that enable or constrain linkage to treatment following RR-
TB diagnosis in the Western Cape Province. South Africa is made up of 9 provinces, including 
the Western Cape Province, which has the third highest provincial burden of diagnosed RR-
TB cases in South Africa (Ndjeka, 2013, p. 13 - 22). 
2.2. Overview of TB and DR-TB in the Western Cape Province 
 
The Western Cape Province is made up of the urban City of Cape Town metropolitan 
municipality and five rural districts: Cape Winelands, Eden, West Coast, Overberg and Central 
Karoo. Sixty four percent of the Western Cape Province’s population resides within the Cape 
Town metropolitan municipality (STATSSA, 2012). During 2011, the City of Cape Town 
metropolitan municipality had the 2nd highest incidence of TB in the country (compared by 
district), falling only behind eThekwini in KwaZulu-Natal Province. However, when adjusted 
for population size, the City of Cape Town had the lowest TB incidence in the province at 740.6 
per 100,000 (Massyn et al., 2013, p. 396 - 415). 
When adjusted for population size, the highest TB incidence was seen in the West Coast 
district at 981.3 cases per 100,000 people, followed in descending order by the Cape 




in Western Cape districts were far higher than the national incidence of 687.3 cases per 
100,000 people (Massyn et al., 2013, p. 396 - 415). 
Between January and March 2013, the largest number of rifampicin-resistant TB cases 
were diagnosed in the Cape Town metropolitan municipality, followed in descending order 
by the Cape Winelands district, the Eden district, the West Coast district, the Overberg district 
and, finally, the Central Karoo district. 
Table 2. Rifampicin resistant diagnoses between January and March 2013 in the Western Cape 
Western Cape district Total RR-TB diagnoses % RR-TB diagnoses 
Cape Town metro 342 60.3% 
Cape Winelands  82 14.5% 
Eden 70 12.3% 
West Coast  47 8.3% 
Overberg 21 3.7% 
Central Karoo 4 0.7% 
Unknown 1 0.2% 
TOTAL 567 100% 
* Data sourced from the National Health Laboratory Services during 2015 
2.3. The cure rate, cost and complexity of treating TB versus DR-TB  
 
The rising rates of DR-TB in South Africa place a dramatic strain on the health system’s 
resources. Patients with DR-TB require longer, more complex and significantly more costly 
treatment regimens than patients with drug susceptible (DS) TB. An economic analysis of the 
comprehensive costs of treating DS-TB, MDR-TB and XDR-TB in South Africa estimated that 
the per patient cost of treating MDR-TB is 26 times greater than per patient cost of treating 
DS-TB. Forty nine percent of the per patient cost of treating MDR-TB is attributable to 
medicine expenditure and the remainder is attributable to laboratory and hospitalisation 
costs (Pooran et al., 2012, p. 1 - 10). The study further found that the per patient cost of 
treating XDR-TB is 103 times greater than the per patient cost of treating DS-TB. Finally, while 




accounted for approximately 45% of total national expenditure on TB (Pooran et al., 2012, p. 
1 -10). 
While treating DR-TB is more costly than treating DS-TB, it is also less effective (WHO & 
NDoH, 2014. p. 6 - 7). Between 2005 and 2011, the national TB cure rate rose from 55 – 75%. 
In comparison the MDR and XDR-TB treatment success rates were 40% and 18%, respectively, 
during 2010 (WHO & NDoH, 2014. p. 6 - 7). The lower treatment success rates are in part due 
to the fact that, as patients develop resistance, their options for effective treatments are 
reduced.  
Furthermore, as patients develop resistance their treatment becomes more complex, 
which increases the burden on the health system. DS-TB is treated with four medicines (often 
combined into a single pill) taken daily for 6 months. Treating DR-TB can take up to two years, 
requiring patients to take around 20 pills per day, including six months of daily injections 
(MSF, 2012, p. 1). Patients with drug resistant TB are also more likely to require periods of 
hospitalisation and surgeries than patients with drug susceptible TB. 
Taking account of the resources needed to treat DR-TB, it is important to curb new 
infections in order to contain the costs and strain placed on the country’s health system.  
2.4. Linkage and incidence 
 
DR-TB disease may occur as a result of developed resistance to the medicines used to treat 
DS-TB. Patients may develop resistance to DS-TB medicines while being treated for TB. This 
risk is heightened when treatment is not taken correctly. Patients that have been previously 
treated for TB are more likely to be diagnosed with DR-TB, than newly diagnosed TB cases 




DR-TB disease may also be transmitted directly from person-to-person. Therefore people that 
have not previously been treated for TB may contract DR-TB from someone with active and 
infectious DR-TB disease. Within South Africa, molecular epidemiological studies have 
demonstrated that the majority of new cases are a result of direct person-to-person 
transmission, rather than developed resistance (Streicher et al., 2012, p. 1). Within 
Khayelistha, an urban township in the Western Cape, DNA finger printing has shown that  
person-to-person transmission may account for as many as 81% of MDR-TB cases (Cox et al., 
2010, p. 5). Within the Eastern Cape, an epidemiological study showed that person-to-person 
transmission accounted for 41% of XDR-TB cases (Kvasnovsky et al., 2011, p. 150). 
Person-to-person transmission of DR-TB in South Africa is fuelled by inadequate infection 
control measures, poor case detection,  as well as delays in diagnosing and treating DR-TB 
(Cox et al., 2010, p. 7; Streicher et al., 2012, p. 686). Diagnostic and treatment delays prolong 
the period during which patients remain infectious, thereby heightening their risk of onward 
transmission of DR-TB to their close contacts (Streicher et al., 2012, p. 691).  
Achieving timeous linkage to treatment for people with DR-TB is therefore critical to 
reducing new infections, yet figures from the Department of Health suggest that South Africa 
is fairing extremely poorly in linking patients to care as shown in the next paragraph. 
2.5. Linkage figures in South Africa and the Western Cape 
 
Rates of linkage to treatment in South Africa are poor. According to figures from the National 
Department of Health, only 45.9% of patients diagnosed with MDR-TB and 45.4% of patients 
diagnosed with XDR-TB during 2012, were initiated onto treatment (Ndjeka, 2013, p. 13 - 22). 




RR and/or MDR TB cases during 2013. According to WHO estimates, 26,023 patients were 
diagnosed with RR and/or MDR-TB during 2013, of whom only 41% linked to treatment (WHO, 
2014, p. 141). 
 In the Western Cape, only an estimated 48.6% of diagnosed MDR-TB patients were 
started on treatment during 2012. The province faired far better with XDR, initiating an 
estimated 99% of patients onto treatment (Ndjeka, 2013, p. 13 - 22). Encouragingly, a recent 
study in the City of Cape Town reported far better linkage rates in the City of Cape Town, than 
previously reported for the province. The observational study, conducted in 10 high burden 
clinics, reported that between 6 and 9% of patients did not initiate treatment within 6 months 
of diagnosis (Naidoo et al., 2014, p. 4).  
















% of XDR 
cases started 
on treatment 
National 14,161 6,494 
 
45.9% 1,545 701 45.4% 
Western Cape 2,072 1,006 
 
48.6% 145 144 99.3% 
KwaZulu- 
Natal 
6,630 2,571 38.8% 754 267 35.4% 
Eastern Cape 2,205 1,062 
 
48.2% 477 204 42.8% 
Gauteng 1,198 417 
 
34.8% 50 26 52% 
Mpumalanga 760 591 
 
77.8% 3 8 266.7% 
Free State 390 201 
 
51.5% 31 9 29% 
Northern 
Cape 
373 243 65.1% 72 26 36.1% 
North West  267 268 
 
100.3% 10 14 140% 
Limpopo 266 135 50.8% 3 3 100% 





2.6. Reporting challenges 
 
The numbers of diagnosed DR-TB cases and patients started on treatment are subject to some 
reporting error. The number of annually diagnosed DR-TB cases is reported by the South 
African National Health Laboratory Services (NHLS). However, currently the Department of 
Health and NHLS do not use unique patient identifiers – such as patients’ ID numbers – to 
recognise patients. As a result of this, duplicate specimens from one patient are sometimes 
reported as different cases. It is therefore expected that NHLS’s reported number of annually 
diagnosed cases is an overestimate of the actual number of diagnosed DR-TB cases in the 
country (Dickson-Hall & Nicol, 2014, p. 1). 
Furthermore, the numbers of patients initiated onto treatment are reported by South 
Africa’s national electronic register for drug resistant TB patients, commonly known as the 
‘EDR registry’. Only patients that initiated DR-TB treatment are registered on EDR.  However, 
some patients that start treatment are never recorded on EDR due to reporting challenges, 
including the centralised nature of reporting systems. As a result of reporting challenges, it is 
anticipated that more patients are linked to care than reflected by EDR (Dickson-Hall & Nicol, 
2014, p. 1; Rose et al., 2013, p. 214 ). Yet, even after accounting for reporting challenges, 
linkage failure in South Africa remains unacceptably high. 
2.7. Summary 
 
Data from the National Department of Health, the National Health Laboratory Services and 
the WHO have demonstrated a growing gap within South Arica between the number of 
patients diagnosed with DR-TB and those initiated onto treatment. Delayed and/or failed 




in an increasing strain on the health system’s resources and budget. This study will seek to 
understand why so many patients fail to link to care through conducting an embedded case 
study analysis of barriers and enablers to DR-TB treatment linkage within the high-burden 
Western Cape Province.  
Part 3: Conceptual framework 
3.1 Overview of conceptual frameworks considered for this study 
 
Health systems are inherently complex, with multiple overlapping and interacting role 
players, programmes and priorities. Health systems are defined as “open systems, with 
interlinked components that interact within the context within which the health system is 
situated, thereby forming a whole with properties beyond the component parts… collectively 
creating a ‘dynamic complexity’” (Atun, 2012, p. iv4). Gilson (2012) recommends that health 
systems researchers utilise conceptual frameworks when conducting health systems research 
in order to deal with the complexity that is inherent within the system. 
Three conceptual frameworks were considered as an analytical guide for this study. These 
frameworks were considered because they provide a lens to understand barriers and enablers 
to treatment linkage during a period of policy implementations – or ‘scale-up’ - within a 
complex health system.  
Scale-up involves “the process of expanding the coverage of health interventions” 
(Mangham & Hanson, 2010, p. 1) - generally following successful pilot testing (Mangham & 
Hanson, 2010, p. 1). During the period of focus in this study, the implementation of two 




decentralisation of DR-TB services (see ‘Part 4: Interventions to improve linkage’). While both 
interventions seek to improve treatment linkage, De Savigny and Adam (2009, p. 30)  explain 
that the outcomes of health systems interventions are often counter-intuitive and 
unexpected. It is therefore critical to take a systems thinking approach which considers 
complex causality. A systems thinking approach takes a wide lens of the health system, 
considering its complexity and multiple interacting sub-systems. This approach considers how 
the scale-up of the two interventions will affect each sub-system in the health systems and 
the relationships between the sub-systems (De Savigny & Adam, 2009, p. 19). 
The following three conceptual frameworks, which allow for a systems thinking approach, 
were considered as an analytical guide for the study: 
1) Agyepong et al.’s (2012) policy resistance framework (derived from Sterman’s (2006) 
conceptual framework). Figure 1 
2) De Savigny and Adam’s (2009) conventional approach to health systems interventions 
using a systems perspective framework. Figure 2 
3) Coker et al.’s (2010) framework for comparative analysis of communicable diseases 






Figure 1. Agyepong 
et al. (2012). 
Agyepong et al.’s 
framework was 
used to identify the 
positive and 
negative effects of 
additional duty 





In developing their conceptual framework, Agyepong et al. (2012) drew from De Savigny and 
Adam’s theory of health systems as complex adaptive systems. De Savigny and Adam explain 
that – as a complex adaptive system – the health system is self-organising and constantly 
changing.  Additionally, dynamics and behaviours of the health system may arise 
spontaneously from the interactions of actors and sub-systems.  De Savigny and Adam further 
explain that the outcome of interventions within complex adaptive systems are difficult to 
predict and may be counter-intuitive (2009, p. 40 – 41). 
Taking a systems thinking approach, it is important to consider all of the potential positive 
and negative effects of an intervention on the health system. These effects, and the causal 
loops that contribute to them are represented in Agyepong et al.’s schematic representation 
of their framework. Agyepong’s et al.’s framework is adapted from Sterman’s (2006) theory 
of policy resistance which explains that an intervention may be thwarted by the health system 
and context in which it is implemented. The framework depicts the causal loops between 
actors, actions, effects and context – although it does not show the relationships between the 
sub-systems of the health system. 
DeSavigny and Adam (2007) adopt the WHO’s building blocks (or sub-systems) of the 
health system  in their framework (WHO, 2007, p. 3). The six building blocks may enable or 
impede the implementation of an intervention. Furthermore, given the tightly-linked nature 
of complex adaptive systems, an intervention may have positive and negative effects on 
different building blocks (De Savigny & Adam, 2009, p. 41).  
DeSavigny and Adam’s (2009) framework looks at the interactions between the health 
systems building blocks and three measurements of health systems performance: access, 




including: equity and health; responsiveness of the health system to the patient population; 








The third framework considered for this study was Coker et al.’s (2010) framework for 
comparative analysis of communicable disease interventions.  The Coker framework was 
developed to allow for comparative analysis of communicable disease programmes using a 
systems thinking approach. Coker et al. write that the framework can be used to compare 
large amounts of data, both qualitative and quantitative from different health programmes, 
systems or countries. While the Coker et al. framework was designed to conduct large-scale, 
cross-comparison of communicable disease programmes, we consider it useful for conducting 
single-case analyses that allows for future comparative analyses. 
While De Savigny and Adam adopted the WHO’s health systems building blocks to enable 
a systems thinking approach, Coker et al. have drawn from Atun et al.’s (2004) theory of key 
health systems functions. Atun et al.’s six functions of the health systems include: stewardship 
and governance, financing, planning, service delivery, demand generation and monitoring 
 
Figure 2. De Savigny 
& Adam (2009). 
DeSavigny and 
Adam’s framework 






and adherence to 





and evaluation. Coker et al. linked Atun et al.’s theoretical framework of health system’s 
functions to Pawson and Tiley’s (1997) framework for evaluation. Pawson and Tiley’s 
framework identifies key elements for evaluation that seek to understand why a health 
programme does or does not work, while taking context into account (Pawson & Tilley, 1997). 
By linking the two frameworks, Coker et al.’s framework supports simultaneous analyses of 







Drawing from Pawson and Tiley (1997), the Coker et al. framework highlights six key domains 
for consideration when evaluating a health systems intervention. The six domains include 
context, epidemiological problem, intervention, mechanism, output and outcome.  
Coker et al. explain that context “denotes the political, legislative, social, economic and 
technical environments within which communicable disease control programmes sit” (p. i23).  
Context encompasses the local, regional and international environments in which the 
programme is operating, which may enable or constrain programmatic success. 
Figure 3. Coker et al. 
(2010). Coker et al.’s 
framework was 











Epidemiological problem “refers to infection levels and various diseases characteristics” (p. 
i23) that the health programme seeks to respond to. For this study, the epidemiological 
problem refers to large burden of DR-TB, coupled with high rates of HIV co-infection. The 
epidemiological problem also encompasses the low rate of treatment linkage, which drives 
onward transmission of DR-TB. 
Intervention refers to “the intervention intended to serve public health” which are 
generally “recommended through clinical and policy guidelines and are evidence-based, thus 
lending themselves to scrutiny against gold standards” (p. i23). The interventions of focus in 
this study are the Xpert rollout and the decentralisation of DR-TB services.  
Mechanisms refer to the “mechanism(s) by which interventions are delivered”, as such it 
encompasses the “mechanisms within a programme, required to function effectively” (p. i23). 
Coker et al. link mechanisms to the health system functions - representing the functions of 
the health system necessary to implement the intervention.  
Output refers to “public health concepts that can be measured or determined and include 
equity, acceptability, efficiency and effectiveness of the control programmes as a result of 
interventions” (p. i23). In health systems, access is commonly used as an output measurement 
of interventions. McIntyre et al. (2009) draw attention to the importance of defining access 
in order to assess it as a goal, and provide a framework that defines three key dimensions of 
access: availability; affordability; and, acceptability. 
McIntyre et al. (2009) explain that “availability is concerned with whether the appropriate 
health care providers or services are supplied in [the right manner] to meet the prevailing 




between the full costs to the individual of using the service and the individual’s ability to pay” 
(p. 186). They further explain that “acceptability is concerned with the fit between provider 
and patient attitudes towards and expectations of each other” (p. 187).  
This study will use outputs of treatment linkage (expedited, delayed and non-initiation of 
treatment) as selection criteria for patients. Knowing patients’ outputs will allow us to 
backward map and explore the association between these outputs and factors that influence 
these outputs. Knowing the outputs a priori also allows for the development of questions on 
how availability, affordability and acceptability as defined by McIntyre et al. (2009) might 
have impacted on differing linkage to treatment experiences.   
Outcome in Coker et al.’s framework refers to the impact of the intervention and health 
programme on the epidemiological problem, “such as reduced incidence of disease or 
decreased mortality” (p. i23). While evaluating outcome is beyond the scope of this study, the 
domain has been included in the amended framework in order to retain cognisance of the 
ultimate aim of the health programme. A feedback loop demonstrates the impact of the 
outcome domain on the epidemiological problem. 
Coker et al.’s framework has been further amended through the addition of a seventh 
domain for the patient. The Coker framework considers whether interventions “reach 
patients and populations” (p. i23). The amended framework brings patient issues to the 
forefront, by creating a separate domain for the patient. This study has drawn from Shippee 
et al.’s (2012) model of patient complexity to define the patient domain, Shippee et al. note 
that “patients exist at the intersection of social, personal, and clinical circumstances, and so 




et al. (2012) highlight the impact of patients’ workloads and capacity on their experiences of 
care. 
Patient workloads “encompasses all the demands in patients’ lives, including everyday 
responsibilities alongside the demands of patient-hood… includ[ing] job, family, 
travel/transportation, childcare, scheduling and attending clinical appointments” (p. 1042). 
Patient capacity “denotes the resources and limitations affecting patients’ ability or 
readiness to do [patient-related] work, such as mental/physical functioning, unpleasant 
symptoms… pain, stress, or fatigue… Capacity also encompasses socioeconomic and 
psychological resources, literacy, language, and social support..., [as well as patients’] 
attitudes and beliefs about health care” (p. 1043). 
In this study, the patient domain encompasses factors arising from patients’ workloads 
and capacity that influence the uptake, or lack thereof, of timeous DR-TB treatment. It is 
crucial for policy makers to identify and consider these patient factors in order to develop 
more acceptable health programmes that respond to individual patient’s needs and 
vulnerabilities in order to better link them to TB care.   
3.2. Motivation for selecting the Coker framework 
 
Following consideration of the Coker, Agyepong and DeSavigny and Adam frameworks, Coker 
et al.’s (2010) framework - incorporating Shippee et al.’s (2012) model of patient complexity 
and McIntyre et al.’s (2009) dimensions of access - was selected as an analytic guide for this 
study. The Coker framework was selected namely because it speaks directly to the study’s 
aim in seeking to answer “why a programme works, for whom and under what circumstances” 




systems mechanisms and patient factors enable or constrain linkage to care during a period 
of intervention scale-up. 
The selection of the Coker et al. (2010) framework was further motivated by its previous 
employment in TB and MDR-TB research in South Africa. Given the previous application of the 
framework, its use in this study will build on an existing body of knowledge regarding TB and 
DR-TB programmes within South Africa and their interactions with the health system. 
Previous case studies have used the Coker framework to evaluate the integration of HIV and 
TB services in South Africa (Loveday & Zweigenthal, 2011), as well as the impact of health 
systems performance on MDR-TB outcomes (Loveday et al., 2014). However, unlike previous 
applications of the framework (Loveday et al. 2014; Coker et al. 2010), a scoring approach will 
not be used to evaluate data collected for this study. Rather the framework will be applied to 
organise data and interpret findings. The amended framework, incorporating Shippee et al.’s 
model of patient complexity and McIntyre et al.’s dimensions of access, is schematically 
represented in Figure 4.  
3.3. Summary 
 
Following consideration of different frameworks, Coker et al.’s framework was selected as an 
analytical guide for this study as it allowed for exploration of “why a programme works, for 
whom and under what circumstances”.  For this study, the Coker framework was amended to 
incorporate aspects of Shippee et al.’s (2012) and McIntyre et al.’s conceptual models. Using 
the amended Coker et al. framework, this study will seek to understand how context, health 
system mechanism and patient factors influence linkage to treatment following the adoption 




Figure 4. Amended Coker et al. (2010) framework incorporating Shippee et al.’s (2012) framework of 
patient complexity and McIntyre et al.’s (2009) dimensions of access. 
 
Part 4: Interventions to improve linkage 
 
During 2011, the National Department of Health embarked on the implementation of two 
health system interventions to improve DR-TB case detection, reduce diagnostic and 
treatment delays, and improve treatment outcomes. The interventions included the rollout 
of Xpert diagnostic tools, coupled with the adoption of updated diagnostic and treatment 
guidelines, and the decentralisation of DR-TB care.   





The National Department of Health embarked on a national rollout of Xpert diagnostic tools 
following their endorsement by the WHO as an initial diagnostic tool amongst suspected DR-
TB patients and patients co-infected with HIV. The recommendations were made in light of 
evidence that the Xpert offered significant improvements over traditional diagnostics in 
diagnosing TB, or DR-TB, amongst these groups (WHO, 2011). 
The Xpert is often able to detect TB that is undetected by smear microscopy amongst 
patients with HIV. In a multi-country study, Boehme et al. (2011) reported that the sensitivity 
of smear microscopy in diagnosing TB amongst culture positive TB patients co-infected HIV 
was as low as 44.6%. In comparison, Xpert’s sensitivity was 82.4%.  The Xpert also offers 
significant reductions in diagnostic turn-around time when compared to culture diagnostics. 
While laboratory diagnostic turn-around time can take up to 6 weeks when using culture 
(FIND, 2006, p. 11) it is reduced to 2 hours when using the Xpert (Menzies et al., 2012, p. 17).  
Finally, the Xpert is able to detect rifampicin resistance without additional testing using 
drug susceptibility testing or line probe assay, as required on sputum smear and culture tests. 
Rifampicin resistance is a good marker of multi drug resistance as around 90% of patients that 
are resistant to rifampicin are also resistant to isoniazid and are therefore categorised as 
MDR. Although, increasing rifampicin-mono resistance has been recently documented in the 
Western Cape and KwaZulu-Natal provinces (Coovadia et al., 2013, p. 1; Dlamini-Mvelase et 
al., 2014, p. 5; Mukinda et al., 2012, p. 4). Patients with rifampicin mono-resistance should be 
given isoniazid, in combination with an MDR-TB treatment regimen (NDoH, 2011b, p. 38). 
South Africa has spearheaded the use of Xpert diagnostic tools to date - purchasing 56% 
of Xpert cartridges sold worldwide between December 2010 and June 2014 (WHO 2014).  




sites around the country and performed more than 2 million tests (NHLS, 2013, p. 3).  The 
national Xpert rollout was coupled with the adoption of a new diagnostic algorithm that 
recommends the use of the Xpert as an initial diagnostic test for all patients with suspected 
pulmonary TB (Scott et al., 2014, p. 1818). As a result of the updated algorithm and Xpert 
rollout, all TB suspects should now also be screened for rifampicin resistance.  
The updated diagnostic algorithm was further coupled with the adoption of updated 
treatment guidelines which recommend immediate initiation of MDR-TB treatment for 
patients diagnosed with RR-TB. Under the updated guidelines, confirmatory testing and drug 
susceptibility testing should still be conducted utilising line probe assay or culture drug 
susceptibility testing, but it should not delay the initiation of treatment. Patients diagnosed 
with RR-TB on Xpert should be immediately initiated onto standard MDR-TB regimens.  
Patients who are later identified as XDR should be switched to an XDR regimen (NDoH, 2013, 
p. 43).   
4.1. DR-TB indicators in South Africa pre and post Xpert 
4.1.1. Case detection 
 
Substantial strides in case detection and diagnosis have been made as a result of the rollout 
of Xpert diagnostics. Prior to the Xpert rollout, it was estimated that as little as 63% of DR-TB 
cases in South Africa were diagnosed, which fuelled onward transmission of DR-TB (Streicher 
et al., 2012, p. 687). Following the Xpert rollout, a large increase in the number of laboratory 
confirmed DR-TB cases has been observed. According to NDoH figures, the number of 
laboratory confirmed DR-TB cases rose from 7,386 in 2010 to 14,161 in 2012 – representing 




XDR-TB cases rose from 741 to 1,545 – representing an increase of 108% over two years 
(Ndjeka, 2013, p. 13 - 22). In other words, the number of laboratory diagnosed MDR and XDR-
TB cases doubled following the rollout of Xpert testing tools. A further escalation in case 
detection was recently reported by the WHO, who estimated that the number of laboratory 
diagnosed rifampicin resistant and/or MDR-TB cases rose to 26,023 during 2013 (WHO, 2014, 
p. 141). 
4.1.2. Time to diagnosis 
 
Prior to the rollout of Xpert diagnostics, health facilities in South Africa relied on line probe 
assay (LPA) or culture drug susceptibility testing (DST) in order to detect resistance. Long 
delays to diagnosis were documented with both methods of testing, which the Xpert rollout 
sought to reduce. 
Line probe assay 
 
LPA is a genotypic test that is able to detect rifampicin and isoniazid resistance within 48 
hours. The WHO has endorsed the use of LPA testing on smear-positive and culture-positive 
sputum samples in order to detect drug resistance. In 2008, the Western Cape adopted LPA 
diagnostic tools to test for rifampicin and isoniazid resistance on smear- and culture-positive 
samples (Jacobson et al., 2013, p. 504). 
While an initial demonstration study showed that LPA testing could allow for the 
processing of drug resistant TB results in under 2 days (Barnard et al., 2008, p. 1), this was not 
observed in a retrospective cohort analysis of MDR-TB results processed using LPA for 
patients diagnosed at Brewelskloof Hospital between 2007 and 2011.  The study found an 




greatest for sputum smear negative patients whose TB was detected on culture (Jacobson et 
al., 2013, p. 506). 
Culture DST 
 
Prior to detecting resistance using culture drug susceptibility testing (DST), a positive TB 
culture must be detected which can take up to 6 weeks for laboratory processing (FIND, 2006, 
p. 11). Once a positive-culture result is available, the same sputum sample can be tested for 
drug susceptibility by exposing the sputum sample to small amounts of different medicines. 
This method is known as culture DST. 
Two retrospective studies – conducted in KwaZulu-Natal and the Western Cape – showed 
laboratory processing time for MDR-TB results using culture DST took an average of 8 weeks 
(Gandhi et al., 2010, p. 83; Jacobson et al., 2013, p. 506).  Worryingly the KwaZulu-Natal study 
found that 40% of MDR-TB cases and 51% of XDR-TB cases died within 4 weeks of providing 
sputum – before receiving their test results (Gandhi et al., 2010, p. 82). 
Xpert 
 
During 2011, Xpert diagnostic tools were adopted within South Africa in order to improve 
detection and diagnosis of TB and drug resistance. A multi-centre study conducted in 6 
countries, including South Africa, compared the time to diagnosis using Xpert diagnostics with 
LPA and culture DST. The study showed that Xpert testing was able to identify rifampicin 
resistant TB on the same day as sputum collection, whereas LPA and culture DST took an 
average of 20 and 106 days, respectively (Boehme et al., 2011, p. 1495). 
While the Xpert was initially lauded as a point-of-care diagnostic tool that would allow for 




constraints (Schnippel et al., 2012, p. 109). While this placement has been criticised (Tre´bucq 
et al., 2011, p. 1567), large reductions in times to diagnosis of DR-TB have been observed in 
clinic settings. An observational study conducted in 10 high burden clinics in Cape Town, 
found that the time to processing drug resistant results in a lab was 1 day when testing was 
done with the Xpert, versus 24 days when using LPA (Naidoo et al., 2014, p. 4). 
4.1.3.  Time to treatment 
 
In an effort to reduce time to treatment, the national Xpert rollout was coupled with updated 
treatment guidelines recommending that patients diagnosed with rifampicin resistance using 
the Xpert be immediately initiated onto MDR-TB treatment. Culture DST or LPA testing should 
still be performed and patients’ treatment regimens should be amended in accordance with 
these results once they are available (NDoH, 2013, p. 43). 
Prior to the rollout of the Xpert, mean delays of 80 days (11.4 weeks) from the date of 
sputum collection to treatment initiation were observed in a retrospective cohort study at 
Brewelskloof Hospital (Jacobson et al., 2013, p. 505). Similarly, a prospective cohort study in 
KwaZulu-Natal identified average delays between 72 and 93 days from the date of sputum 
collection to treatment initiation (Loveday et al., 2012, p. 209). 
A reduction in time to treatment following the Xpert rollout has been observed in the 
Western Cape. According to figures from the City of Cape Town, almost half of patients 
diagnosed with MDR-TB during 2013 initiated treatment within 5 days of sputum collection 
(Caldwell, 2013, p. 27). An observational cohort study conducted in 10 high burden clinics in 
Cape Town showed a reduction in time to treatment following sputum collection from 43 days 




reduction in time to treatment was due to reduced laboratory turn-around times as there 
were ongoing delays to treatment initiation following diagnosis. Time from diagnosis to 
treatment initiation was approximately 10 days when using the Xpert (Naidoo et al., 2014, p. 
4).  
4.1.4. Non-initiation of treatment 
 
Following the Xpert rollout, rates of treatment initiation failed to keep pace with the increase 
in laboratory diagnosed DR-TB cases, which led to a large gap between the number of patients 
diagnosed with DR-TB and those initiated onto treatment. Between 2010 and 2012, the 
percentage of laboratory diagnosed MDR-TB patients that were reported to have not started 
treatment increased from 28% to 54%. During the same period, the percentage of laboratory 
diagnosed XDR-TB patients that were reported to have not started treatment rose from 17% 
to 55% (Ndjeka, 2013, p. 13 – 22). 
Within the Western Cape, it is estimated that the percentage of laboratory diagnosed 
MDR-TB cases that failed to initiate treatment rose from 27% in 2010 to 51% in 2012. Yet, 
simultaneously the percentage of XDR patients that failed to initiate treatment declined to 
below 1% (Ndjeka, 2013, p. 13 – 22). An observational cohort study in Cape Town reported 
far lower rates of non-initiation within 10 high burden clinics (between 6 and 9%). However, 
there was no statistically significant difference in rates of non-initiation between patients 
diagnosed using LPA versus the Xpert (Naidoo et al., 2014, p. 4). 
Table 4. Linkage estimates from the National Department of Health, 2014 






% XDR non 
initiators 2012 
National 28% 54% 17% 55% 
Western Cape 27% 51% 45% 0.7% 
Eastern Cape 48% 51% 30% 57% 




4.1.5.  Morbidity and mortality 
 
Achieving timeous diagnosis and treatment initiation is not only important to preventing new 
infections, but also critical to reducing DR-TB mortality. Two KwaZulu-Natal studies conducted 
before the Xpert rollout showed that between one third and one half of DR-TB patients died 
prior to receiving there results. Furthermore, the majority of patients died within one month 
of providing sputum (Gandhi et al., 2010, p. 83; Heller et al., 2010, p. 424). Similarly, a Gauteng 
retrospective study of patients diagnosed during 2011 (during the Xpert rollout) found that 
one third of patients diagnosed in the province died prior to starting treatment (Ebonwu et 
al., 2013, p. 1046). 
To date there has been no assessment of the Xpert rollout’s impact on DR-TB mortality in 
South Africa, however this is the focus of a current study underway (Linkage to care for drug 
resistant TB following Xpert implementation in South Africa, Department of Medical 
Microbiology, N.d.). Disappointingly, however, two South African trials have shown that the 
Xpert rollout has not reduced morbidity and mortality amongst drug susceptible TB patients 
(Geffen, 2014, p. 1). 
4.1.6. Summary 
 
Following the rollout of Xpert diagnostics, significant increases in diagnosed DR-TB cases were 
observed (Ndjeka, 2013). Furthermore, studies have shown that diagnosis on Xpert (versus 
LPA or culture DST) reduces diagnostic turn-around times, as well as time to treatment 
(Boehme et al. 2011; Naidoo et al., 2014). However, the health system’s capacity to initiate 
new patients onto treatment has failed to keep pace with rapid increases in diagnosed DR-TB 




to understand why many patients fail to link to care, despite improved diagnostic turn-around 
times facilitating expedited treatment initiation. 
Intervention 2: Decentralisation of DR-TB services 
 
The 2011 Xpert rollout was not introduced within a static DR-TB programme or health system. 
Rather, the rollout was coupled with the adoption  of national guidelines recommending the 
decentralisation and deinstitutionalisation of MDR-TB treatment (NDoH, 2011a).  The 
guidelines for decentralised MDR-TB care were adopted in light of evidence that 
decentralised, community-level care could be implemented without compromising treatment 
outcomes (Cox & Ford, 2013, p.1). Additionally, the guidelines were adopted in recognition of 
the fact that traditional centralised treatment sites were increasingly unable to accommodate 
the expanding patient load (Cox & Ford, 2013, p. 1; NDoH, 2011a, p. 16). 
To date, three models of decentralisation have been implemented in different parts of 
South Africa.  At its most basic, ‘decentralisation’ has involved the extension of DR-TB services 
to district hospitals. According to current guidelines, at least one decentralised DR-TB unit 
should be available within each district (NDoH, 2013, p. 15). The Eastern Cape Province, for 
instance, is in the process of decentralising MDR-TB treatment to one hospital per district 
(communication with the ECDoH, May 2014). National policy guidelines recommend that 
complicated MDR-TB patients and smear-positive patients be hospitalised at a decentralised 
DR-TB unit for up to eight weeks, or until they have received two consecutive, smear-negative 
microscopy results (NDoH, 2013, p. 5). 
Along with at least one decentralised DR-TB unit per province, each province should have 




unit is responsible for initiating XDR-TB patients, as well as assessing and overseeing DR-TB 
patients receiving decentralised care in the province (NDoH, 2013, p 5). 
The second model of decentralisation seen in South Africa, has been the extension of DR-
TB services to primary care clinics. This model of decentralisation has been implemented 
across the Western Cape and parts of KwaZulu-Natal. National policy guidelines recommend 
that primary care clinics initiate MDR-TB treatment and provide daily injections to smear 
negative MDR-TB patients. Clinics should also provide ongoing treatment to DR-TB patients 
discharged from hospital. XDR-TB patients and patiens with complicated MDR-TB should still 
be referred by primary clinics to centralised and decentralised DR-TB units for hospitalised 
treatment initiation (NDoH, 2013, p. 16).  
The third and least common model of decentralisation seen in South Africa is home based 
DR-TB treatment. National policy guidelines recommend that patients who are unable to 
reach treatment facilities be treated in their homes by mobile injection teams (NDoH, 2013, 
p. 17). Integrated home-based MDR-TB and HIV treatment was successfully piloted in Tugela 
Ferry in KwaZulu-Natal – a community with a dual high burden of HIV and DR-TB – without 
compromising treatment outcomes (Brust et al., 2012, p. 998). 
4.2. DR-TB indicators in centralised versus decentralised settings 
4.2.1. Case detection and treatment linkage 
 
The decentralisation of DR-TB treatment in South Africa has led to improvements in case 
detection and linkage to care. In Khayelitsha, an urban township in the Western Cape, an 
increase in case detection was observed with the decentralisation of DR-TB services to 




also improved linkage to treatment for DR-TB patients in the area. An estimated 85% of 
patients diagnosed with DR-TB in the area initiated treatment - far above the national average 
of 42%. This success was credited to shortened time to diagnosis, better tracing systems and 
improved access to treatment (Cox et al., 2014, p. 445 - 446). 
4.2.2. Time to treatment 
 
Two KwaZulu-Natal studies have demonstrated reduced times to treatment in decentralised 
sites, versus centralised sites. Time to treatment was reported at 84 days at the community-
based hospital in KwaZulu-Natal, versus 106.5 days at the centralised, provincial hospital 
(Heller et al., 2010, p. 420). Similarly, median time to treatment initiation was reported 72 
days at decentralised sites using mobile injection teams versus 93 days at the centralised 
hospital (Loveday et al., 2012, p. 209). In Khayelitsha in the Western Cape, decentralisation of 
DR-TB services to primary clinics led to reductions in time to treatment from over 2 months 
to 27 days (Cox et al. 2014, p. 441).   
4.2.3. Distance and access to decentralised treatment sites 
 
A number of studies have demonstrated reduced times to treatment initiation following the 
decentralisation of DR-TB services (Cox & Ford, 2013; Heller et al., 2010; Loveday et al., 2012). 
However, the implementation of decentralised care to date has been slow and varied across 
provinces. 
In the City of Cape Town, an estimated 80% of patients are now initiating MDR-TB 
treatment at a primary clinic (Caldwell, 2013, p. 4). The average time to treatment 
commencement for patients diagnosed in the City of Cape Town by the Xpert is 17 days 




are unable to access primary clinics for daily injections due to distance and lack of transport. 
These patients must continue to be hospitalised during the injectable phase of treatment 
(Theron, 2013; Kendal et al., 2013).  It can be anticipated that access to decentralised care is 
even worse in other parts of the country where efforts to decentralise have been slower than 
in the Western Cape. 
 Surprisingly, given evidence that decentralisation improves linkage to care, a recent 
KwaZulu-Natal study that collected data at four DR-TB treatment initiation sites did not find 
any association between patients’ times to treatment and the distances between diagnosing 
and treatment initiating facilities (Smith et al., 2013, p. 1). This finding may be due to 
inadequate decentralisation to date.  
4.2.4. Treatment outcomes and mortality 
 
Studies in South Africa have shown that decentralised programmes have had similar, if not 
better, treatment outcomes than centralised programmes. A Khayelistsha study showed 
improved survival rates amongst patients receiving decentralised care, whereas a KwaZulu-
Natal study showed no significant difference in survival following treatment initiation (Cox et 
al., 2014, p. 446; Loveday et al., 2012, p. 209). Another KwaZulu-Natal study reported shorter 
times to sputum smear and sputum culture conversion amongst patients receiving 
decentralised treatment, when compared to patients receiving centralised treatment (Heller 
et al., 2010, p. 420). Importantly, however, an in-depth analysis of treatment outcomes at 4 
decentralised DR-TB sites in KwaZulu-Natal reported significant differences in treatment 







Decentralisation of DR-TB services can reduce time to treatment and improve rates of 
treatment linkage without negatively impacting on treatment outcomes (Cox et al., 2014; 
Loveday et al., 2012). However, access to decentralised treatment sites remains varied within 
the country and the Western Cape Province. This study will seek to identify barriers and 
enablers to treatment linkage during a period of ongoing scale-up of decentralised care. This 
study will further seek to identify variations in barriers and enablers to DR-TB treatment 
linkage across urban and rural areas with varying level of decentralised care. 
Part 5: Factors that enable or impede timeous treatment 
linkage 
 
Previous studies have demonstrated that rates of treatment initiation and time to treatment 
following DR-TB diagnosis are influenced by the type of diagnostic test used, as well as 
initiation of treatment at a centralised versus decentralised site. However, these factors 
overlap and interact with a numerous other factors, including factors falling within Coker et 
al.’s (2010) context, mechanisms and patient domains. The overlapping factors that influence 
DR-TB treatment linkage, identified in academic literature, are outlined below.  
5.1. Death and loss to follow up 
 
Previous studies have demonstrated that death prior to treatment linkage and loss to follow-
up are the most prevalent drivers of linkage failure within South Africa. Loss to follow-up may 




linkage occurs due to failures of the health system to rapidly process diagnostic results and/or 
link patients to treatment. 
5.1.1. Death prior to treatment linkage 
 
Prior to the rollout of the Xpert and decentralisation, long delays to treatment initiation 
resulted in many patients dying prior to starting treatment.  A retrospective study in KwaZulu-
Natal reported that 40% of MDR and 51% of XDR TB patients died prior to receiving their 
diagnosis (Gandhi et al., 2010, p. 80). In Gauteng, 21% of patients diagnosed between 2004 
and 2007 died between diagnosis and referral to specialist treatment sites (Marais et al., 
2014, p. 411). High rates of death prior to treatment initiation were also reported in Mongolia 
between 2012 and 2013, where average time to treatment initiation was measured at 137 
days (Ganzaya et al., 2013, p. 1). 
Despite efforts to reduce times to treatment through the decentralisation of DR-TB 
services and the rollout of Xpert testing tools, many patients still die prior to starting 
treatment. Following the decentralisation of DR-TB services, death continued to be the most 
common reason for non-initiation of treatment in the area (Cox et al., 2014, p. 443). Similarly, 
two recent studies in Gauteng and KwaZulu-Natal highlighted death as one of the most 
common reasons for non-initiation of treatment. Thirty one percent of non-linkers in Gauteng 
and 24% of non-linkers in KwaZulu-Natal diagnosed in 2011 died prior to starting treatment 
(Dlamini-Mvelase et al., 2014, p. 4; Ebonwu et al., 2013, p. 1046). The high rates HIV co-
infection in South Africa contribute to the high rates of death prior to DR-TB treatment 





5.1.2. Loss to follow up 
 
Patients that are defined as ‘lost to follow up’ are patients that cannot be traced by the health 
system. Loss to follow up may occur due to health system and patient factors, and the 
interactions between these factors. This may occur when inadequate information is collected 
from patients in order to locate and communicate with them further. This may also occur 
when health facilities’ procedures and systems for tracing patients are inadequate. 
 Loss to follow up has been highlighted as one of the most common reasons for linkage 
failure amongst drug resistant and drug susceptible TB patients. It is estimated that 25% of 
sputum smear-positive TB patients in South Africa are lost to follow up prior to starting 
treatment (Churchyard et al., 2014, p. 245). Amongst MDR-TB patients that fail to link to care, 
rates of loss to follow up have been reported to be as high as 46.4% and 72% (Ebonwu et al., 
2013, p. 3; Nkosi et al., 2013, p. 1046).  
A prospective study of TB patients in Stellenbosch in the Western Cape reported that 
patients that were lost to follow up could not be traced because incomplete information was 
collected by health facilities during their initial health facility visit (Botha et al., 2008, p. 1). 
Similar challenges were reported in a Vietnam study, which also reported patients 
purposefully provide wrong names and incorrect addresses (Buu et al., 2003, p. 737). 
5.2. Factors related to health system mechanisms 
 
Mechanisms are the elements of a health system that are required for a programme to 
function effectively. Mechanisms are also the processes of intervention that are often shaped 




have shown that health system mechanisms to link patients to treatment impact on linkage 
outcomes. 
5.2.1. Location of diagnosis and tracing procedures 
 
Studies have demonstrated that patients’ location of treatment initiation impact on linkage 
outcomes. Patients who initiate treatment at decentralised sites tend to have shorter times 
to treatment than patients that initiate treatment at centralised sites. Yet, there is increasing 
evidence that it is not only where patients initiate treatment that influences linkage, but also 
where they are diagnosed. 
A Gauteng cohort study of patients diagnosed with MDR-TB in 2011 found that patients 
that were referred to initiate DR-TB treatment from a hospital were 8 times less likely to 
initiate treatment than patients referred from a clinic. Reasons for non-initiation of treatment 
included death and loss to follow up (Ebonwu et al., 2013, p. 1046). Another Gauteng study 
found that patients referred to initiate DR-TB treatment from a hospital were more likely to 
be lost to follow-up and not initiate treatment than patients referred from a primary care 
clinic (Nkosi et al., 2013, p. 3).  
The different procedures for tracing patients diagnosed with DR-TB at hospitals versus 
at clinics likely contribute to the different rates of treatment linkage between these two types 
of facilities. Hospitals tend to rely on phone calls to follow up with patients, while primary 
clinics will often go beyond this by arranging home visits for patients that cannot be reached 
via phone (Nkosi et al., 2013, p. 3). Relying solely on phone calls may be problematic as some 
patients, particularly in rural areas, do not have phones (Jacobson et al., 2013, p. 507). While 




procedures could be improved at clinics by increasing staffing levels and clarifying staff’s roles 
and responsibilities (Nkosi et al., 2013, p 4).  
5.2.2. Human resources 
 
A KwaZulu-Natal study reported that rapid and constant turnover of staff undermines the 
consistency and quality of MDR-TB care.  The authors reported that facilities with more 
consistent staffing were more likely to notice missed appointments and follow up with DR-TB 
patients when necessary (Loveday et al., 2014, p. 4). A Gauteng study, similarly noted that 
ongoing rotation of staff likely undermines treatment linkage. The study authors 
recommended clarification of staff responsibilities and additional training to improve 
treatment linkage (Nkosi et al., 2013, p. 4). 
In Cape Town, the employment of nurses at a sub-district level to trace patients and 
ensure treatment initiation contributed to improved linkage. A study of 10 high burden clinics 
reported that 6 and 9% of patients diagnosed using the Xpert and LPA, respectively, did not 
initiate treatment (Naidoo et al. 2014, p. 4). This is far below government’s national and 
provincial estimations for non-initiation. 
5.2.3. Health care worker attitudes  
 
A Gauteng study found that patients that reported previously having negative experiences at 
primary clinics were less likely to link to care following diagnosis of TB (Edginton et al., 2005, 
p. 401). Similar challenges have been identified in Vietnam (Buu et al., 2003, p. 1). Patients’ 
negative perceptions of health care worker attitudes also contribute to default following DR-




5.2.4. Adherence to guidelines 
 
Health care workers’ knowledge of, and adherence to, policy guidelines can enable or impede 
treatment linkage. Over recent years, the National Department of Health has published a 
number of updated diagnostic and treatment guidelines, yet many health care workers report 
being unaware of or not having seen the updated guidelines (Loveday et al., 2014, p. 6; Nkosi 
et al., 2013, p. 3). In Gauteng, 86 and 64% of staff interviewed at primary care clinics and 
hospitals, respectively, reported being unaware of the MDR-TB guidelines (Nkosi et al., 2013, 
p. 3). A KwaZulu-Natal study reported that poor adherence to clinical guidelines in 
decentralised DR-TB sites is associated with poor treatment outcomes (Loveday et al., 2014, 
p. 6). Additionally, many eligible patients are not provided with Xpert testing due to poor 
adherence to diagnostic algorithms and therefore continue to face diagnostic delays  
(Churchyard et al., 2014, p. 245; Dlamini-Mvelase et al., 2014, p. 3). 
5.2.5. Systems for processing and returning results 
 
Sputum samples collected at clinics are sent to National Health Laboratory Services (NHLS) 
labs for processing.  Large discrepancies in the times to diagnosis have been reported 
depending on the type of testing done (Xpert, LPA or culture DST). Operational delays at NHLS 
labs may contribute to delayed treatment initiation. A Western Cape study of patients 
diagnosed using LPA and culture DST, reported delays of approximately 1 week between 
processing DST results and returning them to clinics. Further delays were reported between 
the time results were returned to clinics and when patients were contacted to return for 




NHLS’s systems for returning results to facilities can influence facility level delays. One tactic 
that the NHLS is exploring to reduce these delays is the use of cell phone messaging to 
promptly alert both health care workers and patients of TB results. To improve follow up on 
diagnostic results, a cell phone system was piloted by TB/HIV Care in KwaZulu-Natal, which 
used text messages to inform community health care workers of new TB diagnoses. After 
receiving text messages, community health care workers were responsible for contacting 
patients to inform them of their results and refer them to clinics for treatment. The project 
reported initiating 89% of patients onto treatment within 5 days of diagnosis (TB/HIV Care, 
n.d.). 
5.2.6. Counselling and education 
 
The availability and quality and of counselling and education in facilities and communities can 
also influence treatment linkage. Poor awareness and understanding of MDR-TB within 
communities contributes to diagnostic delays and may lead patients to seek care from 
alternative providers (MRC, 2009, p. 8; Niekerk et al., 2013, p. 1). Without proper counselling 
and education, patients may not be aware of the importance of starting treatment (Buu et 
al., 2003, p. 1; Voss De Lima et al., 2013, p. 5) and face a greater risk of default (MRC, 2009, 
p. 8). 
5.2.7. Availability of beds  
  
The 2011 adoption of policy guidelines for decentralised MDR-TB treatment was undertaken 
in recognition of the fact that hospitals are increasingly unable to accommodate the growing 
number of DR-TB patients. Waiting lists for hospital beds of up to 120 days have been 




Department of Health stated that “waiting lists for patients [who] need to be admitted to 
centralised units are long, delaying the initiation of treatment in some provinces for three or 
four months. In addition, several patients die before starting treatment” (NDoH, 2011a, p. 5).  
Waiting lists for beds likely continue to delayed treatment initiation in areas where 
decentralisation has not been fully implemented. Additionally, waiting lists may delay 
treatment initiation for XDR-TB patients, and patients with complicated MDR-TB, who still 
require hospitalisation during the initial intensive phase of treatment.  
5.2.8. Leadership  
 
Leadership is a key component of health systems and may influence whether or not an 
intervention is effectively implemented. Facility managers and local leaders play a crucial role 
in supporting policy implementation, both in terms of making sense of the challenges that the 
policy seeks to respond to and its potential benefit, as well as creating a culture of 
accountability (Gilson et al., 2014, p. 1.). 
The 2011 decentralisation guidelines called for the appointment of district DR-TB 
coordinators to support DR-TB services in the district. A recent KwaZulu-Natal study reported 
that facilities with visible leadership, including regular visits from district coordinators, had 
better treatment outcomes (Loveday et al., 2014, p. 4). Regular visits by the district 
coordinators “led to increased accountability and a commitment to patient care resulting in 
improved adherence and a higher number of successful [treatment outcomes]” (Loveday et 





5.3. Patient factors 
 
Developing responsive and acceptable health programmes is a key component of demand 
generation, identified by Atun et al. (2004) as one of the six key functions of the health 
systems. Understanding patient factors that impact on linkage to treatment is crucial to 
developing health programmes that are responsive to the needs and vulnerabilities of 
different patient groups. Patient factors encompass factors arising from patients’ capacity and 
workloads that influence the uptake, or lack thereof, of timeous DR-TB treatment.  
Patient capacity encompasses individual socio-economic factors, mental and physical 
factors that impact on patients’ ability and willingness to initiate treatment. Patient 
workloads encompass patient’s individual employment, financial and household 
responsibilities, they also encompass the work required to initiate treatment, such as daily 
clinic visits. 
5.3.1. Factors related to patient capacity 
5.3.1.1. Socio-demographic and economic status 
 
A number of studies have sought to identify whether socio-demographic and economic 
factors influence treatment linkage. A Johannesburg study showed that not having a formal 
education results in a two-fold increase in one’s risk of delayed or failed linkage to TB care 
(Voss De Lima et al., 2013, p. 5). This finding was supported by a systematic review (Storla et 
al., 2008, p. 6).  
Previous research has also shown that age and gender may impact on TB treatment 
linkage (Farah et al., 2006; Rojpibulstit et al., 2006; Storla et al., 2008). However, a recent 




age or gender groups (Naidoo et al., 2014, p. 1). Similarly, a Gauteng study did not find any 
difference in rates of treatment initiation between gender groups. However the study did 
observe that patients over 65 had an increased risk of linkage failure when compared to other 
groups (Ebonwu et al. 2013, p. 1046). 
A Johannesburg study showed that non-South Africans are less likely to link to TB 
treatment than South African citizens following diagnosis (Voss De Lima et al. 2013, p. 4). This 
finding was supported by a systematic review that found that patients with a history of 
immigration, and illegal residents, are more likely to face TB diagnostic and treatment delays 
(Storla et al. 2008, p 6), suggesting poor access for these groups. 
5.3.1.2. Substance abuse 
 
Substance abuse has repeatedly been highlighted as a major driver of South Africa’s high DR-
TB default rates (Holtz et al., 2006; Kendall et al., 2013; MRC, 2009).  Substance abuse has 
also been shown to increase diagnostic and treatment delays amongst drug susceptible TB 
patients (Storla et al., 2008, p. 1). Taking these findings into account, it is likely that substance 
abuse also negatively influences DR-TB treatment linkage. 
5.3.1.3. Beliefs and attitudes 
 
A participatory research study in Cape Town found that people with TB may avoid or delay TB 
diagnosis due to fears around anticipated HIV-stigma (Murray et al., 2013, p. 1). In Cape Town, 
TB is seen as related to squalor and dirt over which people living in poverty may have little 
control. The sense of lack of control, combined with the anticipation of HIV-stigma, 





5.3.1.4. Disease and health related patient factors 
Site of TB illness  
 
A Western Cape study reported that patients with extra-pulmonary MDR-TB had shorter 
delays to treatment initiation than patients with pulmonary MDR-TB. The authors posited 
that this is because patients with extra-pulmonary disease tend to be more ill when they are 
diagnosed and may already admitted as hospital in-patients, which allows for immediate 
treatment initiation upon diagnosis (Jacobson et al., 2013, p. 507). While having extra-
pulmonary TB was associated with quicker treatment initiation following diagnosis, it may 
have the opposite effect on time to diagnosis. A systematic review of studies of patients with 
drug susceptible TB, found that patients with extra-pulmonary TB have longer delays to 
diagnosis than patients with pulmonary TB (Storla et al., 2008, p. 3). 
Smear status 
 
A patient’s TB smear status may also impact on their time to treatment. Smear positive DR-
TB patients diagnosed using LPA have significantly shorter times to diagnosis and treatment 
than smear negative patients (Jacobson et al., 2013, p. 506). This is because a positive smear, 
removes the necessity of a positive culture prior to identifying drug resistance. Positive smear 
status has also been shown to reduce time to diagnosis and treatment amongst patients with 
drug susceptible TB (Chiang et al., 2005, p. 1; Storla et al., 2008, p. 1). However, for patients 







A Gauteng study found that HIV positive patients were more likely to initiate MDR-TB 
treatment following diagnosis than HIV negative patients. This is likely due to the integration 
of HIV and TB services, which has also been shown to improve MDR-TB outcomes in KwaZulu-
Natal (Ebonwu et al., 2013, p. 1047; Loveday et al. 2014, p. 1). However, a Cape Town study 
found that HIV contributed to non-initiation of treatment amongst patients diagnosed with 
LPA (Naidoo et al., 2014, p. 4). Two studies further demonstrated that HIV does not increase 
a patient’s risk of treatment default but does increase the risk of death   (Cox et al., 2014, p. 
444; Kendall et al., 2013, p. 4). 
Previous TB treatment, other health conditions and smoking 
 
A recent Gauteng study reported that 84% of patients that did not initiate MDR-TB treatment 
were previously treated for TB and these patients faced a greater risk of death (Ebonwu et al. 
2013, p. 1045). Additionally, patients failing drug susceptible TB treatment may face 
diagnostic delays due to being ineligible for Xpert testing according to diagnostic algorithms 
(Niekerk et al., 2013, p. 1).   
Other health conditions may also impact on time to diagnosis and treatment initiation, 
including the presence of a chronic cough or lung disease (Storla et al. 2008, p. 3). In the 
Western Cape smoking currently, or in the past, is associated with delays to treatment 
initiation (Jacobson et al., 2013, p. 506). 
5.3.2. Factors related to patient workloads 
5.3.1.1.. Employment and household responsibilities 
 
Balancing employment and family responsibilities is particularly difficult during the initial 




Two Cape Town studies reported that patients sometimes miss appointments or delay 
initiating treatment due to family, financial and employment responsibilities (Naidoo et al., 
2014, p. 8; Niekerk et al., 2013, p. 1).  
The National Department of Health further noted that patient’s household responsibilities 
may contribute to treatment delays amongst patients referred to centralised services (NDoH, 
2011a, p. 17). For patients that take care of young children in single headed households, 
initiating in-patient care may not be feasible. Importantly, a study in the KwaZulu-Natal found 
that 75% of MDR-TB patients’ households were headed by females (Marra, 2009, p. 11). 
5.4. Contextual factors 
 
Contextual factors further impact on whether or not patients link to care. Contextual factors 
refer to the context in which the DR-TB programme is operating and encompass “the political, 
legislative, social, economic and technical environments within which communicable disease 
control programmes sit” (Coker et al., 2010, p. i23). 
5.4.1. Rural versus urban residence 
 
A systematic review of factors that impede DS-TB treatment linkage, showed that living in a 
rural area increases one’s risk of diagnostic and treatment delays (Storla et al., 2008, p. 1). 
Similarly, two Western Cape studies reported that patients with a farm address are less likely 
to initiate treatment following MDR-TB diagnosis than patients with a town address  
(Jacobson et al., 2013, p. 506; Kendall et al., 2013, p. 5). 
Interestingly, a Gauteng study detected significant differences in MDR-TB patients’ 




unknown. The Gauteng study also showed that patients living in Gauteng’s central business 
districts were less likely to initiate treatment than people living in the suburbs or informal 
settlements (Ebonwu et al., 2013, p.1047).  
Part 6: Conclusion 
 
In recent years, South Africa has witnessed rapid increases in the number of diagnosed DR-TB 
cases. This is due to a combination of increasing incidence and improved diagnostics (WHO, 
2014, p. 141). However, rapid increases in diagnosed DR-TB cases have outpaced the capacity 
of the country to initiate and treat patients, resulting in a widening treatment gap. According 
to WHO estimates, 59% of patients diagnosed with RR and/or MDR TB during 2013 were not 
linked to care (WHO, 2014, p. 141). 
This study will seek to understand why patients frequently fail to link to DR-TB care 
through conducting an embedded case study within the Western Cape. The Western Cape 
was selected as the site of this case, to allow for exploration of variation in barriers and 
enablers to treatment linkage in high-burden urban and rural areas with varying levels of 
decentralisation. While wide-scale access to decentralised care has been observed in the 
urban City of Cape Town (Caldwell, 2013, p. 4), access remains limited in rural parts of the 
province (Theron, 2013, p. 5). 
While a number of previous studies have identified factors that influence treatment 
linkage, they have also highlighted research gaps. To date, there has been little exploration of 
patients’ perspectives regarding factors that impact on treatment linkage and there is limited 
understanding of how patient factors impact on linkage to care. Additionally, there has been 




scale-up, which can have unexpected consequences that impact on linkage to care (De 
Savigny & Adam, 2009, p. 4). 
This study will apply Coker et al.’s (2010) conceptual framework as a lens to explore the 
impact of context, health system mechanisms and patient factors on linkage to treatment 
during a period of policy intervention. By adopting a systems thinking approach (De Savigny 
& Adam, 2009, p. 19), this study aims to generate insight into the complex dynamics of DR-TB 
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Background: Patients diagnosed with rifampicin resistant (RR) tuberculosis (TB) in South 
Africa frequently fail to link to appropriate drug resistant (DR) TB treatment. The aim of this 
study was to explore barriers and enablers to expedited treatment linkage following RR-TB 
diagnosis in the Western Cape Province, within the context of ongoing decentralisation of DR-
TB services and the scale-up of Xpert MTB/RIF diagnostics. 
 
Methods: An embedded case study approach, using qualitative research methods, was 
employed to explore barriers and enablers to expedited treatment linkage following RR-TB 
diagnosis. The case of investigation in this study was ‘treatment linkage following RR-TB 
diagnosis in the Western Cape Province during the ongoing decentralisation of DR-TB services 
and scale-up of Xpert diagnostics’. DR-TB is used in this study as an encompassing term to 
refer to RR, multidrug resistant (MDR) and extensively drug resistant (XDR) TB. The embedded 
units of analysis in this study were patients’ linkage outputs, defined as: (1) expedited 
treatment initiation, (2) delayed treatment initiation and (3) non-initiation of treatment 
following the collection of sputum on which RR-TB was diagnosed. Seventeen patient, 8 family 
member, 49 healthcare worker and 4 key informant open-ended, in-depth interviews were 
conducted and 59 patient folders were reviewed. A framework approach using an adapted 
version of Coker et al.’s (2010) conceptual framework was applied for analysis. 
 
Results: This study identified multiple factors that enabled and constrained expedited 
treatment linkage following RR-TB diagnosis. Enabling factors included: 1) the availability of 
clinic level DR-TB counsellors and tracers, 2) living in walking distance of decentralised 
services and 3) having a strong social support network. Constraining factors included: 1) low 
usage of Xpert diagnostics, 2) delays in acting on results and missed (or unseen) results, 3) 
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rotation of nurses or the lack of dedicated TB nurses in clinics, 4) limited clinic-level 
administrative support, 5) information systems challenges and 6) waiting lists for beds and 
limited access to transport services in rural areas.  
In linking to treatment, patients commonly face challenges due to competing 
subsistence needs and household or employment responsibilities. Substance addiction, 
having a history of treatment interruption, demonstrating hopelessness regarding treatment, 
as well as not having a stable place to stay or social support may increase a patient’s risk of 
linkage failure. 
 
Conclusion: Within the Western Cape Province there is significant opportunity to improve 
linkage to treatment through strengthening the health systems mechanisms to link patients 
to treatment following RR-TB diagnosis. Expanding access to psychosocial services (substance 
abuse rehabilitation and psychosocial evaluations) following RR-TB diagnosis may assist in 
linking high risk patients to treatment. Additionally, the provision of food support (in addition 
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The World Health Organisation’s 2014 Global TB Report drew attention to the growing gap 
between the number of patients diagnosed with drug resistant (DR) tuberculosis (TB) and 
those initiated onto treatment in a number of high burden countries, including South Africa. 
According to the Global Report, during 2013 only 41% of patients diagnosed with rifampicin 
resistant (RR) TB in South Africa linked to treatment [1] 
Treatment linkage is defined in this study as the initiation of an appropriate DR-TB 
treatment regimen (according to available resistance results) following the detection of RR-
TB. DR-TB is used in this study as an encompassing term to refer to RR, multidrug resistant 
(MDR) and extensively drug resistant (XDR) TB. 
RR-TB requires 18 to 24 months of MDR-TB treatment (in combination with isoniazid 
for rifampicin mono-resistant patients) [2] and is a good indicator of MDR-TB, which is defined 
as resistance to rifampicin and isoniazid [3,4]. According to South Africa’s treatment 
guidelines, patients diagnosed with RR-TB should be immediately initiated onto an MDR-TB 
regimen, while awaiting the results of further resistance testing [5]. 
The DR-TB treatment gap has rapidly grown in recent years as rates of treatment 
linkage have failed to keep pace with escalating rates of diagnosed RR-TB cases. Diagnosed 
RR-TB cases increased by 252% in South Africa between 2010 and 2013, due to a combination 
of improved diagnostics and increasing incidence [1,6]. 
Studies in South Africa have demonstrated that increasing incidence is largely driven 
by person-to-person transmission, rather than acquired resistance [6,7]. Reducing the periods 
during which DR-TB patients remain infectious by decreasing delays to diagnosis and 
treatment initiation and improving rates of treatment linkage is therefore critical to reducing 
DR-TB incidence [7]. 
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In an effort to reduce diagnostic and treatment linkage delays, South Africa’s National 
Department of Health (NDoH) embarked on two ambitious national policy interventions 
during 2011: the rollout of Xpert MTB/RIF (Xpert) diagnostics and the decentralisation of DR-
TB services [5,8]. 
Xpert diagnostics were adopted following demonstration studies that showed Xpert 
significantly reduced diagnostic turn-around times for detecting RR-TB, when compared to 
line probe assay and culture drug susceptibility testing [9]. The Xpert rollout was coupled with 
the adoption of a new diagnostic algorithm recommending Xpert as an initial diagnostic test 
for all TB suspects, and the establishment of a policy target to initiate all newly diagnosed RR-
TB patients onto MDR-TB treatment within 5 days of diagnosis [5,10]. 
National guidelines recommending the decentralisation of DR-TB services were 
adopted in recognition of the fact that the traditional hospitalised system was increasingly 
unable to cope with rising patient numbers and in light of evidence that decentralisation could 
improve treatment linkage [11–13]. 
Treating DR-TB typically involves six months of daily injections and tablets during the 
intensive phase of treatment, followed by eighteen months of tablets during the continuous 
phase of treatment. 1  Prior to the adoption of decentralisation guidelines, patients were 
hospitalised during the intensive phase of treatment. The decentralisation guidelines 
removed the requirement for hospitalisation, allowing for clinic-level treatment initiation and 
management during the intensive phase of treatment [8]. 
                                                     
1 The intensive phase refers to the initial phase of treatment during which medicines to treat DR-TB are taken in 
combination with daily injections. Patients must be hospitalised or visit clinics daily in order to receive injections. This 
phase generally last around 6 months. After the intensive phase, patients initiate the continuous phase. During the 




The decentralisation guidelines recommend clinic-level treatment initiation and management 
for low grade transmission risk, smear negative MDR-TB patients with stable social 
circumstances, as well as patients that refuse hospitalisation. These patients must visit clinics 
daily for injections throughout the intensive phase of treatment. XDR-TB patients, smear 
positive MDR-TB patients, severely ill and complicated patients, as well as patients whose 
social circumstances preclude them from ambulatory care should continue to be hospitalised 
during the intensive phase of treatment [8]. This study defines decentralised care as clinic-
level treatment initiation and centralised care as hospital-level treatment initiation. 
This study qualitatively explored barriers and enablers to DR-TB treatment linkage 
within the Western Cape Province in the context of the national Xpert rollout and ongoing 
decentralisation of DR-TB services using an adapted version of Coker et al.’s (2010) conceptual 
framework as an analytic lens.The Coker framework was designed for evaluating infectious 
disease programmatic interventions within health systems [14]. Using an adapted version of 
this framework, this study explored how issues of context, health systems mechanisms, 
patient factors, and the inter-relationships between these factors impacted on patients’ 
linkage to treatment outputs. Linkage to treatment outputs included: expedited initiation of 
treatment, delayed initiation of treatment and non-initiation of treatment following sputum 




This study employed a single, embedded case study design to explore enablers and barriers 
to DR-TB treatment linkage following RR-TB diagnosis. An embedded case study involves 
8 
 
more than one unit of analysis, which are situated within the wider case [15]. The embedded 
units of analysis in this study were linkage to treatment outputs, defined as: (1) expedited 
treatment initiation, (2) delayed treatment initiation and (3) non-initiation of treatment 
following sputum collection on which RR-TB was diagnosed. 
A case study design was applicable for this study as it allowed for exploration of 
enablers and barriers to expedited treatment linkage within a contemporary field setting over 
which the researchers did not have behavioural control [15]. The case of analysis in this study 
was ‘DR-TB treatment linkage following RR-TB diagnosis within the Western Cape Province, 
during a period of treatment decentralisation and rollout of Xpert diagnostics’.  
Qualitative data collection and analysis techniques were employed in order to gain 
rich insight into patients’ ‘real life’ [16] linkage experiences following diagnosis of RR-TB. 
Qualitative research techniques were selected as they allow for exploration and interpretive 
analysis of complex phenomena that are influenced by context, actors and the inter-
relationships between the different aspects of the phenomena [17]. 
 
Study setting 
The Western Cape Province was selected as the setting for this case study in order to explore 
variation in linkage barriers and enablers across urban and rural areas in a high-burden 
province with varying levels of decentralisation across districts.  The Western Cape Province 
has the third highest burden of DR-TB nationally. According to national estimates, only 49% 
of patients diagnosed with RR-TB during 2012 linked to DR-TB treatment [18]. However, a 
recent observational study conducted in 10 high burden clinics in the City of Cape Town 
reported that more than 90% of patients diagnosed with RR-TB between 2008 and 2012 
linked to treatment within 6 months of diagnosis [19]. 
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The Western Cape Province is made up of the urban Cape Town metropolitan municipality 
and the following rural districts: West Coast, Cape Winelands, Eden and Central Karoo. The 
province began piloting decentralised DR-TB care in 2007 in partnership with Médecins Sans 
Frontières 2  within an urban township in the Cape Town metropolitan municipality [13]. 
Following the adoption of national policy guidelines in 2011, the province sequentially rolled 
out Xpert diagnostics to all provincial sub-districts and expanded decentralised DR-TB 
treatment initiation and management to rural parts of the province [8,20]. 
 
Sampling criteria for patients and re-categorisation following data collection 
 
Forty three patients were purposefully sampled from the National Health Laboratory Services 
(NHLS) diagnostic records from January to March 2013 and the national electronic DR-TB 
registry (EDR). Purposive sampling involves the identification and selection of key individuals 
who are able to provide unique insight into the topic of investigation [21]. Purposive sampling 
was used to identify sample patients for each embedded unit: expedited treatment initiators, 
delayed treatment initiators and non-initiators in each study district. At initial selection, 
patients’ EDR registration dates and locations were used as a proxy for treatment start dates 
and locations. 
Patients that linked to treatment within one month of the date of sputum collection 
on which RR-TB was diagnosed were categorised as expedited initiators. Patients that started 
treatment more than one month and less than six months after sputum collection were 
categorised as delayed initiators. Patients that did not initiate treatment within six months of 
sputum collection on which RR-TB was diagnosed were categorised as non-initiators. 
                                                     
2 Médecins Sans Frontières is an international non-governmental organisation that provides health services in 
a number of countries including South Africa. 
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Following record review, patients were re-categorised as expedited initiators, delayed 
initiators and non-initiators according to the more accurate treatment start dates reflected in 
their folders. Re-categorisation is visually depicted in Figure 1. 
 
Figure 1. Sample patients (and sources of data) at initial selection and following re-
categorisation 
 
         




                        
 
             
 
 
A limitation of this study was that a number of patients initially selected as non-initiators had 
to be re-categorised as expedited or delayed initiators following data collection from patient 
record reviews – leading to low patient numbers in the non-initiator embedded unit.  Effort 
was made to identify additional non-initiators after re-categorisation. Two of the 43 sample 
patients were purposefully selected following initial re-categorisation in order to increase the 
number of non-initiators included in this study. 
   13 expedited initiators   13 delayed initiators 17 non-initiators 
18 expedited 





- 26 folders reviewed 
- 17 healthcare 
workers interviewed 
- 6 patients 
interviewed 







17 delayed initiators 




- 25 folders reviewed 
- 27 healthcare workers 
interviewed 
- 10 patients interviewed 







8 non-initiators (includes 
3 previous interrupters) 
 
Data collected 
- 8 folders reviewed 
- 5 healthcare workers 
interviewed 
- 1 patient interviewed 















Categorisation of sample patients within embedded units at initial selection 
(using EDR registration dates as a proxy for treatment start dates) 
 
         Re-categorisation of sample patients within embedded units following data collection 
 (using treatment start dates reflected in patient folders) 
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Following completion of data collection, 7 patients were further categorised as previous 
interrupters as they previously interrupted DR-TB treatment. This is unsurprising given the 
complicated pathways of DR-TB patients and the high rates of treatment interruption in the 
country [22]. Previous interrupters were categorised as expeditors, delayers or non-initiators 
according to their times to treatment, following their RR-TB diagnosis on sputum collected 
between January and March 2013.  
Sample patients were purposively sampled from the City of Cape Town metropolitan 
municipality, the West Coast district and the Cape Winelands district to explore variation in 
linkage pathways across urban and rural areas. All patients diagnosed in a City of Cape Town 
facility were categorised as ‘urban’ and all patients diagnosed in a Cape Winelands or West 
Coast facility were categorised as ‘rural’. All of the purposively sampled patients were 
diagnosed and, if relevant, initiated onto treatment in 21 facilities within the three study 
districts, excluding 1 patient who was diagnosed and initiated onto treatment in prison. 
Patients were selected from these facilities to examine the linkage pathways of: (1) patients 
that were diagnosed and initiated onto treatment at a clinic; (2) patients that were diagnosed 
and initiated onto treatment at a hospital; and (3) patients that were diagnosed at a clinic and 
referred to hospital to initiate treatment. The number of facilities visited in each district to 
perform record reviews and interviews are listed in Table 1.  
 
Table 1. Facilities visited in this study to conduct HCW interviews and review patient records 
 




Cape Town 0 5 2 1 
Cape Winelands 0 4 0 1 




Non-designated TB hospitals refer to district and tertiary hospitals that are not designated to 
provide in-patient DR-TB treatment. Designated TB hospitals refer to hospitals that are 
designated to provide in-patient DR-TB treatment. There are 6 designated TB hospitals 
located within the Western Cape, 3 of which were included in the study. 
In addition to patients’ linkage to treatment outputs and locations of diagnosis and 
treatment initiation, gender and age were considered in selecting sample patients. Effort was 
made to identify a similar number of male and female patients from a wide age range. This 
was done to allow for consideration of how gender and age impact on treatment linkage. The 
selection of patients by gender and age, as well as urban versus rural location is depicted in 
Table 2. 














N N N N % 
Urban 7 6 2 15 35 
Rural 11 11 6 28 65 
Female 8 10 3 21 49 
Male 10 7 5 22 51 
Age range 22 - 59 23 - 75 21 - 51 21 -75  
Median age 39 46 34 38 
 
Selection criteria for healthcare workers and family members recruited to the 
study 
 
Healthcare workers (HCWs) at diagnosing and treatment initiating facilities were recruited to 
be interviewed regarding sample patients’ journeys. Doctors, nurses and community health 
workers were eligible to be included in this study if they had provided DR-TB diagnostics 
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and/or treatment services to a sample patient and were able to speak to the sample patient’s 
experience of diagnosis and/or treatment linkage. 
Patients and/or their emergency contacts were asked to identify family members that 
could be recruited to the study. The only criteria requested from patients and or their 
emergency contacts in identifying family members was that they be: 1) over 18 years of age; 
2) willing to be contacted by study reseachers; 3) aware of the sample patient’s DR-TB status; 
and 4) able to speak to the patient’s experiences between diagnosis and treatment initiation.  
 
Recruitment and data collection 
Multiple-perspective, in-depth interviews and folder reviews were conducted in order to 
explore linkage barriers and enablers. For each sample patient, effort was made to explore 
multiple perspectives through requesting interviews with the patient, a family member and a 
treating HCW, as well as conducting folder review. This approach was selected to allow for 
exploration of various perspectives, and in anticipation of the fact that some sample patients 
would have died or not be traceable. All interviews and folder reviews were conducted 
between June and September 2014. 
Interviewers fluent in English, Xhosa and Afrikaans were recruited and trained to 
conduct interviews with patients, their family members and HCWs using interview guides. The 
themes covered in the interview guides were informed by available literature on DR-TB 
linkage [4,13,23–25]. Coker et al.’s conceptual framework [14], as well as the researchers’ 
professional knowledge of the South African health system.  
A sequential approach was used to recruit participants and collect data. The 
sequential approach is visually depicted in Figure 2. Initial facility visits were conducted at the 
facilities where patients were diagnosed with RR-TB, as well as the facilities where patients 
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were initiated onto treatment. Twenty two sample patients were initiated onto treatment at 
the same facility where they were diagnosed. Thirteen sample patients were initiated onto 
treatment at a different facility from where they were diagnosed and the remaining 8 patients 
were not initiated onto treatment. 
During initial facility visits, 59 patient folders were reviewed and 49 interviews were 
conducted with 31 HCWs, including 23 nurses, 7 doctors and 1 community care worker. A 
greater number of HCW interviews were conducted than the total number of HCWs who 
participated in the study, as some HCWs were interviewed regarding more than one sample 
patient. Additionally, a greater number of folders were reviewed than sample patients as 
some patients had folders at more than one facility. 
Using open-ended interview guides, interviewers asked HCWs to describe their 
perceptions of sample patients’ experiences following diagnosis, as well as any factors that 
they felt impacted on patients’ linkage to treatment ouputs. HCWs were asked about sample 
patients’ interactions with the health system  following sputum collection on which RR-TB 
was diagnosed, including: whether tracing was required at any point; whether counselling 
was provided; whether the patient was referred between facilities; and, if so, whether 
transport was provided. HCWs were asked whether they perceived any barriers or enablers 
arising due to health system factors that impacted on patients’ linkage to treatment outputs. 
HCWs were also questioned regarding whether they had insight into patients’ personal lives 
and, if so, to describe from their perspectives how personal factors impacted on patients’ 
linkage to treatment outputs. HCWs that had difficulty in recalling patients were given 
patients’ folders to review during interviews. This approach was used to minimise the impact 
of recall bias on the study’s results. HCWs were also questioned about their general 
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perceptions of barriers and enablers to treatment linkage in the facilities and districts where 
they worked.  
 























Step 1: Sample patients identified 
Sample patients meeting selection criteria were identified through reviewing NHLS 
diagnostic data for the Western Cape Province from January to March 2013 and EDR 
records of treatment start dates and locations 
 
Step 2: Patient records reviewed at diagnosing and treatment initiating facilities 
Diagnosing and treatment initiating clinics and hospital visited and patient record review 
conducted 
 
Step 3: Diagnosing and treating HCWs of sample patients recruited and interviews 
conducted 
During facility visits, diagnosing and treating HCWs of sample patients were identified 
and recruited to participate in the study. Interviews were arranged at clinics and 
hospitals at a convenient time for HCWs 
 
Step 4: Permission to contact sample patients and their family members requested by 
HCWs 
Following interviews, HCWs were asked to contact sample patients – or their emergency 
contacts if sample patients could not be reached - to request their permission to be 
contacted by study researchers 
 
 
Step 5: Sample patients and their family members recruited to the study 
Patients and their emergency contacts that consented to be contacted by study 
researchers were contacted by study researchers to request their permission to 
participate in the study. Patients and their emergency contacts were asked to identify a 
family member that could be interviewed and request their permission to be contacted 
by study researchers 
 
Step 6: Interviews arranged and conducted with patients and their family members 
Interviews were arranged and conducted at a convenient time and location for patients 




During initial facility visits, HCWs were asked to contact sample patients to request their 
consent to be contacted by study researchers. All but three HCWs agreed to do this. The three 
HCWs that would not contact their patients explained that the patients were too ill to be 
interviewed and did not have emergency contacts. An additional 4 patients could not be 
contacted as no contact information was known to the facility. HCWs attempted to reach the 
remaining 36 patients and/or their emergency contacts via phone (22 patients), via 
community care workers (9 patients) or during facility visits (5 patients).  
Seventeen of the 43 sample patients were located and interviewed. Reasons for not 
interviewing all 43 purposively sampled patients included: loss to follow up (16 patients), 
death (5 patients), ill health (3 patients), refusal (1 patient) and relocation (1 patient). Patients 
that could not be contacted by HCWs via phone, community care workers or due to having 
no known contact details were categorised as lost to follow up.  
Eight family members of sample patients were recruited to the study and interviewed.  
Of the 8 family members interviewed, four were interviewed jointly with a sample patient 
and four were interviewed individually.  
During interviews, patients and were asked to describe their experiences of diagnosis 
and linking to treatment. Family members were asked to describe the experiences of the 
patient. Open-ended questions were used during patient and family member interviews to 
explore the challenges that patients faced in linking to treatment, as well as enabling factors 
that assisted them in linking to treatment. Questions explored patients’ experiences in 
interacting with the health system between diagnosis and treatment initiation and how this 
impacted on their linkage to treatment outputs. Questions also explored patients’ personal 
circumstances – including household responsibilities, employment, social support and 
economic status - and whether factors related to personal circumstances impact on their 
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linkage to treatment outputs. Patients that did not link to treatment were asked to describe 
what happened following diagnosis and why they never linked to treatment.  
Interviews were also conducted with four key informants (1 provincial and 3 district) 
in order to complement and compare our understanding of enablers and barriers to 
treatment linkage of individuals in leadership positions with those of front line providers. This 
allowed us to pool knowledge to understand the Western Cape more broadly. Key informants 
(KIs) included senior managers at district and provincial levels, as well as senior clinicians 
operating across districts. All four KIs approached for interviews agreed to participate. KIs 
were questioned about challenges faced in facilities diagnosing and treating DR-TB, as well as 
what - from their perspectives – works well and enables patients to rapidly link to treatment. 
All groups of participants (patients, family members, HCWs and KIs) were asked to give 
recommendations for how facilities could improve rates of treatment linkage and reduce 
treatment linkage delays and failure.  
Data collected from interviews and folder review was supplemented by a review of 
NHLS diagnostic records for all RR-TB diagnoses processed in the Western Cape between 
January and March 2013 and data on dates of Xpert installation within Western Cape sub-
districts. This was done to explore how the type of diagnostics tool used, as well as access to 
Xpert diagnostics impacted on linkage to treatment outputs.  
It was determined that data saturation was achieved with regards to the health system 
mechanisms that impacted on treatment linkage, as participants’ responses became 
repetitive at the end of the interview process, and KIs’ explanations of barriers and enablers 
to treatment linkage echoed previously described phenomena [26]. However, data saturation 
was not achieved with regards to patient factors that contributed to linkage failure, given the 
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small number of interviews conducted with patients (or their family members) that failed to 
link to treatment. 
 
Data analysis 
Data analysis was guided by Coker et al.’s conceptual framework, which was adapted for the 
study [14]. The framework approach facilitated a combination of thematic analysis and cross-
synthesis of data across embedded units, perspectives and districts. Unlike previous 
applications of the framework, a scoring approach was not used to evaluate data [14,27]. 
Rather the framework was applied to organise data and interpret findings – related to the 
treatment linkage output data we already had. 
All recorded interviews were transcribed and interviews conducted in Xhosa and 
Afrikaans were translated into English. Interview transcripts and data extracted from patient 
folders were coded in Nvivo using a combination of inductive and deductive coding. Deductive 
codes were drawn out from an extensive literature review and Coker et al.’s framework. 
Inductive codes were drawn from emerging findings recorded in field notes kept throughout 
the data collection process, as well as themes that emerged during the coding process.  
Following the completion of coding, each data source (interview transcripts and 
record notes) was reviewed again for each sample patient and a summary of barriers and 
enablers faced by each patient was drafted. The summarised enablers and barriers were then 
organised into matrix tables for each embedded unit by sample patient and perspective (see 
annexure 1). “The matrix is a tabular format that collects and arranges data for easy viewing 
in one place, permits detailed analysis, and sets the stage for later cross case-analysis with 
other comparable cases or sites” [16: 111].    
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Tactics recommended by Miles, Huberman and Saldana (2013) were used to draw meaning 
from the embedded unit matrices [16]. Within unit analysis was done for each embedded unit 
and patterns and themes were noted. Constant comparison and contrasts were used to 
identify patterns and themes across embedded units. Additionally, counting was used to 
compare the presence of a variable (such as being employed, having a stable place to stay or 
having access to Xpert) with patients’ linkage to treatment outputs [16]. 
Following embedded unit analyses, case-level analysis was conducted using thematic 
matrices. Thematic matrices were used to organise data from all embedded units which 
allowed for visual comparison of the data across the case as a whole. Case-level thematic 
matrices organised all coded data falling within the theme of analysis by: (1) perspective 
(patient, family member, HCW, KI); (2) district (Cape Town, Cape Winelands, West Coast); and 
(3) focus (reported barriers and enablers faced by individual patients versus reported general 
barriers faced in facilities and districts) (see annexure 2). 
Data was organised according to perspective to explore agreement and discrepancy 
between patients’, family members’, HCWs’ and KIs’ perspectives of barriers and enablers. 
Data was organised according to district to explore variation in barriers and enablers across 
rural and urban districts. Finally, data was organised by focus to determine whether 
participants’ general perceptions of barriers and enablers matched those reported for 
individual patients. 
Miles, Huberman and Saldana explain that “there are no fixed canons for constructing a 
matrix” [16: 113] and that a creative and systematic procedure should be used to develop a 
matrix that effectively responds to your research questions.   
A framework synthesis approach was used to synthesize data compiled in thematic 
matrices according to the key domains of Coker et al.’s adapted framework for interpretive 
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analysis. The framework synthesis approach utilises a previously identified conceptual 
framework “to extract and synthesise findings” [28]. Emerging findings from thematic 
matrices were organised by domain for interpretive analyses and write up. 
Use of theory and triangulation were applied as principles to ensure rigour during the 
data analysis process [17]. Coker’s framework was used to synthesize and interpret finding 
from the data. Data was triangulated across sources of data, perspectives, and focus in order 
to identify where ideas converged or not. At an individual level, triangulation of data 
extracted from patient records, NHLS record and transcripts from HCW, KI, patient and family 
member interviews allowed us to piece together different perspectives and sources of 
information to have a more comprehensive understanding of patients’ journeys and factors 
that impacted on their linkage to treatment outputs. At a group level, data triangulation 
allowed us to identify common and conflicting perspectives shared within and across groups 
of participants, as well as variation in challenges and enablers across rural and urban areas.  
Using a framework approach to triangulate data allowed us to manage large amounts 
of data in a systematic way, using data reduction and data display tactics recommended by 
Miles, Huberman and Saldana [16], to demonstrate how reported findings were interpreted 
from the data. Data reduction tactics were used to manage large amounts of data through 
coding and drafting summaries of data to be inputted into tables (provided in the annexures) 
for data display.  The combination of data reduction and data display tactics allowed us to 
test and draw conclusions from the data. 
 
Ethics 
Permission to conduct the study was granted by the University of Cape Town and the Western 
Cape Department of Health. Study participants were given a R100 grocery store voucher and 
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their travel costs were reimbursed. The names of sample patients and other study 
participants were removed from patient records and interview transcripts to protect their 
identities and, when necessary, pseudonyms were used in quotations. Effort was made to 
minimise any disruption to health services through arranging visits and interviews at 
convenient times identified by health facilities. To protect the health of interviewers, an 
infection control training was conducted and N95 masks were worn during interviews 
perfomed inside with sputum smear or culture positive patients. All interviewers received 
counselling training prior to conducting interviews, which was arranged to equip interviewers 
to respond any emotional distress demonstrated by participants during interviews. 
Conceptual framework 
In their framework, Coker et al. (2010) identify the following domains for consideration when 
evaluating an infectious disease programmatic intervention: (1) epidemiological problem, (2) 
intervention, (3) context, (4) mechanisms, (5) outputs and (6) outcomes. For this study, the 
framework was adapted to include a seventh domain for the (7) patient, in order to explore 
how patient factors impact on linkage to treatment. 
Coker et al. define epidemiological problem as “infection levels and various disease 
characteristics” and intervention as “the intervention intended to serve public health” [14: 
i23]. In this study the epidemiological problem refers to the drastic increase in reported RR-
TB incidence and poor treatment linkage fuelling onward transmission. The intervention 
refers to the rollout of Xpert diagnostics and decentralisation of DR-TB services. Both of these 
domains have been described in detail in the study background. 
Outputs are defined in Coker at al.’s framework as “public health concepts that can be 
measured or determined” [14: i23]. In this study the scope of the output domain was 
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amended to incorporate aspects of McIntyre et al.’s framework that defines three key 
dimensions of access: availability, affordability and acceptability [50]. The outputs of interest 
in this study are patients’ linkage to treatment outputs, including: expedited initiation, 
delayed initiation and non-initiation of treatment. Using patients’ linkage to treatment 
outputs as an initial selection criteria, backward mapping was performed to explore the 
impact of context, mechanisms and patient factors on patients’ linkage to treatment outputs. 
Backward mapping involves working backwards from endpoints (generally desired endpoints) 
to answer a policy evaluation question [29].  Knowing the linkage to treatment outputs a priori 
also allowed for the development of questions and exploration of how our other outputs of 
interest, namely availability, affordability and acceptability, [50] shaped patients’ linkage to 
treatment journeys.  
Definitions of the context, mechanisms and patient domains, as well as factors 
encompassed in these domains are described in detail in the study results. 
Finally, Coker et al.’s outcome domain considers the impact of the interventions on 
the epidemiological problem. For example: has the programme successfully reduced 
incidence of the disease? While evaluating outcomes is beyond the scope of this study, this 
domain has been preserved in the diagram to retain recognition of the ultimate aim of the 
programmatic interventions. The amended framework and its application in this study is 
visually depicted in Figure 3.  
Results 
Backward mapping from patient’s linkage to treatment outputs, this study explored how 





Coker et al. explain that contextual environments may enable or constrain the success of 
programmatic interventions. The context domain encompasses “the political, legislative, 
social, economic and technological environments within which communicable disease control 
programmes sit” [14: i23]. 
All KIs and multiple HCWs noted social and economic contextual factors that 
negatively impact on linkage to treatment, including: high rates of poverty, high rates of 
substance abuse, poor community knowledge regarding DR-TB, as well as seasonal labour 
migration in rural areas. While this study was unable to draw conclusions regarding the impact 
of these contextual factors on linkage to treatment in the province, these factors were 
explored at an individual level and are discussed further under the patient domain. 
This study was able to identify factors relating to the technological, environmental and 
financing contexts that negatively impacted on linkage to treatment. At the outset of this 
study, it was expected that all facilities had access to Xpert diagnostics between January and 
March 2013. However, this study found that low Xpert usage amongst sample patients 
contributed to linkage delays. To better understand why few sample patients were diagnosed 
using Xpert, data was requested from the National Department of Health on the rollout of 
Xpert diagnostics and a review of all RR-TB diagnoses processed by the NHLS in the Western 
Cape between January and March 2013 was performed.  
Data from the NDoH showed that Xpert diagnostics were rolled out sequentially to 
Western Cape sub-districts between January and March 2013 [20]. Xpert diagnostic tools 
were installed in NHLS laboratories in the City of Cape Town (excluding Mitchells Plain) and 
the West Coast prior to 2013. Whereas, in the Cape Winelands, Xpert diagnostics were only 
installed during February 2013 [20]. Data from the NHLS revealed low usage of Xpert between 
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January and March 2013, even in areas where Xpert was installed (see Table 3). The reasons 
for low usage are discussed under the mechanisms domain. 
 
Table 3. RR-TB diagnoses processed between January and March 2013 in the Western Cape 
Province by diagnostic tool and district 
 
 
* Data compiled from NHLS diagnostic records 
  
Three KIs and several healthcare workers further observed that efforts to decentralise 
services in rural areas have been hampered by factors related to the environmental context. 
Participants explained that, for many patients, clinic-level treatment initiation is not feasible 
as they live beyond walking distance of clinics capacitated to initiate and manage DR-TB care. 
In addition to environmental challenges, this study found that the perception of some KIs and 
HCWs that hospitalised services are superior to clinic services contributes to an ongoing 
reliance on hospitalised services for rural patients that are eligible for, and able to access, 
decentralised services. 
Barrier: 
“We’ve always admitted patients [to hospital] for the first four to six months of 
treatment - everybody. We wouldn’t start patients outside [of hospitals] on treatment, 
because our initial experience was bad outcomes… When the decentralised model of 
National came out we realised that we cannot keep people here for four to six months. 
They don’t want to be here… So we made a decision to at least admit them for the first 













total Location N % N % N % 
City of Cape 
Town 
191 55,4% 152 44,1% 2 0,58% 345 60,6% 
Cape 
Winelands 
12 15,0% 68 85,0% 
 
80 14,1% 
Eden 34 48,6% 36 51,4% 70 12,3% 
West Coast 10 20,4% 39 79,6% 49 8,6% 
Overberg 3 14,3% 18 85,7% 21 3,7% 




250 43,9% 317 55,7% 2 0,4% 569 100,0% 
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Finally, funding constraints within the province led to clinic-level staffing reductions that 
negatively impacted on linkage to treatment. Clinic-level staffing reductions are described 
under the mechanisms domain. 
 
Mechanisms domain 
The mechanisms domain refers to “the mechanisms within a programme, required to 
function effectively”. Coker et al. link the mechanisms domain in their conceptual framework 
to Atun et al.’s key functions of the health system [29] explaining that the “functions [of the 
health system] consist of mechanisms that enable interventions to impact upon the health of 
populations” [15: i23]. Atun et al.’s six functions of the health systems include: stewardship 
and governance, financing, planning, service delivery, monitoring and evaluation, and 
demand generation. 
While the functions establish the mandates of the health system, the mechanisms are 
the means by which they are delivered. Within the DR-TB programme, multiple interacting 
mechanisms must come into play in order to link patients to timeous treatment. 
This study identified the following factors - falling within the mechanisms domain - 
that impacted on linkage to treatment, including: (1) diagnostic delays, action delays and 
missed results, (2) human resource challenges, (3) information system challenges, (4) 
availability of hospital beds and (5) availability of transport. 
 
Diagnostic delays, action delays and missed results 
Diagnostic delays are defined as delays between the collection of sputum and the processing 
of results. As found by previous studies [10,20], diagnostic delays contributed to overall delays 
to treatment initiation amongst patients diagnosed on line probe assay (LPA). Only 1 of the 
26 
 
16 patients categorised as delayed initiators was diagnosed using the Xpert. Diagnostic delays 
contributed to almost half of the overall delays to treatment initiation for this group. 
 
Table 4. Time to diagnosis and treatment initiation following sputum collection by embedded 
















Diagnosis on Xpert  9 50,0% 1 5,9% 1 12,5% 11 25,6% <1 days 
Diagnosed on LPA 9 50,0% 16 94,1% 7 87,5% 32 74,4% 17 days 
Median time to 
diagnosis following 
sputum collection by 
linkage category *  
3 days 19 days 16 days  
Median time to 
treatment following 
sputum collection by 
linkage category * 
6 days 43 days   
* expeditors, delayers, non-initiators. ** Xpert versus LPA. 
 
 
Of the 43 sample patients included in this study, 32 were diagnosed on LPA. This is in part due 
to the sampling method used, as patients were selected according to their linkage to 
treatment outputs.  The reasons as to why 32 sample patients were diagnosed on LPA (as 
opposed to Xpert) were assessed to better understand the factors contributing to diagnostic 
delays. Amongst the 32 patients diagnosed on LPA the reasons for not using Xpert included: 
ineligibility due to receiving drug susceptible TB treatment (13 patients) or due to previous 
interruption of DR-TB treatment (2 patients); non-adherence of HCWs to diagnostic 
algorithms (5 patients); no access to Xpert diagnostics (7 patients); and failure of Xpert to 
detect TB (2 patients). 
Seven HCWs reported not having access to Xpert diagnostic tools between January 
and March 2013. Access issues occurred due to the phased nature of the rollout and should 
now be resolved as the Xpert rollout has been completed [20]. One doctor explained that 
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non-adherence was largely due to the learning curve required for HCWs to switch to these 
new diagnostics. Two KIs noted that low levels of confidence in Xpert results of some HCWs 
in the early days of the Xpert rollout further contributed to non-adherence – this was 
observed in some HCW interviews. The failure of Xpert to detect rifampicin resistance further 
contributed to diagnostic delays. 
Barrier: 
“Usually we would take a culture… we don’t actually diagnose them on the GeneX… 
We have patients that are GeneX ‘RIF’ here and then they are not ‘RIF- resistant’.”  
(Nurse 15, Rural clinic) 
Action delays and missed results further contributed to overall linkage delays and failure. 
Action delays are defined as delays between processing diagnostic results and recalling 
patients. Missed results are defined as results that were never seen by HCWs at diagnosing 
and/or referral facilities. Action delays and missed results were assessed through 
triangulating data collected from patients’ medical and diagnostic records with healthcare 
worker and patient interviews. For instance, action delays were identified if a patient 
reported returning immediately to the clinic after receiving an urgent phone call, yet this 
phone call was weeks or months after results were processed.  
Action delays and missed results contributed to overall delays amongst 5 patients 
categorised as delayers (out of a total of 17 delayers), and linkage failure amongst 2 patients 
categorised as a non-initiators (out of a total of 8 non-initiators). An urban patient 
categorised as a delayer experienced delays of one month and six months, respectively, in 
initiating MDR and XDR-TB treatment due to action delays. Her doctor explained that both 
delays were due to her results being missed (never seen) by HCWs at the clinic where she 
was diagnosed with MDR, and subsequently XDR, TB. A rural patient categorised as a non-
initiator was treated for regular TB and discharged. Her doctor explained that her resistance 
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result was missed by HCWs at the clinic that diagnosed her - despite the fact that her 
husband was simultaneously receiving MDR-TB treatment at the same clinic.  
All KIs and 9 HCWs reported that delays in acting on results and missed results occur 
due human resources and/or information system challenges described below. 
 
Information systems  
Within the Western Cape, sputum samples are collected by courier daily and sent to NHLS 
laboratories for testing. Once diagnostic results are ready they are uploaded to NHLS’s 
electronic database (www.disa) and faxed to facilities [19]. In this study, all KIs and several 
HCWs reported that information systems challenges contributed to action delays following 
the processing of results. Information systems challenges included: limited access to the 
internet, limited access authorisation to NHLS’s diagnostic database, broken fax machines, 
paper and ink stock-outs, as well as the lack of unique patient identifiers3. 
Barrier:  
“I think last week when I was up in [that clinic] I moaned about results not [being] 
available… That lady hasn’t got an admin assistant, nothing… And sometimes their faxes 
doesn’t work at the clinics.... They say the computers are there but nobody has got an 
email address, so they are still trying to get the email addresses to them or to get - to 
give them access to NHLS on the computer.”   
(Senior clinician 2, Rural TB hospital and clinics) 
 
Availability of staff 
 
The availability of dedicated TB nurses, DR-TB counsellors and tracers, as well as support 
staff were highlighted by HCWs and KIs as a critical mechanisms for linking patients to 
treatment. 
The rotation of nurses between disciplines, or the lack of a dedicated TB nurse, was 
highlighted as a challenge contributing to linkage to treatment delays and failure by 3 KIs 
                                                     
3 Unique patient identifiers would allow HCWs to view all previous diagnostic reports for patients from all 
facilities visited in the province or country. 
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and 9 HCWs. HCWs reported that the rotation of nurses results in an ongoing loss of skills in 
the TB programme and a breakdown in consistency of services. KIs explained that nurses are 
rotated between disciplines in order to achieve better integration of services, which is a 
policy goal of the Department of Health [31]. The provincial KI further observed that the lack 
of a dedicated person in clinics for receiving and signing off on results contributes to missed 
results and delays in acting on results. 
Barrier: 
“One of our MDR patients who has died, she came to do a sputum last year and her sister 
came to get the result and what the patient told us subsequently this year was that she 
was told that the sputum was negative – [that]  she didn’t have TB. I think that somebody 
looked at the smear so if you have a change of staff or you suddenly get an untrained staff 
member, they look at a smear result. They didn’t then look at the GeneXpert result. They 
were two separate results. She came back ill this year, so I mean that is months and months 
later.”  (Doctor 1, Urban clinic) 
 
 
According to all KIs and 4 HCWs, facility level administrative backlogs further contributed to 
missed results and delays in acting on results. Backlogs were exacerbated by the removal of 
TB clerks from a number of facilities. Two KIs explained that TB clerks (who previously 
provided administrative support to TB nurses in clinics) were phased out in early 2013 due 
to budget constraints.  
Barrier: 
“TB is a very administratively difficult programme that involves lots of paper work. 
There are not enough hands [in clinics] to keep paper work up to date.” (Notes from 
interview with district manager of the TB programme, Urban) 
 
 
The budget constraints also led to a removal of TB assistants – previously responsible for 
tracing patients and linking them to treatment. Two KIs explained that TB assistants were 
phased out in early 2013 and their roles were meant to be absorbed by community care 
workers hired through NGOs. In facilities where community care workers were trained and 
funded to trace DR-TB patients, nurses and doctors reported that tracing was working well. 
However, community care workers’ roles were not consistent across facilities visited. Five 
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out 14 clinics visited did not have community care workers that were trained or allowed to 
trace DR-TB patients. 
Enabler: 
“We’ve got the community carers. We ask 
them to go and trace out the patient for us. 
We luckily in our facilities there are people 
that are staying mos in the community so 
they know the patients then ... like our... 
[community care] worker, she knows most 
of the persons, most of the people in this 
community. Then sometimes when we 
struggle then we just go to her. Then we tell 
her that ‘Gogo, we are looking for this 
patient, don’t you know?’ And then she’ll 
say, ‘Yes, I know and I know where she 
stays’. Then she must go to get the patient.” 
(Sister 11, Rural clinic) 
Barrier: 
“The one I know, it’s this follow-up, because 
the system we are using here which is the 
CCWs, if someone is missing the 
appointment and all that stuff, it could be 
easily recalled back to the clinic. But when 
it comes to the MDR patient, we don’t have 
that system of recalling. It’s only the MDR 
counsellor but who’s working for all [the] 
district, not only based on the facility that 
can do that… and even before, the 
counsellor here at the clinic, they were not 
doing the counselling on MDRs, only on 
TB.”  (Community care worker 1, Urban 
clinic) 
 
While the removal of TB clerks and assistants reduced staff capacity within clinics during a 
period of decentralisation, KIs highlighted parallel efforts underway to strengthen support for 
clinics to manage DR-TB care. DR-TB coordinators were appointed at a sub-district level during 
2011 to support clinics in tracing patients and assist with data collection and monitoring. 
Additionally, in rural areas, doctor outreach programmes – involving monthly visits by doctors 
located at TB hospitals to clinics – were underway. 
The availability of DR-TB counsellors at a clinic-level further emerged as a factor 
influencing linkage to treatment. HCWs frequently emphasised the role of counselling as a 
critical mechanism for linking patients to treatment. Patients’ reports of receiving counselling 
were inconsistent and contradictory. However, the messages that patients most likely learnt 
through counselling and education enabled treatment linkage, as patients repeatedly noted 













“So she was the one that didn’t want to 
come every day but we did try to give 
education and counselling every time. She 
didn’t want, she didn’t want to go to 
hospital… when we told her that she is 
going to be admitted - it was not an easy... 
It was a very, very big challenge for us 
because we have to counsel her several 
times… we did try to convince her… we told 
her that at least if she can start the 
treatment then at least [she] will be very 
much better.” (Nurse 11 on delayed 
initiator, Rural clinic) 
Barrier: 
“You can see he is ill. He refuses 
[treatment] and he is still on drugs… 
Maybe he doesn’t maybe know the 
seriousness of this TB he has… Or I will say 
he is not educated on it because no-one 
did speak actually with him about this 
resistant TB…  He wasn’t counselled about 
it or, you see… We don’t got [an] MDR 
counsellors in the clinic facility… So when 
we recalled him the sister explained to 
him, but not - she didn’t went into it.” 
(Nurse 22 on non-initiator, Urban clinic) 
 
 
Healthcare worker attitudes 
Patients were questioned about the treatment that they received from HCWs following 
diagnosis. Overall, patients reported having good relationships with HCWs and that HCWs 
were a source of support in initiating and continuing treatment. Three patients reported being 
treated poorly by a HCW. These three patients engaged in the following actions to avoid the 
HCWs that treated them poorly: (1) switching to another clinic, (2) purposefully seeking care 
from another HCW at the clinic and (3) interrupting treatment.
Enabler: 
“I can’t complain, the Sister treats me well. 
Sometimes I get here and there are a lot of 
people sitting there then they call me first 
and they help me. I am happy. I told them 
the other day and I thanked them for 
treating me so well. I told the Sister that I 
notice that when she sees me sitting there 
then it is never long before she calls me and 






“I was scared of the sisters because they 
shout and I also understand that I am 
wrong in the way I take my treatment 
because in the two days that I did not go 
and go on the third day, they tell me and 
scold me and say what I’m doing is just 
not on. So when it happens again and 
don’t go for about a week.” (Patient 16, 
Non-initiator [this patient was categorised 
as a non-initiator due to experiencing a 
delay of over 6 months in initiating 
treatment], Rural) 
 
Clinic versus hospital initiation of treatment 
 
Table 5 summarises the location of diagnosis and treatment initiation for sample patients 
according to their linkage to treatment outputs and urban versus rural location. Sample 
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patients from the City of Cape Town are categorised as urban and sample patient from the 
Cape Winelands and West Coast are categorised as rural. 
 
Table 5. Location of diagnosis and treatment initiation by facility type and embedded sub-unit  
 
Location of diagnosis 
and treatment initiation 





















Clinic 4 8 12 5 10 15 1 4 5 
Hospital 2 3 5 1 1 2 1 2 3 




Clinic 3 8 11 4 1 5  
Hospital 3 3 6 2 10 12 
Prison 1 0 1 0 0 0 
 
Clinic-level treatment initiation enabled expedited linkage to treatment amongst sample 
patients. Eleven of 18 patients categorised as expeditors initiated treatment at a clinic. Six of 
18 patients categorised as expediters initiated treatment at a hospital.  For all 6 expediters 
that started treatment in a hospital, mitigating circumstances were identified that assisted 
them in rapidly linking to treatment. Four patients were diagnosed with RR-TB while admitted 
to hospital (designated and non-designated TB hospitals) and immediately initiated onto 
treatment. One patient was sent to hospital before his results were processed due to his 
history of DR-TB treatment interruption and another patient was able to arrange his own 
transport to access the hospital - circumventing waiting periods for transportation. 
 
Availability of transportation, beds and mobile clinics 
While clinic-level treatment initiation enabled expedited treatment linkage, access to 
decentralised services remained limited in rural areas due to vast distances between patients’ 
homes and clinics capacitated to manage DR-TB care [32]. HCWs’ and rural district KIs’ 
perceptions that hospitalised services are superior to clinic-level services further contributed 
to an ongoing reliance on hospitalised services in rural areas (see context domain). 
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Given limited access to decentralised services in rural areas, the mechanisms to link patients 
to hospitalised treatment emerged as critical factors influencing rural patients’ linkage to 
treatment outputs. Eight HCWs and 2 KIs explained that severely limited access to transport 
services contribute to linkage delays and failure in rural areas. 
Barrier: 
“[Transportation] is the main problem… So they book [a bed] for the next Friday but 
then the transport / health-net transport, the bus is full, so they wait for the next Friday 
and sometimes for the next one. So that is where your three weeks and a month comes 
in before they start treatment.” (Senior clinician 2, Rural TB hospital and clinics) 
  
Waiting lists for beds at designated TB hospitals further emerged in this study as a barrier to 
expedited treatment linkage within rural areas. In urban areas, HCWs were generally able to 
circumvent this challenge through initiating out-patient treatment or referring patients to 
non-designated TB hospitals to manage treatment while waiting for beds at designated TB 
hospitals.
Enabler: 
“Then just bear in mind that sometimes 
there are some clients that are on the 
waiting list for a bed, so you give the 
client the treatment while she is 
waiting for a bed. And some people 
actually recover very quickly when they 











“From then I stayed home from the 4th of 
March, and in April I was still waiting for 
a place and they said there was no bed, 
and I only got there on 30th May. [The 
sister] phoned and said they said there 
was a bed available but she could not get 
hold of me, so I missed out on that week. I 
waited the next week and the vehicle of 
Health-net was full and I did not have a 
place, so I came on the 30th May and 
started treatment for pre-XDR in June’.” 
(Patient 16, Non-initiator [this patient was 
categorised as a non-initiator due to 
experiencing a delay of over 6 months in 
initiating treatment], Rural) 
 
Mobile clinics operating in some rural areas played an important role in linking patients living 
on farms and in remote areas to treatment, although patients diagnosed by mobile clinics 
were prone to linkage delays. Two HCWs and 1 KI explained that mobile clinics undertake 
monthly routes to collect sputum and recall patients. Patients that do not have phones and 
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are diagnosed by mobile clinics therefore have to wait for the next monthly route to receive 
their diagnostic results.  
Patient domain 
In an effort to bring patient issues to the forefront of this study, Coker et al.’s framework was 
amended to include a patient domain. Shippee et al.’s (2012) model of patient complexity 
was used as a framework to identify patient factors that impact on linkage to treatment 
outputs [33]. In their model, Shippee et al. explain that patient complexity occurs due to a 
combination of factors, categorised under patient workloads and capacity. 
Patient workloads encompass “all the demands in patients’ lives” [33: 1042], including 
demands resulting from employment, household and financial responsibilities, and the 
demands of patient-hood, such as daily clinic visits for injections. Patient capacity “denotes 
the resources and limitations affecting patients’ ability or readiness to do [patient-related] 
work” [33: 1043]. Capacity issues encompass a range of influences, including mental health, 
mobility and pain, social support, literacy, as well as beliefs and understandings regarding DR-
TB. 
 
Barriers and enablers related to patients’ workloads 
Employment and household responsibilities 
Employment responsibilities were noted as challenges in initiating treatment by several 
patients and their family members. For the most part, HCWs in this study were empathetic to 
linkage challenges resulting from employment responsibilities, raising them in their 
descriptions of patients’ linkage journeys. 
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In this study, being self-employed or having a supportive employer that allowed patients to 
take time off for hospitalisation or daily clinic visits enabled expedited treatment linkage. 
However, five patients reported having to quit their jobs to initiate treatment, due to: being 
refused time off by employers for daily clinics visits or hospitalisation, or being too ill to 
continue working, or being instructed by HCWs that they could no longer work. Three HCWs 
and 2 KIs further noted seasonal employment as a barrier to treatment linkage, as seasonal 
workers frequently relocate and cannot be traced to link them to treatment.
Enabler: 
“I went to work and I explained it to my 
boss and ... I said to her she must also go 
and check herself out… but she was very 
supportive of me and she speaks to her 
husband and they said, ‘No, as long as you 
go for your treatment we have no 
problem’. And she was supportive of me all 
the way up till now she still does.” (Patient 
1, Expeditor, Urban) 
 
Barrier: 
“We have seasonal workers here, you know, 
they travel all over the Western Cape… So 
they will work here for a couple of months… 
Now they come to the hospital or the clinic. 
They get diagnosed, h’m, and then, but 
when you look for them on the farm they 
already have moved to another town.” 
(Nurse 19, Rural non-designated TB 
hospital)
 
Household responsibilities were further identified as a barrier to initiating treatment for 
patients requiring hospitalisation by several patients, HCWs and KIs. These challenges were 
faced by patients in all linkage categories, and contributed to delays for 3 patients categorised 
as delayers. While household responsibilities contributed to delayed linkage, having 
dependents enabled treatment linkage as 6 patients noted concern for dependents as a 
motivating factor for initiating treatment following diagnosis.
Enabler: 
“What motivated me is that my child does not 
have a father. The father passed away, so when 
I looked at my child, I always thought I would 
rather die when he is older than while he is still 
young. He is 6 years old. So when I look at him 
I always think it will be better if I die and he’s 
older and he’s educated than while he is young. 
I don’t have a mother or father so I can’t leave 
him.” (Patient 5, Delayer, Rural) 
Barrier: 
“She had a problem when she came, that 
she’s got a daughter that is sick at home so 
she don’t know what is she going to do if 
she is admitted to the hospital. 
[Eventually] she told us that… her sister 
came from Eastern Cape to look after her 





Competing subsistence needs and grant support 
Competing subsistence needs including food insecurity and/or not having a stable place to 
stay were raised as challenges by 9 of 17 patients interviewed and/or their family members. 
Grant support assisted patients in managing these needs, but did not always remove them 
entirely as some patients reported being unable to stretch grants to cover monthly 
subsistence needs. The impact of competing subsistence needs and grant support on linkage 
could not be judged as patients in all linkage categories reported these challenges and grant 
support was generally only available weeks to months after initiating treatment. However, 
participants from all categories recommended the provision of food support to improve rates 
of treatment linkage, adherence and completion. 
Barrier 
“He did not have food and [would] be weak to walk because at that time he had nobody to 
support him and he was not working and staying alone, so he always came to me and I would 
give him whatever I had… [But] there [are] many people who are poor and have no food at 
their homes. Maybe if every morning they can be given soup when they arrive and again at 
about 13:00 they [can] be given bread and be encouraged in that way [then] they will come 
[to the clinic].”  (Family member 5 of delayer, Urban) 
 
Patients’ beliefs and concerns regarding DR-TB 
For the most part, patients’ beliefs and concerns regarding DR-TB and the services provided 
by public health facilities positively contributed to treatment linkage. Only 2 out of 17 patients 
interviewed reported seeking out alternative care from traditional or faith healers. Both of 
these patients only sought out alternative treatment after initiating DR-TB treatment. Overall, 
patients indicated good confidence in the services provided from public sector facilities. 
However, the difficult regimens required for treating DR-TB were noted by all groups of 
participants as a barrier to treatment initiation and adherence. 
  Patients that successfully linked to treatment also demonstrated a good 
understanding of DR-TB disease. All but 1 of the interviewed patients that linked to treatment 
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reported concerns regarding their health and/or infecting others as motivating factors for 
initiating treatment. Although, 2 patients further noted stigma and fear of being blamed for 
spreading DR-TB as an impetus for starting treatment. 
Enabler: 
“I thought about the children in the house, my family, I could infect them. That is why I went 
back, never mind the lot of tablets.” (Patient 17, Expeditor, Rural) 
 
  
Patient characteristics, risk factors and social support 
HCWs frequently noted patients’ characteristics as factors influencing treatment linkage. 
Patients that initiated expedited treatment were described as responsible and reliable, 
whereas patients that experienced long delays or failed to link to treatment where described 
as unreliable.  Patients that were described as unreliable, experienced one or more of the 
following risk factors that contributed to delayed or failed linkage to treatment: history of 
treatment interruption (HIV and TB), alcohol and/or drug addiction, participation in criminal 
activity, lack of social support, or lack of concern or hopelessness regarding treatment.  
All participant groups perceived patients’ support networks as a key factor influencing 
their linkage to treatment outputs. The role of support networks also emerged in narratives 
of patients’ linkage journeys. After receiving their DR-TB diagnosis, patients generally reported 
being frightened and distressed and drawing on their support networks who encouraged them 
to initiate treatment. Support networks were also drawn on to manage competing subsistence 
























“When I started treatment [my 
boyfriend] was the one that always 
encouraged me to go to the clinic, and I 
would say, wait about the clinic. He 
would remind me that he had long been 
asking me to go to the clinic and he 
could see that I was losing weight and 
not wanting to go to the clinic…. I can 
say he is the one that always supported 
me because he always gave me the 
tablets even now that I am taking 
treatment he is also cooking porridge 
for me and giving me tablets when it is 





“He told us he was stabbed. That was years 
ago and at the time… they found out that he 
had TB… Maybe it was resistant [at] that time 
or maybe it was susceptible that time and 
converted to MDR…  He just refused 
[treatment]… I think it is for the everyday 
coming and the injection and the two years - 
it seems for him too long… and the gangster-
related story he won’t be able to walk up and 
down every day. They are always in hideout.  
He is a gangster in his own area… And when 
they are on drugs they believe the drug keep 
the pain away. So for him he don’t see the 
need to start the treatment.” (Nurse 22 on 
non-initiator, Urban clinic) 
 
Discussion 
This study identified multiple factors falling within the context, mechanisms and patient 
domains that enabled and constrained expedited treatment linkage following RR-TB 
diagnosis. The enablers and barriers to expedited treatment linkage identified in this study 
are visually depicted in the amended Coker et al. framework in Figure 3. Enabling factors and 
constraining factors were experienced by patients in all linkage categories and it was often 
not a single factor, but the combination of multiple interacting factors that determined 
patients’ linkage to treatment outputs.  
Between January and March 2013, limited access to Xpert diagnostics emerged as 
barrier to expedited linkage, most commonly amongst patients that were ineligible for Xpert 
diagnosis according to diagnostic algorithms. Limited access due to the phased nature of the 
Xpert rollout further contributed to delays. This challenge should now be resolved as the 
rollout has been completed [20]. Amongst eligible patients with access to Xpert diagnostics, 
non-adherence by HCWs to diagnostic algorithms and failure of Xpert to detect rifampicin 
resistance further contributed to delays. A recent retrospective study conducted in 
Khayelitsha township, in the Western Cape, reported that between 2012 and 2013 only half 
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of patients diagnosed with RR-TB were diagnosed on Xpert [54]. The most common reason 
for this was the failure of Xpert to detect RR-TB and subsequent culture diagnostics  [54]. 
 
Figure 3. Barriers and enablers to expedited treatment linkage identified in this study 
organised according to the amended Cocker et al. framework 
 
 
Previous studies have also documented poor adherence to the Xpert diagnostic algorithms 
within South Africa [4,34]. Dlamini-Mvelase et al. suggested that poor adherence to the 
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diagnostic algorithm occurred due to limited training prior to the Xpert rollout [4] and 
Churchyard et al. recommended a simplification of the diagnostic algorithm to improve 
adherence [34]. Participants in this study reported that poor adherence was due to the 
learning curve required to switch to the new diagnostic tools, which was exacerbated by 
ongoing rotation of staff, as well as low levels of confidence in Xpert results by some HCWs. 
This study found that the ongoing rotation of staff contributed to action delays and 
missed results following RR-TB diagnosis. Similarly, Loveday et al. reported that rotation of 
staff between disciplines contributes to a loss of skills from the DR-TB programme in South 
Africa and a breakdown in consistency of services [23]. Given the complexity of interpreting 
TB results, rotation of staff can contribute to missed results and delays in acting on results, as 
new staff may have difficulty in interpreting results and may be less likely to follow up on 
pending results. Action delays and missed results were exacerbated by the recent removal of 
TB clerks from a number clinics in this study, resulting in greater administrative workloads for 
nurses. 
The ongoing rotation of nursing staff and removal of TB specific support staff revealed 
the tensions that exist between the health system’s goals to integrate health services versus 
DR-TB programmatic goals [35,36]. These challenges further highlighted disconnect between 
financing priorities and policy mandates, as a number of clinics experienced reductions in TB 
support staff at the same time as their workloads and responsibilities for managing DR-TB 
care rapidly increased.  
Information systems challenges further contributed to action delays and missed 
results. The lack of a unique identifier to allow HCWs to review all of a patient’s previous 
diagnostic results has been repeatedly highlighted as a challenges in South Africa, including 
in the NHLS’s strategic plan [34,37,38]. Implementing unique patient identifiers would 
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improve diagnostic follow up for patients that move between facilities, districts and 
provinces. Within clinics, broken fax machines, paper and ink stock-outs, internet connectivity 
challenges and limited staff access to NHLS’s diagnostic database contributed to delays. 
Similar challenges have been previously documented in South African clinics, negatively 
impacting on the provision of antiretroviral therapy [39]. 
Within the Western Cape, the decentralisation of DR-TB services has been shaped by 
the context in which it has been implemented. Widespread access to decentralised services 
has been achieved in the City of Cape Town, but in rural areas decentralised treatment 
initiation remains unrealistic for many patients that live beyond walking distance of clinics 
capacitated to manage DR-TB care [32,40]. Additionally, the perception of some HCWs and 
some KIs that hospitalised services are superior to decentralised services contributed to an 
ongoing reliance on hospitalised services in rural areas -  highlighting the importance of 
generating buy-in from front line providers when implementing health systems interventions 
[41,42]. 
Amongst rural patients referred to hospitalised care, limited access to transport and 
waiting lists for beds at designated TB hospitals contributed to delays. Previous studies have 
reported similar challenges [11,43–45]. Additionally, in a recent costing study Sinanovic et al. 
observed that decentralised services may not be appropriate for all groups of patients in 
South Africa [46]. Sinanovic et al. stressed that proper referral systems between clinics and 
hospitals continue to be necessary to link XDR, complicated MDR and patients in low density, 
rural areas in South Africa to treatment [46]. 
Hospital diagnosis during an in-patient stay was identified as an enabler to expedited 
treatment linkage. This finding may be due to the small sample size and was only relevant to 
patients that were diagnosed while admitted to hospital. Previous studies provide strong 
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evidence that, in general, DR-TB diagnosis within a hospital, as opposed to a clinic, increases 
a patients’ likelihood of linkage failure [24,25]. Ebonwu et al. demonstrated that in Gauteng 
MDR-TB patients diagnosed in hospitals are 8 times less likely to link to treatment than 
patients diagnosed in clinics and that the high rates of death amongst patients diagnosed by 
hospitals contributed to linkage failure for this group [25]. Nkosi et al. further theorised that 
hospitals may be less effective than clinics at tracing patients, resulting in higher rates of 
linkage failure [24]. 
In this study, HCWs at hospitals reported relying on phone calls or clinics to trace 
patients that failed to return for results or treatment, whereas clinics generally utilised 
community care workers to trace patients at their homes. However, some facilities were 
unable to trace DR-TB patients at their homes as community care workers (hired through non-
profit organisations) were not trained, funded or allowed to visit DR-TB patients.  
This study further highlighted reporting challenges within the DR-TB programme as 
more than half of patients initially selected as non-initiators from EDR were later re-
categorised as treatment initiators. Reporting challenges within the DR-TB programme have 
been previously documented [47] and likely contribute to overestimates of the treatment gap 
[48]. One participant noted that reporting challenges can result in demotivation of HCWs 
providing DR-TB care, as their successes are often punished rather than rewarded. Franco et 
al. emphasize the importance of collecting quality information and providing proper feedback 
and recognition when seeking to improve HCW motivation [49]. 
For the most part, in this study HCWs attitudes positively contributed to acceptability 
of services. However, difficult treatment regimens negatively impacted on the overall 
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acceptability of services. McIntyre et al. define acceptability as “the fit between provider and 
patient attitudes towards and expectations of each other” [50: 187].  
Food insecurity was repeatedly noted as a key concern of patients and their family 
members, negatively impacting on the acceptability of services. Similar challenges have been 
documented amongst patients with HIV/AIDS. Weiser et al. note that “food insecurity and 
other competing subsistence needs are associated with worsened access and adherence to 
care” [51: 1773s].   Food insecurity remained a concern even amongst patients receiving social 
grants, as grants could often not be stretched to cover food costs for the entire month. 
Patients’ household and employment responsibilities further emerged as challenges 
in linking to treatment. Similarly, a previous study conducted in the City of Cape Town 
reported that patients contribute to delays to treatment initiation by missing appointments, 
often due to family, financial and employment responsibilities [52]. In this study a number of 
patients reported having to quit their jobs in order to initiate treatment. This is concerning as 
a Western Cape cohort study recently  demonstrated that steady employment reduces ones’ 
risk of DR-TB treatment interruption [22]. 
Other psychosocial and economic challenges faced by patients in linking to treatment 
included: not having a stable place to stay or social support, substance abuse and 
hopelessness regarding treatment. Patients with unstable social circumstances and substance 
addictions not only face challenges in linking to treatment, but also face a high risk of default 
following treatment initiation [22,53]. Kendall et al. highlight that policy guidelines 
recommend psychosocial evaluation, substance abuse rehabilitation, and food aid following 
treatment default. They recommend that resources are rather allocated to provide 
adherence-focussed interventions prior to treatment default for high risk patients [22]. 
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Expanding these services to high risk patients following RR-TB diagnosis may further assist in 
improving linkage to treatment. 
Conclusions 
This study identified a number of barriers to expedited treatment linkage related to health 
systems mechanisms to link patients to treatment. Within the Western Cape there is 
significant opportunity to improve linkage to treatment through strengthening these 
mechanisms. At a clinic-level, staffing and information systems challenges impeded on 
expedited linkage to treatment. In rural areas, access to decentralised, clinic-level services 
remained limited and waiting lists for beds at designated TB hospitals, as well as limited access 
to transportation services impeded on expedited linkage to treatment.  
 In linking to treatment, patients commonly face challenges due to competing 
subsistence needs and household or employment responsibilities. Additionally, substance 
addiction, having a history of treatment interruption, hopelessness regarding treatment, as 
well as not having a stable place to stay or social support may increase patients’ risk of linkage 
failure. Expanding access to psychosocial services (substance abuse rehabilitation and 
psychosocial evaluations) following RR-TB diagnosis may assist in linking high risk patients to 
treatment. Additionally, the provision of food support (in addition to social grants) should be 
evaluated as a tactic to improve treatment linkage and adherence. 
Limitations 
 
There are a number of limitations to the findings reported in this study. Firstly, many of the 
patients initially selected as non-initiators were recategorised as expedited or delayed 
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initiators following data collection - leading to low patient numbers in the non-initiator group. 
Data saturation was therefore not achieved regarding contributing factors to non-initiation.  
An additional limitation of this study was that a number of sample patients from all 
embedded units and their family members could not be located. As a result of this, the factors 
identified as barriers and enablers to treatment linkage in this study are more representative 
of the views of HCWs than those of patients and their family members. 
Additionally, data collection occurred between 15 months and 18 months after 
patients were diagnosed with RR-TB. Therefore the findings of this study may contain some 
recall bias. To minimise the impact of recall bias on the study’s findings, patient folders were 
reviewed prior to data collection and participants were questioned regarding the timeline 
reflected in folders. Additionally, HCWs that had difficulty in recollecting events were 
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2. Example of matrix outline used for case-level thematic matrices 
Theme: Transport 
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Health system challenges and opportunities to strengthen linkage to 




 There is significant opportunity in the Western Cape to improve linkage to treatment 
following RR-TB diagnosis through addressing staffing, information system, infrastructure 
and transport challenges. 
 There is also opportunity to leverage and build on mechanisms that facilitate linkage to care 
following RR-TB diagnosis in the Western Cape by increasing usage of Xpert diagnostics and 
improving perceptions of decentralised services, as well as mechanisms to link patients to 




During the past few years, South Africa has experienced a 
growing gap between the number of patients diagnosed 
with RR-TB and those initiated onto treatment. According 
to estimates from the World Health Organisation (WHO), 
only 41% of patients diagnosed with RR-TB in South Africa 
during 2013 initiated treatment. 
The Western Cape Province has the third highest burden 
of RR-TB, after KwaZulu-Natal and the Eastern Cape.  
Estimates of treatment linkage in the Western Cape are 
similarly low to the rest of the country. According to 
estimates from the National Department of Health, only 
45.9% of patients diagnosed with MDR-TB in the Western 
Cape during 2012 linked to treatment.i 
However, a recent study reported that high burden clinics 
in the City of Cape Town fare significantly better than 
provincial estimates in linking patients to treatment – 
reporting that around 90% of patients in 10 high burden 
Cape Town clinics linked to treatment within 6 months of 
diagnosis [1]. 
Methodology 
To understand why patients diagnosed with RR-TB in the 
Western Cape frequently fail to link to treatment, we 
conducted an embedded case study to explore barriers 
and enablers to treatment linkage following RR-TB 
diagnosis within the context of ongoing decentralisation of 
DR-TB services and the rollout of Xpert diagnostics. 
Rifampicin resistant (RR) TB is a good 
indicator of MDR-TB. According to 
treatment guidelines, patients 
diagnosed with RR-TB should be 
immediately initiated onto treatment 
– while undergoing further resistance 
and confirmatory testing. 
Additionally, the National Strategic 
Plan on HIV, TB and STI’s (2012 – 
2016) established a target to initiate 
all RR-TB patients onto MDR-TB 
treatment within 5 days of diagnosis. 
What is an embedded case study? 
A case study is a research method 
that involves in-depth analysis of a 
particular case. A case may be a 
person, place, process or situation. 
The case in this study is linkage to 
treatment following RR-TB diagnosis 
in the Western Cape. An embedded 
case study is a case study with more 
than one natural unit of analysis. The 
embedded units that were analysed 









To better understand enablers and barriers to expedited treatment linkage, we conducted an 
in-depth analysis of 43 patients’ journeys following RR-TB, considering multiple perspectives 
on the factors that influenced their linkage outcomes. 
The journeys of 43 patients diagnosed with RR-TB between January and March 2013 were 
explored through reviewing their NHLS records, 
reviewing clinical notes in their folders at facilities 
and conducting interviews with 31 healthcare 
workers that oversaw their care at diagnosing and 
treatment initiating facilities. When possible 
interviews were also conducted with sample 
patients and/or a family member.  
The 43 sample patients included: 18 patients that 
started treatment within one month of sputum 
collection on which RR-TB was diagnosed; 17 
patients that started treatment more than one 
month and less than six months after sputum 
collection on which RR-TB was diagnosed; and 8 
patients that did not start treatment within six 
months of sputum collection on which RR-TB was 
diagnosed.  
All sample patients were diagnosed and (when 
relevant) initiated onto treatment in the urban 
City of Cape Town metropolitan municipality, the 
rural Cape Winelands district and the rural West 
Coast district. We selected sample patients from 
these districts in order to explore variation in 
treatment linkage barriers and enablers across 
urban and rural areas with varying level of 
decentralisation. In this study, decentralisation 
was defined as clinic-level MDR-TB treatment 
initiation, in line with the commonly accepted 
definition of decentralisation in the Western 
Cape. 
This study also aimed to understand barriers and 
enablers to treatment linkage in Western Cape 
facilities and districts beyond our sample patients’ experiences. All 31 HCWs interviewed 
regarding sample patients were also asked to describe their general perceptions of barriers 
and enablers to treatment linkage following RR-TB diagnosis in the facilities and districts where 
they worked. The 31 HCWs included in this study worked at 21 health facilities in the City of 
Cape Town, the Cape Winelands and the West Coast. The 21 health facilities included: 1 mobile 
clinic, 14 clinics, 3 non-designated TB hospitals (district and tertiary) and 3 designated TB 
hospitals.  
National interventions to improve 
treatment linkage 
 
1. The rollout of Xpert diagnostics 
During 2011, the NDoH embarked on a 
national rollout of Xpert diagnostics. The 
rollout was coupled with the adoption of 
a new diagnostic algorithm 
recommending Xpert as an initial 
diagnostic test for all TB suspects. Xpert 
significantly reduced diagnostic turn- 
around time for detecting RR-TB in 
comparison to line probe assay 
(previously used to detect RR-TB in the 
Western Cape). A recent study 
conducted in the City of Cape Town 
reported that average diagnostic turn -
around time for detecting RR-TB was < 1 
day for the Xpert versus 24 days for line 
probe assay [1]. 
 
2. The decentralisation of DR-TB services 
During 2011, the NDoH adopted a 
national policy for the decentralisation 
of DR-TB services, recognising that 
traditional hospitalised services were 
increasingly unable to accommodate 
rising RR-TB patient numbers. Previous 
experience in piloting decentralised 
services in an urban township in the City 
of Cape metropolitan showed that 
decentralisation of services could 
improve linkage to treatment and 
reduce delays to treatment initiation 
following diagnosis [2].  
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In addition to the 31 HCWs that we spoke to, we also interviewed 4 key informants (1 provincial 
and 3 district) in order to complement and contrast the perspectives of enablers and barriers 
to treatment linkage of individuals in leadership positions with those of front line providers. 
Key informants included senior managers at district and provincial levels, as well as senior 
clinicians operating across districts. 
 
Findings 
This study explored barriers and enablers related to 1) the Western Cape context, 2) the 
mechanisms of the health system to link patients to treatment and 3) patient related factors. 
Multiple barriers and enablers related to the health system mechanisms to link patients to 
treatment were identified - illuminating opportunities to improve treatment linkage following 
RR-TB diagnosis through strengthening these mechanisms.  Some barriers and enablers were 
relevant to both urban and rural areas, and some were unique to rural areas.   
Low Xpert usage contributed to linkage 
delays amongst sample patients. Low Xpert 
usage is this study was due in part to the 
phased nature of the rollout, as not all 
facilities had access to Xpert diagnostics prior 
to 2013. However, where Xpert diagnostics 
were available, low usage remained a 
challenge. Low usage occurred due to: 
i) Ineligibility: Patients already receiving 
treatment for regular TB were ineligible 
for Xpert diagnosis according to 
diagnostic algorithms. 
ii) Poor adherence to diagnostics 
algorithms: A number of patients that 
were eligible for Xpert diagnosis were 
not diagnosed on Xpert due to poor 
adherence of HCWs to diagnostic 
algorithms.  
iii) Failure of Xpert to detect RR-TB: Xpert 
did not detect RR-TB on two patients. 
HCWs and key informants reflected that the 
learning curve required to switch to Xpert 
diagnostics, as well as low levels of 
confidence of some HCWs in Xpert results 
during the early stages of the rollout 
contributed to poor adherence. Additionally, 
HCWs and key informants reflected that the 
ongoing rotation of staff likely contributed to 
poor adherence to diagnostic algorithms, as 
it often takes time for HCWs to become 
confident with complicated TB diagnostics 
algorithms. 
Delays in acting on diagnostic results after 
they were returned to facilities, as well as 
missed (unseen) results contributed to 
linkage delays and failure amongst sample 
patients. HCWs and key informants explained 
that delays in acting on results and missed 
results occurred due to the following 
challenges: 
1) Rotation of staff: New staff rotated into 
the TB programme may have difficulty in 
interpreting complex TB results and may 
Barriers and enablers related to 
mechanisms of the health system in 
urban and rural contexts: 
 
Barrier 1: Low Xpert usage  
 






be less likely to follow up on pending 
results. 
2) Administrative backlogs: Limited 
administrative support and the lack of a 
dedicated person for receiving and signing 
off on results in clinics contributed to 
backlogs in seeing and acting on results. 
3) Information systems challenges: Broken 
fax machines, paper and ink stock-outs, 
limited internet access, and limited HCW 
access to NHLS’s diagnostic database led 
to delays in seeing and acting on results. 
4) No unique patient identifiers: The lack of 
unique patient identifiers prevented 
healthcare workers from reviewing all 
previous diagnostics results for patients 
that moved between facilities.  
Initiation of treatment at a clinic, as opposed to 
a hospital, contributed to expedited treatment 
linkage amongst sample patients. In urban 
areas, decentralised services were widely 
available, yet in rural areas access remained 
limited (see right column).  
The availability of clinic-level DR-TB counsellors 
and tracers enabled treatment linkage – 
particularly for patients that were resistant to 
starting treatment or failed to return for 
diagnostic results or treatment. However, not all 
clinics included in this study had clinic-level DR-
TB counsellors or tracers.  
Good patient/ provider relationships positively 
contributed to treatment linkage and retention.  
 
Limited access to decentralised services 
constrained expedited treatment linkage in 
rural areas. Access was limited by distances 
between patients’ homes and clinics, as many 
patients live beyond walking distance of 
clinics that have the capacity to initiate and 
manage MDR-TB treatment. 
Negative perceptions of decentralised 
services of some HCWs and key informants 
also negatively impacted on treatment 
linkage. As a result of negative perceptions, 
some patients that are eligible forii and able to 
access decentralised services continue to be 
referred to hospitalised services. 
Waiting periods for beds at designated TB 
hospitals contributed to linkage delays for 
rural patients requiring hospitalised 
treatment initiation. Waiting periods of up to 
a few weeks were commonly reported. 
Limited access to transport services 
constrained expedited treatment linkage for 
rural patients requiring hospitalised 
treatment initiation. HCWs and key 
informants explained that, due to limited 
availability of transport, ambulances are 
often full and patients must sometimes wait 
for weeks before receiving transport. HCWs 
and key informants also reported that 
ambulance pick up points are often far from 
Enabler 1: Access to decentralised services 
 
Enabler 2: Availability of DR-TB counsellors and 
tracers 
 
Enabler 3: Good patient/ provider 
relationships 
 
Barrier 1: Limited access to, and negative 
perceptions of, decentralised services 
 
Barrier 2: Waiting periods for beds 
 
Barrier 3: Limited access to transport services 
 
Barriers and enablers related to 
mechanisms of the health system unique 




patients’ homes and often very difficult for 
patients to access. 
Food insecurity throughout treatment periods 
was repeatedly raised as a key concern of 
patients.  Food insecurity was a concern for 
patients with and without social grants, as 
social grants could often not be stretched to 
cover monthly expenses. Patients, their family 
members, HCWs and key informants all 
recommended the provision of   food support 
to improve treatment linkage and adherence. 
 
Limitations 
The findings of this study give us a lens into the life of patients who need care and help us to 
build the knowledge to improve services in the WC, these findings however, due to the sample 
size, cannot be generalised to the Western Cape as a whole.   
 
A limitation of this study is that a number of sample patients and their family members could not 
be located, and therefore the findings of this study are more representative of the views of HCWs 
and key informants than those of patients and their family members. An additional limitation of 
this study was that very few patients and family members of patients that did not initiate 




This study identified a number of barriers and enablers to expedited treatment linkage 
following RR-TB diagnosis in the Western Cape in the context of the introduction of 
Xpert diagnostics and decentralisation of DR-TB services. The barriers and enablers 
identified in this study demonstrate that there is significant opportunity in the Western 
Cape to improve linkage to care through strengthening the health systems mechanisms 
for linking patients to treatment. Based on the findings of this study, the following policy 




 The Western Cape Department of Health (WCDoH) should assess different models 
of rotating staff in and out of TB programme as the current model negatively impacts 
on linkage to care. Additionally, the WCDoH should ensure that clinics have adequate 
administrative support to deal with the administrative workloads of the TB programme. 
For a ‘quick win’ the WCDoH could ensure that all clinics have an assigned staff member 
responsible for receiving and signing off on TB diagnostic results. 
  
 DR-TB counsellors and tracersiii play an important role in linking patients to 
treatment. Ensuring that all clinics have staff that are trained and funded to provide DR-
TB counselling and tracing could improve linkage to care. 







 While decentralised treatment initiation is not feasible for all rural patients, 
generating buy-in for decentralisation from healthcare workers and TB programme 
managers in rural areas would assist in increasing use of decentralised services by 
patients that are eligible for, and able to access, decentralised sites (recognising that 
some factors are associated with the social determinants of health and will need inter-
sectoral collaboration). Educating front-line providers regarding the reasons for 
decentralisation, ensuring their ongoing participation in the policy process and adapting 
the policy to the local context can assist in generating buy-in. 
 
Information systems interventions:  
 
 To reduce linkage delays and failure, broken fax machines must be urgently dealt 
with and adequate supplies of ink and paper must be available in all clinics. Additionally, 
the WCDoH should urgently deal with internet connectivity and NHLS access issues 
(limited staff log-ins and email addresses) to ensure that staff can rapidly access 
patients’ diagnostic reports. 
 
 Working together with the NHLS, the National Department of Health should 
implement unique patient identifiers to allow health care workers to view all previous 
diagnostic results of patients. This would assist in reducing linkage failure and delays, as 




 Given limited access to decentralised care in rural areas, the WCDoH should assess 
the ongoing need for beds at designated TB hospitals and consider increasing bed 




 The WCDoH and HealthNET emergency transportation services must jointly tackle 
transportation challenges in rural areas as a critical intervention to improve treatment 
linkage. Increasing the frequency of ambulance routes and expanding pick-up locations 
to improve accessibility for patients would assist in reducing linkage delays and failure 
in rural areas. 
 
Food support interventions:  
 
 The WCDoH should evaluate the provision of food support (in the form of 
vouchers, food parcels or daily meals) in addition to social grants as a strategy to 







This study was conducted towards the fulfilment of a Master’s degree at the University of Cape Town 
(UCT) under the supervision of UCT’s Health Economics Unit. The study was completed as part of the 
requirements for the ‘Linkage to care for drug resistant TB following Xpert implementation in South 
Africa’ that is being conducted by the University of Cape Town’s Department of Medical 
Microbiology. This study was funded by the Bill and Melinda Gates Foundation, as well as bursary 
support for the master’s student from the Wits Health Economics and Epidemiology Research Office 
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i Estimates for linkage are subject to some error due to reporting and monitoring challenges in the TB 
programme. 
ii The decentralisation guidelines recommend clinic-level treatment initiation and management for low grade 
transmission risk, smear negative MDR-TB patients with stable social circumstances, as well as patients that 
refuse hospitalisation. These patients must visit clinics daily for injections throughout the intensive phase of 
treatment. XDR-TB patients, smear positive MDR-TB patients, severely ill and complicated patients, as well as 
patients whose social circumstances preclude them from ambulatory care should continue to be hospitalised 
during the intensive phase of treatment. 
iii DR TB tracing may be performed by CCWs or TB assistants. 
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PARTICIPANT INFORMATION AND CONSENT FORM 
 
Consent form for participation in an in-depth interview regarding [your / your family 
member or friend’s / your patient’s] experience following diagnosis with rifampicin or drug 
resistant tuberculosis 
 
Study Title: Linkage to Care for Drug Resistant TB Following Xpert Implementation in South Africa  
 
Investigators: 
 University of Cape Town, South Africa: Prof Mark Nicol (Principal Investigator),  Dr Helen Cox 
(Co-Investigator), Dr Lindy Dickson-Hall (Co-Investigator) 
 National Health Laboratory Service/University of Witwatersrand, South Africa: Prof Wendy 
Stevens (Co-Principal Investigator) 
 University of Amsterdam/Amsterdam Institute for Global Health and Development: Prof Frank 
Cobelens (Co-Investigator), Dr Anja van’t Hoog (Co-Investigator) 
 London School of Hygiene & Tropical Medicine, UK: Prof Alison Grant (Co-Investigator) 
 
Collaborators: 
 National Department of Health: Dr David Mametja, Dr Norbert Ndjeka, Dr Lindiwe Mvusi, Ms 
Nontobeko Mtshali, Ms Lorna Nshuti 
 Eastern Cape Department of Health: Dr John Black 
 
Researcher (MPH Student): 
 University of Cape Town, South Africa: Ms. Catherine Tomlinson  
 
Research supervisor: 




Good day, my name is ____________, and I am a researcher with the Linkage to Care study team. 
We would like to invite you to take part in a research study that is investigating why patients that are 
diagnosed with DR-TB do or do not start treatment, and why the patients that start treatment do or 
do not experience a delay in starting treatment. 
 
Research is the process to learn the answer to a question. We are seeking to understand what 
factors influence whether and when patients start treatment by learning more about patients’ 
experiences through interviewing patients, family members and friends of patients, as well as health 
care workers. 
 
UNIVERSITY OF CAPE TOWN 
Faculty of Health Sciences 








You are free to decide whether you wish to participate in the study or not. Before you decide this, 
it is important that you understand why the research is being done and what it will involve. This 
information sheet explains our study and what participation in the study entails.  Please feel 
free to ask me questions at any stage if there is anything which is not clear. If you decide to 
take part in the study then we will ask you to answer a few simple questions to demonstrate that 
you understand what your participation in the study will entail. We will also ask you to sign a form 
to demonstrate that you consent (agree) to be interviewed. 
 
Your decision to take part in the study or not will not affect [your/ your family member or friend’s/ 
your patient’s] healthcare in any way. 
 
Why are we doing this study? 
Drug-resistant Tuberculosis (TB) is a major health problem in South Africa, but most forms of TB can 
be cured if treated early and well. In our study we want to find out: 
- what factors contribute to whether a patient starts treatment after being 
diagnosed 
- what factors contribute to when a patient starts treatment after being 
diagnosed 
 
This study is a national study that will look at a number of health facilities and patient experiences 
across South Africa, and will take one year to complete. The study is funded by the Bill and Melinda 
Gates Foundation. A report from this study will also be submitted to the University of Cape Town 
towards the fulfilment of a Master’s Degree in Public Health. 
 
Who will be asked to participate in the study? 
DR-TB patients, friends and family members of DR-TB patients, as well as health care workers 
responsible for providing care to DR-TB patients will be asked to participate in this study. Key 
informants that oversee or provide services for DR-TB may also be interviewed. 
 
If I take part in this study, what will happen? 
Through agreeing to participate in this study, you are agreeing to be interviewed regarding [your/ 
your family member or friend’s/ your patient’s] experience following diagnosis with drug resistant 
TB. During the interview the researcher will ask you a series of questions regarding whether or not 
[you / your family member or friend / your patient] started treatment following diagnosis. In the case 
that [you / your family member or friend/ your patient] did start treatment, the researcher will ask a 
series of questions regarding whether or not a delay was experienced between diagnosis and 
treatment initiation. Finally, the researcher will ask questions in order to gain an understanding of 
why the person diagnosed with DR-TB did or did not start treatment and/or experience a delay. Each 
interview will last approximately 30 to 40 minutes.  
 
Who may choose to be interviewed together with another participant? 
Some of the study participants will be given the option to be interviewed on their own, or together 
with another participant. The following study participants will be given the option to be interviewed 
individually or together with another participant: 
- In the event that a patient, as well as a family member or friend of the patient 
consent to be interviewed then they may choose to be interviewed jointly. 
- In the event that a patient has died or cannot be traced and a family member or 
friend consents to be interviewed then he/she may choose to be interviewed 
jointly with another family member or friend. 
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- In the event that more than one health care worker at the facility provided care 
to a single patient, then the health care workers may choose to be interviewed 
jointly regarding this patient’s experience. 
 
What are the risks and benefits of taking part in this study?                                                                                                                    
This study poses little to no risk to you if you agree to take part. All the information that you give us 
will be kept confidential. You will not benefit medically from participating in this study, however you 
will be able to share your experiences with us and so broaden our understanding of the challenges 
faced by patient’s following diagnosis. 
 
Reimbursement:                                                                                                                                                                                           
Healthy snacks will be provided during the interview. Additionally you will be given a once off 
R100.00 food voucher for Shoprite Checkers to compensate for your time. Patients and their family 
members that are interviewed away from their homes or regular clinic visits will also receive 
transport reimbursement of up to R50. 
  
What happens if I do not agree to take part in this study?                                                                                                                        
You do not have to take part in this study. If you do not take part, this will not affect the medical 
care that you receive. You can stop taking part in the study at any time, without giving a reason. 
 
How will the information collected during this study be recorded? 
If you take part in the study, your interview will be recorded using an audio recording device and the 
interviewer may write some notes on paper during the interview. 
  
How will the information collected during this study be kept confidential?               
Audio recordings and notes from your interview will be kept securely and confidentially in locked 
suitcases by study staff during transportation of the information from the study site until it is 
brought back to the research station at the University of Cape Town.  Upon reaching the University, 
the audio and paper records will be transferred to a securely, locked cabinet. The audio recordings 
and paper records will also be uploaded to an electronic database that is securely password 
protected. Only restricted University staff members will have access to the locked cabinet and 
secure database.  
 
Study information may be reviewed by the Ethics Committee and independent monitors to check 
that the study procedures were done correctly and the information is correct. Your information will 
remain confidential, unless we are required by law to release information. The records from your 
interview will be destroyed either 6 years after study is finished if the research findings are not 
published, or after 2 years if the findings are published. 
 
Will what I say during the interview appear in the study report or any published papers? 
With your permission, we might quote things you say during the interview. If you are quoted in the 
study report, your name will be replaced by a pseudonym to protect your identity. Your name or any 
other identifiable information will not be included in any reports about the study or published 
papers. 
 
If I am interviewed jointly with another participant, how will the information be kept confidential? 
The researchers will ensure that there is no cross disclosure of what is said during interviews to 
other participants, unless the participants choose to be interviewed jointly. In other words, what you 
say during your interview will not be disclosed to [your patient / your family member or friend / your 




If you choose to be interviewed jointly with another participant, you must indicate that you 
understand that we cannot ensure that the person with whom you are jointly interviewed does not 
disclose what was said during the interview. However, we ask that you both agree to protect each 
other’s confidentiality by not disclosing what was said during the interview by the participant with 
whom you were jointly interviewed.  
   
What if I have questions about this study?                                                                                                                                                        
If you have any questions about this study, please feel free to ask me now. If you have questions 
later you may contact Dr Lindy Dickson-Hall at 021 406 6616. The committee reviewing this study is 
the Research Ethics Committees of the University of Cape Town. If you have any questions or 
concerns about your rights as a person taking part in a research study, or if you wish to make a 
complaint about the study, you may contact Professor Marc Blockman, Chairperson of the University 
of Cape Town, Human Research Ethics Committee, at 021 406 6338. 
 
We will give you a copy of this sheet which explains the study to take away with you. If you would 
like a copy of a report on this study, and you give us an email or postal address, we will send you a 







Participant Informed Consent Form Study ID No:  _______________ 
 




 University of Cape Town, South Africa: Prof Mark Nicol (Principal Investigator),  Dr Helen Cox 
(Co-Investigator), Dr Lindy Dickson-Hall (Co-Investigator) 
 National Health Laboratory Service/University of Witwatersrand, South Africa: Prof Wendy 
Stevens (Co-Principal Investigator) 
 University of Amsterdam/Amsterdam Institute for Global Health and Development: Prof Frank 
Cobelens (Co-Investigator), Dr Anja van’t Hoog (Co-Investigator) 
 London School of Hygiene & Tropical Medicine, UK: Prof Alison Grant (Co-Investigator) 
 
Collaborators: 
 National Department of Health: Dr David Mametja, Dr Norbert Ndjeka, Dr Lindiwe Mvusi, Ms 
Nontobeko Mtshali, Ms Lorna Nshuti 
 Eastern Cape Department of Health: Dr John Black 
 
Researcher (MPH Student): 
 University of Cape Town, South Africa: Ms. Catherine Tomlinson  
 
Research supervisor: 
 University of Cape Town, South Africa: Ms. Veloshnee Govender 
Participant’s Understanding: 
UNIVERSITY OF CAPE TOWN 
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 I understand that my participation is voluntary     (Yes/ No) 
 I understand that I will not be identified by name in the finished study report or in any published 
papers          (Yes/ No) 
 I understand that the interview will be recorded     (Yes/ No) 
 I acknowledge that the contact information of the researcher and the researching institution have 
been made available to me       (Yes/ No) 
 I understand that I may withdraw from this study at any time without giving a reason and without 
affecting my normal care and management      (Yes/ No) 
 I have had the opportunity to ask questions about the study and any questions I have asked have been 
answered to my satisfaction       (Yes/ No) 
 I agree to take part in the study       (Yes/ No) 
For participants that are interviewed jointly: 
 I agree not to disclose what was said during the interview by the person with whom I was jointly 




Study participant name (printed) Signature/mark/thumbprint   Date 




Research staff name  (printed) Signature Date 
 
 




If the information sheet and consent form were translated or explained to the participant, enter 
the name of the translator here and their signature: 
 
 
Translator name (printed) Signature/mark/thumbprint Date 
 
If the participant gave verbal consent (with a thumb print), enter the name of the person who 
witnessed the consent here and their signature: 
 
 








INTERVIEW GUIDE COVER PAGE 
INTERVIEW GUIDE 1 
This guide should be used to interview health care workers (HCWs) at the diagnosing facility of patients that 
have initiated treatment (this facility may or may not have initiated treatment) 
 
INTERVIEW GUIDE 2 
This guide should be used to interview health care workers (HCWs) at the facilities that initiated treatment 
following diagnosis and referral from elsewhere 
 
INTERVIEW GUIDE 3 
This guide should be used to interview health care workers (HCWs) of patients that never initiated 
treatment following diagnosis 
 
INTERVIEW GUIDE 4 
This guide should be used to interview patients that started treatment  
 
This guide may also be used to do joint interviews with patients that started treatment and their family 
members 
 
INTERVIEW GUIDE 5 
This guide should be used to interview patients that never started treatment 
 
This guide may also be used to do joint interviews with patients that never started treatment and their 
family members 
 
INTERVIEW GUIDE 6 
This guide should be used to interview family members of patients that started treatment 
 
INTERVIEW GUIDE 7 







INTERVIEW GUIDE 1 
This guide should be used to interview health care workers (HCWs) at the diagnosing facility of 
patients that have initiated treatment (this facility may or may not have initiated treatment).  
To interview HCWs of patients that did not start treatment, use interview guide 3. 
To interview HCWs who initiated treatment following diagnosis and referral from another facility, 
use interview guide 2. 
 
INTERVIEW GUIDE 1 INSTRUCTIONS: 
 
1. SKIP INSTRUCTIONS ARE PROVIDED THROUGHOUT THE INTERVIEW GUIDE IN  red, italicised 
text  
 
2. PROBES AND EXAMPLES ARE PROVIDED THROUGHOUT THE INTERVIEW GUIDE IN blue, 
italicised text  
 




- Can you tell me more? 
 
4. BEFORE STARTING THE INTERVIEW QUESTIONS, CLARIFY THE FOLLOWING FOR THE HEALTH 
CARE WORKER 
- When and where the patient was diagnosed 
- When and where the patient started treatment. 
 
INTERVIEW GUIDE 1 QUESTIONS: 
1) What do you remember about this patient? 
 
2) What was this person like as a patient? 
 
3) Do you think the length of time that passed between the patient being diagnosed with Drug 
Resistant Tuberculosis (DR-TB) and started treatment was good, bad or acceptable? 
Follow up: Why? 
4) Do you think anything else could have been done to shorten the time between when the 
patient was diagnosed and started treatment? 
Follow up:  If no, why?  




5) Can you describe what happened to the patient between receiving their diagnosis and 
starting treatment? 
If the HCW ask for more clarity, ask them to describe whatever they can 
recall about the patient’s journey and the steps they took to start 
treatment 
 
6) Do you know whether the patient faced any challenges in starting treatment? 
Examples: 
Lack of transport 
No beds available for patients requiring hospitalisation 
Delays in receiving diagnostic results, records unavailable 
Doctor unavailable when visiting treatment site 
Medicine shortages 
No one to take care of children 
Unable to take time off work to visit the facility 
Other… 
Follow up: If the patient did experience challenges, did the challenges impact on 
when the patient started treatment? 
Follow up:  How? 
 
7) Do you know what factors enabled this patient to start treatment, when many other patients 
that are diagnosed with DR-TB never start care? 
Examples: 
Started treatment close to home 
Unemployed or able to take time off work 
Transport available  
Received social grant 
Had a good understanding of DR-TB, received counselling and education 
Good social and emotional support system 
Doctor available 
Other… 
Follow up: Did any of these factors impact on when the patient started treatment? 
Follow up:  If yes, how? 
 
8) Do you have any insight regarding what happened in the patient’s personal life between 
finding out their diagnosis and starting treatment and how this might have impacted on the 
time to treatment? 
Examples: 
Dependants (new caregiver needed)  
Employment (quit or lost job) 
Place and location of residence (moved) 
Substance abuse 
Use of traditional or alternative medicines 
Other… 
 
INSTRUCTIONS: If the patient was referred to a different facility to start treatment after diagnosis, ask 
questions 9 through 16. If the patient initiated treatment at this facility, skip to question 17 (page 6) 
9) Under what circumstances are patients usually referred elsewhere (to another facility) to 




All patients are referred elsewhere 
Sputum positive patients are referred elsewhere 
XDR and children are referred elsewhere 
Patients with substance abuse issues are referred elsewhere 
Other… 
 
10) In general, how does referral impact on time to treatment? 
 
11) Why was this patient referred elsewhere for treatment and did this influence time to 
treatment? 
  Follow up: If yes, how was their time to treatment impacted? 
12) Do you know how this patient reached the referral site and whether the patient experienced 
any difficulties in reaching the site? 
 
13) Are there any services available to assist patients in reaching referral sites (ie. ambulances)? 
 
Follow up: If yes, why were they or were they not provided to this patient? 
 
14) Are there any systems to track whether patients referred elsewhere, reach the referral site 
and initiate treatment? 
Follow up: If yes, please describe 
15) Was there any follow up for this patient following their referral? 
 
  Follow up: If yes, please describe 
INSTRUCTIONS: Ask question 17 through 21 for patients that were initiated onto treatment at this 
facility  
16) Under what circumstances are patients initiated onto treatment at this facility versus being 
referred elsewhere? 
 
17) In general, how does referral impact on time to treatment? 
 
18) Why was this patient initiated onto treatment at this facility rather than being referred 
elsewhere? 
 
19) Do you have systems to follow up with patients that fail to initiate treatment at this facility 
following diagnosis? 
  Follow up: If yes, please describe 
20) Was there any follow up for this patient, following their diagnosis? 
 
Follow up may be done by a HCW from the health facility, or a 
city/provincial environmental health officer 




INSTRUCTIONS: Ask all HCWs questions 22 – 24 
Note: If the HCW has already responded to these questions for a previous patient, then you do not 
need to ask them again. Simply note on the recording that the HCW has already responded to these 
questions in a previous interview. 
21) What is the average (usual time) that passes between diagnosis and treatment initiation for 
patients that are diagnosed with DR-TB at your facility? 
 
22) Do you face any challenges personally in dealing with DR-TB patients and linking them to 
treatment? 
 
23)  Do you have recommendations for how your facility, organisation, or district could improve 




INTERVIEW GUIDE 2 
This guide should be used to interview health care workers (HCWs) at the facilities that initiated 
treatment following diagnosis and referral from elsewhere. 
 
INTERVIEW GUIDE 2 INSTRUCTIONS: 
1. SKIP INSTRUCTIONS ARE PROVIDED THROUGHOUT THE INTERVIEW GUIDE IN red, italicised 
text  
 
2. PROBES AND EXAMPLES ARE PROVIDED THROUGHOUT THE INTERVIEW GUIDE IN blue, 
italicised text  
 




- Can you tell me more? 
 
4. BEFORE STARTING THE INTERVIEW QUESTIONS, CLARIFY THE FOLLOWING FOR THE HEALTH 
CARE WORKER 
- When and where the patient was diagnosed 
- When and where the patient started treatment 
 
INTERVIEW GUIDE 2 QUESTIONS: 
1) What do you remember about this patient? 
 
2) What was this person like as a patient? 
 
3) Do you think the length of time that passed between the patient being diagnosed with Drug 
Resistant Tuberculosis (DR-TB) and started treatment was good, bad or acceptable? 
Follow up: Why? 
4) Do you think anything else could have been done to shorten the time between when the 
patient was diagnosed and started treatment? 
Follow up:  If no, why?  
Follow up: If yes, what could have been done? 
 
5) Can you describe what happened to the patient between receiving their diagnosis and 
starting treatment? 
If the HCW asks for more clarity, ask them to describe whatever they can 




6) Do you know whether the patient faced any challenges in starting treatment? 
 
Examples: 
Lack of transport 
No beds available for patients requiring hospitalisation 
Delays in receiving diagnostic results, records unavailable 
Doctor unavailable when visiting treatment site 
Medicine shortages 
No one to take care of children 
Unable to take time off work to visit the facility 
Other… 
Follow up: If the patient did experience challenges, did these impact on when the 
patient started treatment? 
Follow up: How? 
 
7) Do you know what factors enabled this patient to start treatment, when many other patients 
that are diagnosed with DR-TB never start treatment? 
Examples: 
Started treatment close to home 
Unemployed or able to take time off work 
Transport available  
Received social grant 
Had a good understanding of DR-TB, received counselling and education 




Follow up: Did any of these factors impact on when the patient started treatment? 
Follow up: If yes, how? 
 
8) Do you have any insight regarding what happened in the patient’s personal life between 
finding out their diagnosis and starting treatment and how this impacted on their time to 
treatment? 
Examples: 
Dependants (new caregiver needed)  
Employment (quit or lost job) 
Place and location of residence (moved) 
Substance abuse 
Use of traditional or alternative medicines 
Other… 
 
9) Under what circumstances are patients referred to your facility to start treatment? 
 
10) Why was this patient referred to your facility for treatment? 
 
11) How far away is your facility from the facility where this patient was diagnosed? 
 
12) Do you know how this patient reached your facility and whether the patient experienced any 




13) Are there any services available to assist referred patients in reaching your facility (ie. 
ambulances)? 
 
Follow up: If yes, why were they or were they not provided to this patient? 
 
14) Are there any systems to track or follow up with patients that are referred to your facility to 
start treatment, but do not arrive? 
Follow up: If yes, please describe 
15) Was there any follow up for this patient, following their referral? 
 
Follow up: If yes, please describe 
 
Follow up may be done by a HCW from the health facility, or a 
city/provincial environmental health officer 
Note: If the HCW has already responded to questions 16 - 18 for a previous patient, then you do not 
need to ask them again. Simply note on the recording that the HCW has already responded to these 
questions in a previous interview. 
16) What is the average (usual time) that passes between diagnosis and treatment initiation for 
patients that are initiated onto DR-TB treatment at your facility? 
 
17) Do you face any challenges personally in dealing with DR-TB patients and linking them to 
treatment? 
 
18) Do you have recommendations for how your facility, organisation, or district could improve 





INTERVIEW GUIDE 3 
This guide should be used to interview health care workers (HCWs) of patients that never initiated 
treatment following diagnosis 
 
INTERVIEW GUIDE 3 INSTRUCTIONS: 
1. SKIP INSTRUCTIONS ARE PROVIDED THROUGHOUT THE INTERVIEW GUIDE IN red, italicised 
text  
 
2. PROBES AND EXAMPLES ARE PROVIDED THROUGHOUT THE INTERVIEW GUIDE IN  blue, 
italicised text  
 




- Can you tell me more? 
 
4. BEFORE STARTING THE INTERVIEW QUESTIONS, CLARIFY THE FOLLOWING FOR THE HEALTH 
CARE WORKER 
- When and where the patient was diagnosed 
 
INTERVIEW GUIDE 3 QUESTIONS: 
1) What do you remember about this patient? 
 
2) What was this person like as a patient? 
 
3) Can you describe what happened to this patient following their diagnosis with Drug Resistant 
Tuberculosis (DR-TB)? 
 
4) In your opinion, why did this patient never start treatment? 
 
5) Do you have any insight regarding what happened in the patient’s personal life after finding 
out his/her diagnosis and whether this affected why the patient never started treatment? 
Examples: 
Dependants (new caregiver needed)  
Employment (quit or lost job) 
Place and location of residence (moved) 
Substance abuse 
Used traditional or alternative medicines 
Other 
 
Follow up: If yes, please describe 
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6) Is failure to initiate treatment following DR-TB diagnosis a common challenge in this area? 
 
7) Do you think the reasons that this patient did not start treatment are typical of most patients 
in the area that fail to initiate care? 
Follow up: Why or why not? 
8) Following diagnosis, was the patient referred elsewhere to start care? 
Follow up: If yes, why? 
Follow up: If yes, how far away is the facility that the patient was referred to? 
 
9) Under what circumstances are patient referred elsewhere to start treatment?  
 
10) Are there any systems to track whether patients referred elsewhere, reach the referral site 
and initiate treatment? 
 
  Follow up: If yes, please describe 
 
11) Are there any services available to assist patients in reaching referral sites (ie. ambulances)? 
 
  Follow up: If yes, why were they or were they not provided to this patient? 
 
12) Are there any systems to trace or follow up with patients that do not start treatment? 
Follow up may be done by a HCW from the health facility, or a 
city/provincial environmental health officer 
Follow up: If yes, please describe 
13) Was there any follow up for this patient? 
Follow up: If yes, please describe 
Follow up: If no, why not?    
 
14) What is the average (usual time) that passes between diagnosis and treatment initiation for 
patients that are diagnosed with DR-TB at your facility? 
 
15) Do you face any challenges personally in dealing with DR-TB patients and linking them to 
treatment? 
 
16) Do you have recommendations for how your facility, organisation, or district could improve 







INTERVIEW GUIDE 4 
This guide should be used to interview patients that started treatment  
This guide may also be used to do joint interviews with patients that started treatment and their 
family members 
 
INTERVIEW GUIDE 4 INSTRUCTIONS:  
1. SKIP INSTRUCTIONS ARE PROVIDED THROUGHOUT THE INTERVIEW GUIDE IN  red, italicised 
text  
 
2. PROBES AND EXAMPLES ARE PROVIDED THROUGHOUT THE INTERVIEW GUIDE IN blue, 
italicised text  
 




- Can you tell me more? 
 
4. WHEN DOING JOINT INTERVIEWS, ASK FOLLOW UP AND PROBING QUESTIONS TO FIND OUT 
MORE FROM THE FAMILY MEMBER REGARDING THE PATIENT’S RESPONSES 
  Examples: 
- Would you like to add anything? 
- Can you tell me more? 
 
5. WHEN DOING JOINT INTERVIEWS, OPEN UP QUESTIONS TO BE INCLUSIVE WHEN 
APPROPRIATE 
 
  Examples: 
- Change: Do you have recommendations… 
- To: Do either of you have recommendations…  
 
INTERVIEW GUIDE 4 QUESTIONS: 
1) Where did you first find out that you had Drug Resistant Tuberculosis (DR-TB)?  
 
2) How were you informed of your DR-TB diagnosis? 
Examples: 
The patient may have been asked to return a few days after 
sputum collection to receive their diagnosis 
The patient may have returned to the facility many times after 
giving sputum before receiving their diagnosis 
The patient may have received a phone call or home visit where 




3) Did you experience any symptoms of TB before being diagnosed with DR-TB? 
Examples: 
Bad cough 
Coughing up blood or sputum/ phlegm 
Pain in chest 
Fever and/or chills 
Night sweats 




Follow up: If yes, for how long did you experience these symptoms? 
Follow up: If the patient experienced symptoms for more than a couple of weeks, 
ask why they were not tested for TB sooner.  
 
Examples: 
The patient visited a facility sooner but was not tested for TB 
because: 
Test not offered 
The wait at the clinic was too long 
The health care worker was not available  
Other… 
 
The patient put off visiting the facility because he/she was: 
Afraid that health care workers would be rude (may have 
previously defaulted) 
Afraid of being diagnosed with TB (may have been previously 
treated for TB) 
Unable to get time off work or find a caregiver for children 
Too ill to travel to the health facility 
Other… 
 
4) After being diagnosed with DR-TB, what were you told to do in order to start treatment? 
Examples: 
Was the patient told to go to the hospital 
Was the patient told he/she could start treatment from home 
Was the patient told he/she could start treatment immediately 
or was there a waiting list 
 
5) How were you treated by health care workers after you were diagnosed with DR-TB? 
 
6) Did the facility that diagnosed you provide you with any educational materials or counselling 
sessions explaining DR-TB and the importance of starting and completing treatment? 
Follow up: If yes, please describe 
7) How did you feel after finding out you had DR-TB? 
 
8) What did you do after you found out you had DR-TB? 
 
Ask the interviewee to describe anything that they can recall - 
there are no wrong answers. 
 




10) Can you describe what happened during this time? 
Ask the patient to describe anything that they recall about this 
time – there are no wrong answers. 
17) What were the main challenges you faced in starting treatment? 






Fear about medicines or death 
Stigma from others in the community 
No beds, waiting lists at facilities 
Shortages of medicines 
Other….. 
 
Follow up: Did any of these challenges impact on when you started treatment? 
Follow up: If yes, how? 
 
18) Were there any factors that helped you in starting treatment? 
These may be personal challenges or challenges related to the 
facility 
Examples: 
Strong support system 
Able to take time off work 
Good understanding of DR-TB 




Follow up: Did any of these factors impact on when you started treatment? 
Follow up: How? 
 
19) Did you have to make any changes to your personal life in order to start treatment? 
Examples: 
Quit job 
Found caregiver for dependents 
Moved 
Stopped drinking or using drugs 
Other 
 
20) Who supported you in starting treatment? 
 
21) At any point after finding out your diagnosis, did you choose to delay starting treatment? 
 
Follow up: If yes, why? 
 
22) At any point between learning your diagnosis and starting treatment did you seek out care 
from a private provider, traditional healer, alternative practitioner or faith healer?  
         




9) At any point, between learning your diagnosis and starting treatment, did you receive a home 
visit or call from the diagnosing facility or anyone else? 
Follow up: If yes, by whom and what was the purpose of this contact? 
10) Did you start treatment from a hospital or from your home with daily facility visits? 
Follow up: Where would you have preferred to start treatment? 
11) How far from your home was the facility where you started treatment? 
(Time according to mode of transport used, i.e. 30 minutes by foot) 
12) Did you face any difficulties in travelling to the facility where you started treatment? 
Follow up: If yes, please describe 
13) Overall, what was the most difficult thing about starting treatment? 
 
14) Do you have any suggestions for how facilities could make it easier for patients to start DR-TB 
treatment? 
 
15) Are you still on treatment today? 
Follow up: If no, why not? 
INSTRUCTIONS: When doing joint interviews with family members, direct the question at the family 
member 







INTERVIEW GUIDE 5 
This guide should be used to interview patients that never started treatment 
This guide may also be used to do joint interviews with patients that never started treatment and 
their family members 
 
INTERVIEW GUIDE 5 INSTRUCTIONS: 
1. SKIP INSTRUCTIONS ARE PROVIDED THROUGHOUT THE INTERVIEW GUIDE IN  red, italicised 
text 
 
2. PROBES AND EXAMPLES ARE PROVIDED THROUGHOUT THE INTERVIEW GUIDE IN  blue, 
italicised text  
 




- Can you tell me more? 
 
WHEN DOING JOINT INTERVIEWS, ASK FOLLOW UP AND PROBING QUESTIONS TO FIND OUT 
MORE FROM THE FAMILY MEMBER’S REGARDING THE PATIENT’S RESPONSES 
  Examples: 
- Would you like to add anything? 
- Can you tell me more? 
 
WHEN DOING JOINT INTERVIEWS, OPEN UP QUESTIONS TO BOTH INTERVIEWEES 
WHENEVER APPROPRIATE 
 
  Examples: 
- Change: Do you have recommendations… 
- To: Do either of you have recommendations…  
 
INTERVIEW GUIDE 5 QUESTIONS: 
1) Where did you first find out that you had Drug Resistant Tuberculosis (DR-TB)? 
 
2) How were you informed of your DR-TB diagnosis? 
 
Examples: 
The patient may have been asked to return a few days after 
giving sputum to receive their diagnosis 
The patient may have returned to the facility many times after 
giving sputum before receiving their diagnosis 
The patient may have received a phone call or home visit where 









Coughing up blood or sputum/ phlegm 
Pain in chest 
Fever and/or chills 
Night sweats 




Follow up: If yes, for how long did you experience these symptoms? 
Follow up: If the patient experienced symptoms for more than a couple of weeks, 
ask why they were not tested for TB sooner 
 
Examples: 
The patient visited a facility sooner but was not tested for TB 
because: 
Test not offered 
The wait at the clinic was too long 
Health care worker not available  
Other… 
 
The patient put off visiting the facility because he/she was: 
Afraid that health care workers would be rude (may have 
previously defaulted) 
Afraid of being diagnosed with TB (may have been previously 
treated for TB) 
Unable to get time off work or find a caregiver for children 
Too ill to travel to the facility 
Other… 
 




Was the patient told to he/she would need to be hospitalised to 
start treatment 
Was the patient told he/she could start treatment from home 
with daily visits to the clinic 
Was the patient told he/she could start treatment immediately 
or was there a waiting list 
 
5) How were you treated by health care workers after you were diagnosed with DR-TB? 
 
6) Were you informed that you would need to be hospitalised to start treatment or that you 
could take treatment from home if you visited a facility daily? 
 
Follow up: Did this impact on why you did not start treatment? 
7) Did the facility that diagnosed you provide you with any educational materials or counselling 
sessions explaining DR-TB and the importance of treatment? 
 
Follow up: If yes, please describe 
 




9) What did you do after finding out you had DR-TB? 
 
Ask the interviewee to describe anything that they can recall - 
there are no wrong answers. 
 
10) Why did you not start treatment after finding out that you had DR-TB? 
 
Try to clarify if this was a personal choice or if it was due to 
problems at the facility, such as lack of beds or rude health care 
workers. 





Personal responsibilities i.e. care giving 
Substance abuse 
 
Follow up: If yes, how 
12) At any point after learning your diagnosis did you seek out care from a private provider, 
traditional healer, alternative practitioner or faith healer?   
 
Follow up: If yes, from where? 
 
13) Has anyone from the diagnosing facility or elsewhere contacted you – either via telephone or 
home visit – to follow up regarding your health condition and why you have not started 
treatment? 
 
  Follow up: If yes, by whom and what was the purpose of this contact? 
 
14) Have you returned to the facility since your diagnosis? 
 
Follow up: If yes, was your DR-TB discussed? 
Follow up: Why or why not? 
 
15) Why have you still not initiated treatment? 
 
16) Like yourself, many other people that have been diagnosed with DR-TB never started 
treatment. According to government estimates about half of the people diagnosed with DR-
TB in 2013 did not start treatment. 
 
Do you have any recommendations for how the Department of Health could make it easier 




INTERVIEW GUIDE 6 
This guide should be used to interview family members of patients that started treatment 
 
INSTRUCTIONS: 
1) XXX appears throughout the document. Wherever XXX appears, insert the patient’s first 
name 
 
2) PROBES AND EXAMPLES ARE PROVIDED THROUGHOUT THE INTERVIEW GUIDE IN  blue, 
italicised text  
 




- Can you tell me more? 
 
4) WHEN DOING JOINT INTERVIEWS ASK THE PARTICIPANTS TO STATE THEIR FIRST NAME 
BEFORE EACH ANSWER THEY GIVE. THIS IS NECESSARY FOR TRANSCRIBING THE 
INTERVIEW. 
WHEN DOING JOINT INTERVIEWS, ASK FOLLOW UP AND PROBING QUESTIONS IN ORDER 
TO FIND OUT BOTH PARTICIPANTS’ PERSPECTIVES 
  Examples: 
- Would you like to add anything? 
- Do you agree that…? 
- Can you tell me more? 
 
WHEN DOING JOINT INTERVIEWS, OPEN UP QUESTIONS TO BOTH INTERVIEWEES 
WHENEVER APPROPRIATE 
 
  Examples: 
- Change: Do you have recommendations… 
- To: Do either of you have recommendations…  
 
INTERVIEW GUIDE 6 QUESTIONS: 
1) What is/was your relationship with XXX? 
 
2) When did you find out that XXX had Drug Resistant Tuberculosis (DR-TB)? 
3)  How did you find out that XXX had DR-TB? 
 





Coughing up blood or sputum/ phlegm 
Pain in chest 
Fever and/or chills 
Night sweats 




Follow up: If yes, for how long did XXX experience these symptoms? 
Follow up: If XXX experienced symptoms for more than a couple of weeks, ask why 
they were not tested for TB sooner 
 
Examples: 
The patient visited a facility sooner but was not tested for TB 
because: 
Test not offered 
The wait at the clinic was too long 
The health care worker was not available  
Other… 
 
The patient put off visiting the facility because he/she was: 
Afraid that health care workers would be rude (may have 
previously defaulted) 
Afraid of being diagnosed with TB (may have been previously 
treated for TB) 
Unable to get time off work or find a caregiver for children 
Too ill to travel to the facility 
Other…. 
 
5) How did XXX react to the news that he/she had DR-TB? 
 
6) What did XXX do after learning that he/she had DR-TB? 
 
Ask the interviewee to describe anything that they can recall - 
there are no wrong answers. 
 
7) Can you describe what happened to XXX between finding out that he/she had DR-TB and 
starting treatment? 
 
Ask the interviewee to describe anything that they can recall 
- there are no wrong answers. 
 
8) Do you know whether XXX received any educational materials or counselling sessions 
explaining DR-TB and the importance of treatment? 
Follow up: If yes, please describe 
9) How was XXX treated by health care workers after he/she was diagnosed with DR-TB? 
 
10) Do you know whether XXX experienced any challenges in starting treatment? 
Examples: 
Lack of transport 
No beds available for patients requiring hospitalisation 
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Delays in receiving diagnostic results, records unavailable 
Doctor unavailable when visiting treatment site 
Medicine shortages 
No one to take care of children 
Unable to take time of work to visit the facility 
Other… 
 
Follow up: If yes, did any of these challenges impact on when XXX started treatment? 
Follow up: How? 
11) Was there anything that helped XXX to start treatment? 
Examples: 
Started treatment close to home 
Unemployed or able to take time off 
Transport available  
Received social grant 
Had a good understanding of DR-TB, received counselling and 
education 




Follow up: Did any of these factors impact on when XXX started treatment? 
Follow up: How? 
12) At any point after finding out his/her diagnosis, did XXX choose to delay starting treatment? 
Examples: 
Dependants (new caregiver needed)  
Employment (quit or lost job) 
Place and location of residence (moved) 
Substance abuse 
Use of traditional or alternative medicines 
Other… 
 
Follow up: If yes, why? 
13) At any point between learning his/her diagnosis and starting treatment did XXX seek out 
care from a private provider, traditional healer, alternative practitioner or faith healer? 
 
Follow up: If yes, from where? 
 
14) Did XXX start his/her treatment for DR-TB from a hospital, or from home with daily visits to 
the facility? 
Follow up: From where would XXX preferred to have started treatment? 
Follow up: Did this impact on when XXX started treatment? 
15) How far from his/her home was the facility where XXX started taking treatment for DR-TB? 
  (Time according to mode of transport used, i.e. 30 minutes by foot) 
16) Did XXX face any challenges in reaching the facility where he/she started treatment? 
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Follow up: If yes, did these challenges impact on when he/she started treatment? 
Follow up: If yes, please describe 
17) Was XXX given any assistance in reaching the facility where he/she started treatment? (I.e. 
ambulance) 
 
18) Overall, what were the biggest challenges that XXX faced in starting treatment? 
 
19) What were the biggest challenges that your family faced as a result of XXX’s diagnosis? 
 
20) Do you have any suggestions for how facilities could make it easier for patients to start DR-
TB treatment? 
 
21) Is XXX still on DR-TB treatment today? 





INTERVIEW GUIDE 7 
This guide should be used to interview family members of patients that never started treatment 
INSTRUCTIONS: 
5) XXX appears throughout the document. Wherever XXX appears, insert the patient’s first 
name 
 
6) SKIP INSTRUCTIONS ARE PROVIDED THROUGHOUT THE INTERVIEW GUIDE IN  red, italicised 
text  
 
7) PROBES AND EXAMPLES ARE PROVIDED THROUGHOUT THE INTERVIEW GUIDE IN blue, 
italicised text  
 




- Can you tell me more? 
 
9) WHEN DOING JOINT INTERVIEWS ASK THE PARTICIPANTS TO STATE THEIR FIRST NAME 
BEFORE EACH ANSWER THEY GIVE. THIS IS NECESSARY FOR TRANSCRIBING THE 
INTERVIEW. 
WHEN DOING JOINT INTERVIEWS, ASK FOLLOW UP AND PROBING QUESTIONS IN ORDER 
TO FIND OUT BOTH PARTICIPANTS PERSPECTIVES 
  Examples: 
- Would you like to add anything? 
- Do you agree that…? 
- Can you tell me more? 
 
WHEN DOING JOINT INTERVIEWS, OPEN UP QUESTIONS TO BOTH INTERVIEWEES 
WHENEVER APPROPRIATE 
 
  Examples: 
- Change: Do you have recommendations… 
- To: Do either of you have recommendations…  
 
 
INTERVIEW GUIDE 7 QUESTIONS: 
22) What is/was your relationship with XXX? 
 
23) When did you find out that XXX had Drug Resistant Tuberculosis (DR-TB)? 
 
24) How did you find out that XXX had DR-TB? 
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25) Did XXX experience any symptoms of TB before being diagnosed with DR-TB? 
Examples: 
Bad cough 
Coughing up blood or sputum/ phlegm 
Pain in chest 
Fever and/or chills 
Night sweats 




Follow up: If yes, for how long did XXX experience these symptoms? 
Follow up: If XXX experienced symptoms for more than a couple of weeks, ask why 
they were not tested for TB sooner 
Examples: 
The patient visited a facility sooner but was not tested for TB 
because: 
Test not offered 
The wait at the clinic was too long 
Health care worker not available  
Other… 
The patient put off visiting the facility because: 
Afraid that health care workers would be rude (may have 
previously defaulted) 
Afraid of being diagnosed with TB (may have been previously 
treated for TB) 
Unable to get time off work or find a caregiver for children 
Too ill to travel to the facility 
Other…. 
 
26) How did XXX react to the news that he/she had DR-TB? 
 
27) What did XXX do after learning he/she had DR-TB? 
 
Ask the interviewee to describe anything that they can recall - 
there are no wrong answers. 
 
28) Did finding out that he/she had DR-TB affect XXX’s personal life? 
 









29) Do you know whether XXX received any educational materials or counselling sessions 
explaining DR-TB and the importance of treatment? 
Follow up: If yes, please describe 






Was the patient told to he/she would need to be hospitalised 
to start treatment 
Was the patient told he/she could start treatment from home 
with daily visits to the clinic 
Was the patient told he/she could start treatment immediately 
or was there a waiting list 
Other… 
 
31) How was XXX treated by health care workers after he/she was diagnosed with DR-TB?  
 
32) Was XXX given instructions regarding where he/she should start treatment?  
 
Follow up: If not, was it explained to XXX why he/she was not referred to treatment 
(i.e. bed shortages or other issues)? 
 
 
INSTRUCTIONS: Ask family members that reported that patients were referred to care (informed where 
they should start treatment) questions 12 through 14. For patients that were not referred to care, skip 
to question 15. 
 
33) Was XXX told that he/she would need to be hospitalised to start treatment or that he/she 
could be treated from home with daily visits to the facility? 
 
Follow up: Did this impact on why XXX did not start treatment? 
 
34) How far away from XXX’s home was the facility where he/she was instructed to start 
treatment? 
 
(Time according to mode of transport used, i.e. 30 minutes by foot) 
 
Follow up: Did this impact on why XXX did not start treatment? 
 
35) Did XXX ever arrive at the facility where he/she was referred to start treatment? 
Follow up: If not, why not? 
Follow up: If yes, can you describe what happened and why XXX was not initiated 
onto treatment after arriving at the facility? 
 
INSTRUCTIONS: Ask all family members the following questions 
36) In your opinion, why did XXX never start treatment? 
 
37) Did anyone from the diagnosing facility or elsewhere contact XXX – either via telephone or 
home visit – to follow up regarding his/her health condition and why he/she has not started 
treatment? 
  Follow up: If yes, by whom and what was the purpose of this contact? 
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38) At any point after learning his/her diagnosis did XXX seek out care from a private provider, 
traditional healer, alternative practitioner or faith healer?   
`  Follow up: If yes, from where? 
39) What were the biggest challenges that your family faced as a result of XXX’s diagnosis? 
 





Patient record data extraction form 
 
Date:  
Patient linkage ID:  
Facility name:  
District:  
Province:  




Patients contact number:  
Emergency contact number:  
Emergency contact name:  
 
 
Current treatment status (select 
one) 
Did not start treatment  
On treatment  












Most recent culture test results  
 
Date __________________        Result (positive/ negative) ________________________ 
 
Any previous culture test results 
 
Date __________________       Result (positive/negative) _________________________ 
 
Date __________________       Result (positive/negative) _________________________ 
 
















Most recent sputum microscopy result 
 
Date ________________   Result ______________________ 
 
Any previous sputum microscopy test results 
 
Date __________________       Result _________________________ 
 















































DRUG RESISTANT TB INFORMATION:  
 
Understanding drug resistant tuberculosis 
 
This pamphlet provides guidance for people diagnosed with drug resistant tuberculosis (DR TB), as 
well for their family members and friends. This pamphlet explains what DR TB is and how it is 
treated. It provides advice on dealing with the side effects of DR TB treatment and explains the 
importance of completing treatment. The pamphlet also explains steps that people with DR TB and 
their contacts can take to reduce the risk of DR TB transmission between people. 
 
What is tuberculosis (TB)? 
 
TB is very common illness and the leading cause of death in South Africa. People that are HIV 
positive and HIV negative can get TB – although people that are HIV positive are more vulnerable to 
developing active TB illness.  
 
TB can be treated. Treatment for TB involves a combination of four medicines that are taken every 
day for six months. The four medicines used to treat TB are rifampicin, isoniazid, ethambutol and 
pyrazinamide. Often the four medicines are combined into a single tablet or pill.  
 
What is DR TB? 
 
DR TB is a disease caused by TB germs, but the germs are resistant to the normal medicines used to 
treat TB. What this means is that regular TB medicines cannot be used to treat TB and different 
medicines must be used to treat DR TB. 
 
The medicines that a DR TB patient is given will depend on his/her level of resistance. In other 
words, in selecting a medicine regimen health care workers must consider what medicines a patient 
is resistant to. The more resistance a patient develops, the more difficult TB is to treat. Treatment 
for DR TB usually lasts between 18 and 24 months. 
 
How does one become infected with DR TB? 
 
A person may become infected with DR TB in two ways: 
 
1) If a patient with regular TB is not able to take their medication every day for six months, 
then he/she may develop resistance to some of the medicines used to treat TB.  Patients 
that develop resistance to both rifampicin and isoniazid must be switched to DR TB 
treatment. 
 
2) DR TB may also be transmitted directly from people with DR TB to others in their close 
contact. Many DR TB patients in South Africa contracted DR TB from other patients, rather 
than because of medicine interruptions. 
 
How are TB and DR TB spread between people? 
 
TB and DR TB are spread in the same way. When a person infected with TB or DR TB coughs, spits, 
sneezes, laughs, or sings, they produce small drops into the air that can carry TB germs.  These drops 
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can be inhaled by people in close contact with someone who has TB, and can cause them to get 
infected and possibly sick as well.  
 
Who is most at risk of getting DR TB? 
 
Close contacts  
 
People who spend a lot of time in close contact with DR TB patients often face a risk of infection. But 
this risk can be reduced by improving ventilation in shared spaces.  
 
The risk of contracting DR TB is highest when in poorly ventilated spaces indoors as TB germs may 
linger in droplets in the air. When spending time together indoors, DR TB patients and their family 
members and friends should open doors and windows to allow air to move through the room.  As 
much as possible, DR TB patients and their close contacts should spend time together outdoors 
where the risk of contracting DR TB is very low.  
 
People with HIV  
 
People living with HIV face a higher risk of becoming sick with TB or DR TB than people who are HIV 
negative. People with HIV can reduce their risk of becoming ill with TB or DR TB by monitoring their 
CD4 count and starting antiretroviral treatment as soon as they become eligible 
 
People with HIV that are in close contact with DR TB patients must inform their health care workers 
to discuss additional strategies to protect their health. It is also advisable that everyone know their 
HIV status and anyone in the household who is not sure of their status should consider having a HIV 
test. 
 
Children under 5 years   
 
Children under 5 years old and especially those under a year old face the greatest risk of developing 
TB or DR TB. All children under 5 that are in close contact with DR TB patients should be taken to the 
clinic to be screened for TB and to discuss taking treatment that may prevent them from getting 
infected or sick from DR TB. 
 
How can people with DR TB protect the health of their friends and family? 
 
If you have DR TB, there are additional steps that you can take to protect the health of your friends 
and family 
 
• The most important way to avoid spreading TB is to take your treatment on time every day 
and complete the full course of treatment. You are still infectious to others until your culture 
is negative. With proper treatment adherence your sputum culture test should convert from 
positive to negative. Once your culture has converted to negative it is important to continue 
taking your medicines until you have completed the full course of treatment. If you stop 
taking medicines before you have completed your full treatment course then your culture 




• Avoid close contact with others, especially children under 5, until your sputum culture test is 
negative. If possible, sleep in a bedroom on your own. Or at least try not to share a bed with 
others. 
 
• Open the doors and windows in your home to allow air to move through the rooms. 
Whenever possible, spend time with other people outside. Try wearing a mask when you are 
sharing indoor spaces with poor ventilation. 
 
• Wear a mask or cover your mouth with a disposable tissue when you cough. Make sure to 
properly dispose of tissues and masks you have coughed in. If you do not have a tissue or 
mask, cover your mouth with your sleeve or elbow when you cough. Do not spit on the 
ground. Spit in a tissue and throw it away. 
 
Why is starting treatment as early as possible important for DR TB patients? 
 
Without proper treatment, DR TB is usually a fatal illness. Therefore it is important for people 
diagnosed with DR TB to start treatment as early as possible in order to protect their health. 
 
What does DR TB treatment entail? 
 
DR TB can be cured with proper treatment, although the treatment is often physically and 
emotionally difficult on patients.  DR TB treatment involves a combination of medicines that are 
taken for 18 to 24 months. Many patients are also given injections for the first six months or longer. 
Some patients are hospitalised at the start of treatment.  
 
Patients have to see their doctor monthly for a check-up.  Patients must produce sputum every 
month around the same date, this sputum will be taken to the lab and the results will tell your 
doctor if your treatment is working speedily or not.  
 
What are some of the challenges you might experience with the treatment? 
 
There are lots of pills to swallow and most patients have to be given injections every Monday to Friday 
for at least 6 months. It will not be easy to continue your treatment but your TB nurse and doctor are 
there to help you get through this.  
 
Do you need to eat before taking your medicines? 
 
It is not necessary to eat before taking your medicines. It is safe to take your TB treatment on an empty 
stomach. 
 
What are the side effects of DR TB treatment? 
 
DR TB treatment is often associated with difficult side effects. Minor side effects include nausea, 
vomiting, stomach pains, diarrhoea, dizziness, ringing in the ears, rashes, aching joints and painful or 
burning feet.  Serious side effects may include vision loss, hearing loss, seizures or fits, depression, 




Tell your doctor or nurse if you experience any of these side effects as the may be able to change 
your medicines or give you additional medicines to reduce or stop the side effects. If you experience 
vision loss, report this immediately to your doctor as it may lead to blindness if not dealt with. It is 
also important that you have regular hearing screening tests so that changes in hearing may be 
picked up early as hearing loss may be permanent. 
 
What happens if I take my treatment well? 
 
• You should start feeling better  and healthier 
• You should start gaining weight 
• Your sputum tests should come back negative 
• You will prevent any further damage to your lungs or infected organ 
• You will stop being infectious to others  
 
What happens to you if you stop your treatment? 
 
• Every time you do not take your DR TB treatment, you give the germs a chance to grow again 
and you will eventually become sick again. 
• Every time the germs grow again there is a chance that further resistance will develop. The 
more resistance a patient develops, the more difficult TB becomes to treat as fewer medicines 
are available with even more difficult side effects. 
• You may become infectious again and spread DR TB germs to other people, including your 
children, family, friends and others in the community. 
 
Your best chance to beat DR TB is to complete your treatment!   
 
If you are having difficulty with side effects or adherence, do not stop treatment, rather seek out 
support 
 
• Tell your health care worker if you are experiencing side effects as there may be ways to 
reduce or manage the side effects. 
• Find out if there is a support group for DR TB patients at your clinic. If there is no support 
group, talk to other patients or the community health worker/ nurse at your clinic about 
starting one. 
• Call a free counselling support line  
 
Can DR TB be treated with faith healing, alternative or traditional medicine? 
 
Being on DR TB treatment is quite difficult and it is normal to seek alternative treatment and 
spiritual support. Please discuss you this with your doctor as some traditional medicines may 
interfere with the DR TB treatment and could be quite dangerous to use together. Alternative or 
traditional medicines that cause diarrhoea or vomiting should be avoided as they will prevent your 
DR TB medicines from being properly absorbed and working in your body. Leaning on your faith at 
this time is quite important but remember to keep using your treatment. If you are feeling unsure 
about continuing treatment talk to your doctor first and invite you pastor or spiritual healer to 





Who can I contact for support and counselling? 
 
The Depression and Mental Health Helpline  0800 567 567 
 
Lifeline       0861 322 322 
 
The National AIDS Helpline                                                     0800 012 322 
(also provides TB assistance)  
 
The National HIV & TB Health Care Workers Hotline 0800 212 506 
 
The Social Grants Helpline    0800 601 011 
 
You may also contact one of the following NGOs for information and support 
 
TB/HIV Care      021 425 0050 
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